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ABSTRACT 
 
Hao Tang : Prioritizing Small molecules for Drug Discovery or Chemical Safety 
Assessments using Ligand- and Structure-based Cheminformatics Approaches 
(Under the direction of Professor Alexander Tropsha) 
 
Recent growth in the experimental data describing the effects of chemicals at the 
molecular, cellular, and organism level has triggered the development of novel computational 
approaches for the prediction of a chemical’s effect on an organism.  The studies described in 
this dissertation research predict chemical activity at three levels of biological complexity:  
binding of drugs to a single protein target, selective binding to a family of protein targets, and 
systemic toxicity. Optimizing cheminformatics methods that examine diverse sources of 
experimental data can lead to novel insight into the therapeutic use and toxicity of chemicals.   
In the first study, a combinatorial Quantitative Structure-Activity Relationship 
(QSAR) modeling workflow was successfully applied to the discovery of novel bioactive 
compound against one specific protein target: histone deacetylase inhibitors (HDACIs). Four 
candidate molecules were selected from the virtual screening hits to be tested experimentally, 
and three of them were confirmed active against HDAC.  
Next, a receptor-based protocol was established and applied to discover target-
selective ligands within a family of proteins. This protocol extended the concept of 
protein/ligand interaction-guided pose selection by employing a binary classifier to 
discriminate poses of interest from a calibration set. The resulting virtual screening tools 
were applied for enriching beta2-adrenergic receptor (β2AR) ligands that are selective 
against other subtypes in the βAR family (i.e. β1AR and β3AR). Moreover, some 
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computational 3D protein structures used in this study have exhibited comparative or even 
better performance in virtual screening than X-ray crystal structures of β2AR, and therefore 
computational tools that use these computational structures could complement tools utilizing 
experimental structures. 
Finally, a two-step hierarchical QSAR modeling approach was developed to estimate 
in vivo toxicity effects of small molecules. Besides the chemical structural descriptors, the 
developed models utilized additional biological information from in vitro bioassays. The 
derived models were more accurate than traditional QSAR models utilizing chemical 
descriptors only. Moreover, retrospective analysis of the developed models helped to identify 
the most informative bioassays, suggesting potential applicability of this methodology in 
guiding future toxicity experiments. 
These studies contribute to the development of computational strategies for 
comprehensive analysis of small molecules’ biological properties, and have the potential to 
be integrated into existing methods for modern rational drug design and discovery. 
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Chapter 1. Introduction 
1.1. Overview 
The famous “central dogma” of molecular biology explains the information flow through 
macromolecules from DNA to RNA to proteins. Yet, many essential biological processes cannot 
be fulfilled with macromolecules alone. A variety of small molecules, such as transmitters, 
hormones, metabolites, and xenobiotics, are essential to understand the big picture of life and are 
arguably the “missing link” of the “central dogma” (1 Figure1.1). Acquiring good knowledge of 
these small molecules and how they interact with biological systems could significantly enhance 
our abilities to characterize protein functions, decipher the signaling pathways, and direct the 
optimization of drug leads for treatments of diseases.  In order to investigate the effects of small 
molecules, rapid growing disciplines including chemical biology, chemogenomics, and chemical 
genetics have evolved at the interface between chemistry and molecular biology, statistical 
modeling and computational sciences 2-4. Despite the diversity and complexity of researches in 
these fields, the major themes are perhaps best described as to use small molecules as probes to 
study biological functions, with an ambitious goal to comprehensively explore all possible drug 
candidates, potential pharmaceutical relevant targets, and the entire drug-target interaction 
network 5,6.  
With the increasing amount of data produced in this field, computational tools are 
recently developed to either help with interpretation of the data, or convert the information into 
knowledge and predictive tools that can be applied to guide future studies. Many of these 
computational tools are derived from conventional cheminformatics and bioinformatics methods 
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including, for instance, the analysis of small molecule similarity and structure-activity 
relationships, the study of ligand-target associations through molecular docking and scoring, or 
the construction of target associations through sequence/structure similarity and the ligand-target 
interaction network 7-9 (Figure 1.2). A comprehensive overview of computational tools 
developed in this field is beyond the scope of this chapter; rather, the focus here is to provide a 
brief summary of the cheminformatics and virtual screening tools that have been explored and 
evaluated in this dissertation, as well as highlight the contributions of  this study.     
1.2. Quantitative Structure-Activity Relationships Analysis 
The major assumptions underlying any Quantitative structure-activity relationship 
(QSAR) analysis is that “similar molecules are most likely to obtain similar properties” (the 
Similarity Property Principle), which has shown to be generally valid. Classical QSAR models 
attempt to quantitatively relate structure variations of small molecules to changes in their 
biological properties, such as binding affinities and inhibition constants. Any QSAR practice can 
generally be represented by a mathematical formula: ܲ ൌ ෠݇ሺܦଵ, ܦଶ, … , ܦ௡ሻ   where P is a 
biological property of interest for the molecules; ܦଵ , ܦଶ … ܦ௡  are calculated structural 
descriptors that characterize molecules’ physical-chemical properties, and ෠݇  is some 
mathematical transformation to derive the property for the molecule from the descriptors 10. The 
success of a QSAR modeling campaign thus depend on the robustness of the structural 
descriptors employed, as well as the statistical learning strategies applied to the construction of 
the structure-activity relationships. Recently, there is an increasing emphasis in the QSAR 
community to carry out rigorous model validation to afford robust and predictive models, which 
can be applied to virtual screening of external compounds with unknown activities 10-14.  
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Most of the traditional QSAR models assume a single mode of action for the tested small 
molecules, as well as a linear relationship between a biological activity and molecular descriptors. 
This may be a reasonable approximation for relatively small data sets. However, it is often not 
the case for the data from chemical biology, especially when the monitored biological functions 
can be phenomenological in nature, and a large set of structurally diverse compounds is 
considered. During the past decades, we have witnessed a great interest in using more complex 
machine learning techniques, such as the Bayesian Classifier 15, k nearest neighbors (kNN) 16, 
randomForest (RF)17, and support vector machines (SVM) 18,19, to assist computational modeling 
in this field. As it is highly impossible to decide a priori as to which modeling technique could be 
most effective, it is usually recommended to use the combi-QSAR approach that explores all 
possible combinations of various descriptor types and statistical learning algorithms along with 
external model validation. Chapter 2 describes an example that employed the combi-QSAR 
approach and rigorous model validation to identify novel histone deacetylase inhibitors.  
Despite the increasing complexity and diversity of statistical learning algorithms applied, 
it is difficult to develop predictive tools for chemical biology data using most traditional QSAR 
models that are based on chemical descriptors alone. There are two major challenges: the 
significant structure diversity of the data set on one hand, and the variety of structural features 
that can cause similar effect, on the other hand. These challenges are most prominent in the 
assessment of environmental chemicals’ toxicological effects, where chemicals were designed 
for different reasons with various scaffolds, and can act through multiple mechanisms and hit 
various physiologically important targets to cause similar adverse effects 20,21. On the other hand, 
the development of various in vitro toxicity testing methods, such as cell-based and cell-free 
HTS techniques, as well as toxicogenomic technologies, offered potential biological basis for 
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estimating the adverse effects of environmental chemicals 22-24. Therefore, it is intriguing to 
develop novel QSAR modeling approaches that can combine traditional chemical descriptors 
with the knowledge extracted from the in vitro testing results. Indeed, our recent studies showed 
that it is possible to improve QSAR models’ predictivity by including in vitro testing results as 
biological descriptors with traditional chemical descriptors 25,26. However, this approach is not 
always effective, partially owing to the overwhelming influence of chemical descriptors when 
modeling with hybrid descriptors. Recently, we showed that it is also beneficial to utilize the 
correlation between rodent acute toxicity data (in vivo data) and cytotoxicity data (in vitro data) 
to enhance the performance of traditional QSAR models with chemical descriptors only 27,28. In 
Chapter 5, we illustrated when it is difficult to build predictive models from traditional QSAR 
modeling approach using either chemical descriptors or hybrid descriptors (chemical plus 
biological descriptors), we can still manage to utilize the in vitro vs. in vivo correlations and a 
novel two-step hierarchical QSAR modeling workflow to construct models for three rat 
reproductive toxicity endpoints.  
1.3. Molecular Docking 
Receptor-ligand docking has become a fundamental component of modern drug 
discovery process. It consists of two distinct steps: docking and scoring. The docking step 
attempts to explore all possible conformations and orientations of a candidate ligand into the 
active site. Each solution is named a pose. The scoring step deals with determining the binding 
affinity of each pose, and ranks the ligands according to the predicted values. The goal is to find 
the most appropriate pose for each ligand and to indentify the ligands with the highest potential 
as drug candidates. Following the pioneering work form the first docking-based virtual screening 
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approaches, namely UCSF Dock, there are currently more than 60 docking programs (e.g. Dock, 
AutoDock, eHiTs, FlexX, Fred, Glide) and more than 30 scoring functions9,29. To date, structure-
based virtual screening (SBVS) has been successfully applied in numerous studies and enabled 
well documented discovery of several approved drugs, e.g. dorzolamide 30,31 and relenza 32.  
A docking study provides concomitantly the estimates on small molecule’s binding 
pattern and affinity to the target macromolecule. When there is a set of related protein targets, 
docking studies would, ideally, provide good estimates on small molecule’s binding selectivity 
across these targets (ligand profiling). Compared with ligand-centric methods that use small 
molecule information alone, docking represents a promising complementary approach that 
include 3D information about the target protein to predict compounds binding selectivity. 
Therefore, there is an increasing interest to use docking approaches in both retrospective and 
prospective studies of small molecules’ binding selectivity33,34. Nevertheless, due to the inherent 
limitations of docking programs, this is never a trivial task. 
Typically, the 3D structures of biomolecules obtained by X-ray crystallography and 
NMR spectroscopy are needed for the purpose of SBVS, whose performance is strongly affected 
by the quality of biomolecular structure, especially with respect to binding site description. 
When no experimentally determined structures are available, theoretical models based on either 
homology or de novo modeling approaches are employed instead 35-38. In principle, the success 
of structure models is typically measured by how close the models could reproduce experimental 
structures, which implies that the latter are inherently more appropriate choice for SBVS 
applications. However, this may not always be true, especially when one takes into account of 
the fact that some of the computational models are actually manually refined with known 
medicinal chemistry data to reproduce conserved protein-ligand contacts. There have been some 
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discussions about the accuracy and applicability of theoretical models 38-44 in SBVS. The G-
protein coupled receptors (GPCRs) serves as a good example where theoretical models have 
been used widely because of GPCRs’ importance as targets for many drugs, on one hand, and the 
lack of experimental structures, on the other hand. Thus, the recent publications of the crystal 
structure of human beta-2 adrenergic GPCR (β2AR)45-47 cleared the way for the validation of 
previous theoretical models, as well as provided critical guide for building structural models of 
other GPCRs. To assess the accuracy and applicability of structure models in SBVS, we have 
compared several beta-2 adrenergic receptor (β2AR) structural models versus the β2AR-T4L 
crystal structure in terms of both their global similarity and effectiveness of use in search for 
β2AR specific agonists and antagonists (Chapter 3). 
Another critical issue for using docking as a ligand profiling approach is the inaccuracy 
of the predicted binding pose and affinities. While most docking program can reproduce 
experimentally resolved binding conformations, those poses are not always picked by the scoring 
functions 48. The generated scores also do not correlate with the order of measured activities, 
thus most docking programs demand further visual inspections of the top-scored poses 49,50. To 
overcome this problem, the scoring functions are constantly modified to enable more accurate 
prediction of the binding energy of a small molecule. The developed approaches, however, are 
often very computationally intensive, resulting in less pracitical approaches for large scale virutal 
screening. Alternative approaches are to use pre- or post-docking filters to eliminate 
unreasonable ligand poses or uninterested compounds. The examples of several approaches that 
allow pharmacophore constraints during docking runs include Glide 51, Gold 52, LIDAEUS53, and 
FlexX 54.  Several other groups aim at selecting only ligand poses that possess known conserved 
protein-ligand contacts. Singh and colleagues 55,56 defined a series of protein-ligand interactions 
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properties to generated Structural interaction fingerprint (SIFt) at protein-ligand’s binding site. 
Virtual screening studies using SIFt revealed superior performance as compared with traditional 
scoring functions. Graaf and Rognan et al. showed that a topological scoring function based on 
another ligand protein interaction fingerprint (IFPs) was able to selectively identify agonists or 
antagonists of the β2AR 57-59.  
Our lab has developed a novel type of four-body statistical descriptor to effectively 
represent the protein-ligand interface: the PL/MCT-tess (Protein-Ligand atoms’ pair wise 
Maximal Charge Transfer potential based on Delaunay Tessellation) descriptor. A recent study 
by Hsieh et al. in our group suggested that QSAR models developed based on PL/MCT-tess 
descriptors can effectively distinguish native-like docking poses from decoy poses, thus 
dramatically increased the virtual screening performance when combined with the traditional 
force-field based scoring functions60,61. Herein, we continue to use the PL/MCT-tess descriptors 
as an effective representation of the protein-ligand interface, and explored novel pose-filters that 
enable selective exclusion of irrelevant binding poses. The developed pose-filters have been 
further customized to learn significant contacts that relate to subtype specificity, and the derived 
filters were applied to search for selective ligands within the βAR sub-family (Chapter 4).  
1.4. Thesis Outline 
This dissertation has aimed to develop and validate computational approaches for the 
analysis of small molecules’ toxicity and binding selectivity, both of which have high potential 
for application in the fast evolving fields of chemical biology and chemogenomics. A series of 
QSAR-based and docking-based computational tools have been developed and customized for 
this purpose.  
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Chapter 2 illustrates the power of combi-QSAR VS as a general approach for the 
identification of structurally novel bioactive compounds. Histone deacetylases inhibitors 
(HDACIs) have emerged as a new class of drugs for the treatment of human cancers and other 
diseases due to their effects on cell growth, differentiation, and apoptosis. To produce predictive 
QSAR models, a combi-QSAR approach that employ k Nearest Neighbor (kNN) and Support 
Vector Machines (SVM) QSAR modeling algorithms using both MolConnZ and MOE chemical 
descriptors have been employed. The validated QSAR models were used concurrently to screen 
large publically and commercially available compound databases totaling over 9.5 million 
molecules for novel HDAC inhibitors.   
Chapter 3 and Chapter 4 contribute to the development and validation of a target-biased 
SBVS approach that can be further tailored to search target selective ligands. Selective small 
molecules provide an important library for probing biological functions in the field of chemical 
biology. To develop computational tools that are capable of discriminating selective ligands 
requires a paradigm shift from the previous single-target focus. The emphasis is on exploring 
interactions between individual ligand to a set of (related) protein targets. To perform ligand 
profiling based on SBVS requires a priori the 3D structures of all the protein targets, which may 
not always have experimentally solved structures available. In these situations, structure models 
via homology modeling or de novo design are used instead. This has been a long time debate 
whether SBVS using structure models can achieve reasoanble quality and applicability. Studies 
in Chapter 4 compare the SBVS applicaility of a set of well established β2AR theoretical models 
with that of the recently solved β2AR X-ray crystal structure. Employed both the carefully 
selected structural models and the recently solved β2AR X-ray crystal structure, Chapter 5 
describes the development and validation of novel target-biased pose filters for selectively enrich 
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sub-type ligand within the βAR GPCR subfamily. The developed pose filters could not only help 
with ligands identification, but are also useful in finding potential binding residues that are 
essential for ligand selectivity.  
In Chapter 5, traditional QSAR models, as well as the specialized QSAR models that 
incorporate biological information from in vitro testing data have been evaluated for their 
potential to forecast environmental chemicals’ in vivo toxicity effects. Others’ studies as well as 
our previous efforts showed that while it is possible to construct predictive QSAR models using 
chemical descriptors alone, it is usually not a simple task for most toxicity endpoints. We 
hypothesize that model performance could be improved by including additional information 
about how molecules’ can perturb important signaling pathways and interact with the biological 
system. The available in vitro testing data could serve as biological probe to predict chemicals’ 
systemic adverse effects. Therefore, we proposed to develop a novel two-step QSAR approach 
that incorporates the in vitro testing results to complement traditional chemical-descriptors-based 
QSAR models in predicting compounds’ toxicity effects.  
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Figures and Tables 
 
Figure 1.1.  Illustration of the role of small molecules as viewed by a chemical biologist. (Adapted 
from 1) 
 
 
Figure 1.2. Contribution of cheminformatics to systems biology. Computational modeling helps with 
the prediction of compounds activity against single/multiple targets, while the PBPK models will 
provide estimation on compound distribution and accumulation in tissues. (Adapted from 62) 
 
 
Chapter 2.  Novel Inhibitors of Human Histone Deacetylase (HDAC) 
Identified by QSAR Modeling of Known Inhibitors, Virtual 
Screening, and Experimental Validation 
(This chapter has been published as Tang, H., et al. J Chem Inf Model, 2009. 49(2): p. 461-76) 
 
2.1. Introduction 
The dynamic posttranslational modification of nucleosomal histones plays a critical 
role in transcriptional regulation. Hyperacetylation of core histones results in transcriptional 
activation, while hypoacetylation leads to expression repression63. This kind of regulation is 
considered to be the critical step in normal cell differentiation and chromatin condensation 
and is believed to be regulated by the balance between two groups of enzymes: histone 
deacetylases (HDACs) and histone acetyltransfereases (HATs) 64,65. Inhibition of HDACs 
represents a novel approach to interfere with cell cycle regulation; therefore, it has a great 
therapeutic potential in the treatment of diseases of aberrant cellular proliferation 66. It has 
been reported that hyperacetylation of histones and non-histone proteins induced by small 
molecule HDACs inhibitors (HDACI) leads to cell growth arrest, cellular differentiation 
and/or apoptosis of malignant cells 67-70. For these reasons, HDACI has become a promising 
class of chemical agents for the treatment of cancer and other diseases associated with 
uncontrolled cell proliferation.  
To date, a number of structurally distinct classes of HDACI have been reported, 
including hydroxamates, cyclic peptides, aliphatic acids and benzamides 71,72. The natural 
product Trichostatin A (TSA) 73 is the most well-known member of the hydroxamates class; 
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this compound is considered to be a mimetic of the natural substrate, i.e., histone acetyl 
lysine side chain. Extensive structure-activity relationship (SAR) studies have been 
conducted for TSA and TSA-like compounds resulting in several potent HDACs inhibitors 74-
77. A TSA analog suberoylanilide hydroxamic acid (SAHA) 78 was recently approved by the 
FDA for the treatment of cutaneous T cell lymphoma (CTCL), stimulating further 
investigations of HDACI in the treatment of various diseases 79.  
HDACs have been classified so far into four classes (Classes I-IV) depending on the 
sequence identity and domain organization. Among the Class I HDACs, HDACs 1,2 and 8 
are primarily found in the nucleus, whereas HDAC 3 is found in the nucleus, cytoplasm and 
the membrane. In comparison, Class II HDACs subdivided into IIa (HDAC 4, 5, 7, 9) and IIb 
(HDAC 6, 10) are able to shuttle in and out of the nucleus depending on different signals. 
Class III HDACs include the SIRTs (sirtuins) or Sir2- related proteins; they are NAD-
dependent 80 and are insensitive to TSA or other hydroxamate inhibitors. Class IV comprises 
of HDAC 11, based on a phylogenetic analysis and is the least characterized to date 81. It has 
been considered important in recent years to develop class/subtype selective HDACI. 
Considering the number of pathways in which HDACs are involved, the HDACI that act 
exclusively on Class I or Class II enzymes are viewed as likely candidates as anticancer 
therapeutic agents.  
The crystal structures of the histone deacetylase like protein (HDLP) both in the apo 
form and in complexes with TSA and SAHA were first published by Finnin et al. in 1999 82. 
Five years later, Somoza's group and Di Marco's group both solved the x-ray structures of 
another class I histone deacetylase, histone deacetylase subtype 8 (HDAC8) in complex with 
several small molecule HDACI 83,84. The crystallographic structures revealed that both HDLP 
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and HDAC8 contain a conserved tunnel-like binding pocket with the polar active site at the 
bottom. In the x-ray structure of the HDLP/TSA complex, the long aliphatic chain of TSA 
(linker domain) spans the whole length of the tunnel-like pocket and the hydroxamic acid 
moiety interacts with the polar residues at the bottom of the pocket. The chelating atoms of 
hydroxamic acid coordinate zinc ion in a bidentate fashion, and form hydrogen bonds with 
the His-Asp diad 72,82,84. At the other end of the aliphatic chain, the aromatic group of TSA 
(surface recognition domain) interacts with the hydrophobic rim of the pocket 72. Thus, SAR 
studies have been typically focused on three regions of HDACI: the metal binding group, the 
linker domain, and the surface recognition domain 77. 
Because of their potential clinical importance, HDACI have been a subject of several 
Quantitative Structure-Activity Relationship (QSAR) modeling studies 75,76,85. The results of 
these studies are summarized in Table 2.1. Most of them focused on a series of hydroxamates 
and employed 3D QSAR modeling methods. This preference was partially due to the fact 
that a number of HDACs crystallographic structures have been solved in recent years and 
thus could be used for structural alignment of inhibitors to enable 3D QSAR modeling. The 
size of HDACI datasets varied among different reports, ranging from 19 to 124. The best 
reported models were characterized by leave-one-out cross-validation (LOO-CV) ܴଶ  of 
0.870 and ܴଶ of 0.987. For the test set, the  ܴଶ was as high as 0.896. It should be pointed out 
that none of these earlier studies had employed an independent dataset for model validation, 
and none used models for virtual screening of chemical libraries to identify novel hits.  
In the present study of HDACI, we have applied the modeling strategy that has been 
under development in our laboratory for several years 86. The important feature of our 
approach is that it combines validated QSAR modeling of historic data and virtual screening 
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of available chemical libraries for the identification of novel active compounds, as illustrated 
in Figure 2.1. We have used experimental data for 59 histone deacetylase subtype 1 (HDAC1) 
inhibitors that were generated in one of our laboratories. All of the compounds in the dataset 
were hydroxamates but incorporated many novel chemical modifications in the three major 
domains, i.e., the hydroxamic acid, the linker domain and surface recognition domain. Our 
studies resulted in externally predictive QSAR models of HDAC1 inhibitors. Furthermore, 
the application of these models to virtual screening of a large (ca. 9.5 million) collection of 
commercially available chemical compounds identified several computational hits, and three 
of them were confirmed experimentally as novel active HDAC1 inhibitors. 
2.2. Materials and Methods 
2.2.1. Datasets for Model Building and Validation. 
 59 compounds with known HDAC1 inhibition activities were employed for the 
QSAR study (cf. Appendix I ). All data were generated in the laboratories of Dr. Kozikowski 
(chemistry) and Dr. Jung (biology) at the George Washington University and most of them 
were reported earlier 87-92. The data for eight compounds, BC-2-87, BC-3-63, BC-3-70, BC-
3-94, BC-4-93, BC-6-30, BC-6-33 and BC-6-34, are reported here for the first time. The half 
maximal (50%) inhibitory concentration of a substance (IC50) was measured on HDAC1 
from HeLa cell extracts. It was then converted to the pIC50 scale (-logIC50), in which higher 
values indicate exponentially greater potency.  
Two independent external validation sets of different nature were employed in the 
later phase of our modeling workflow (cf. Figure 2.1): one included 9 HDAC1 inhibitors 
randomly selected from the original set of 59 compounds, and another comprised 54 diverse 
HDAC1 inhibitors collected from two general reviews on HDACIs 72,74. These external sets 
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have covered most chemical classes of known HDACI 77,93-97. Other compounds discussed in 
the reviews were excluded either because their HDAC1 binding affinity data were not 
reported or they were duplicates of compounds included in the modeling set. The observed 
pIC50 values of 54 compounds ranged between 4.0 and 8.0 which are similar to the activity 
range observed for the 50 compounds used for model development. 
2.2.2. Libraries for Virtual Screening.  
The virtual screening was performed on our in-house collection of ca. 9,500,000 
molecules, including the ZINC7.0 database of ca. 6,500,000 compounds98, the World Drug 
Index (WDI) database of ca. 59,000 compounds 99, the ASINEX Synergy libraries (2006.04) 
of ca. 11,000 compounds 100, the InterBioScreen screening libraries (2007.03) of ca. 400,000 
compounds 101, the Chemizon Progenitor databases (2006 v1.1) of ca. 3,300 compounds 102, 
and several other commercial databases. None of the compounds present in the modeling set 
were found in the screening libraries. MolConnZ4.09 (MZ4.09) descriptors were calculated 
for each compound in the databases and linearly normalized based on the maximum and 
minimum values of each descriptor type in the modeling dataset of 59 HDAC1 inhibitors. 
2.2.3. Generation of MolConnZ Descriptors. 
 The MolConnZ4.05 (MZ4.05) software 103 affords the computation of a wide range 
of topological indices (descriptors) of molecular structure such as simple and valence path, 
cluster, path/cluster and chain molecular connectivity indices, kappa molecular shape indices, 
topological and electrotopological state indices, differential connectivity indices, graph's 
radius and diameter, Wiener and Platt indices, Shannon and Bonchev-Trinajsti, information 
indices, counts of different vertices, counts of paths and edges between different kinds of 
vertices 104-111. Overall, MZ4.05 produces more than 400 different descriptors. In this study, 
16 
 
only 262 chemically relevant descriptors were eventually used after removing those with zero 
value or zero variance. MZ4.05 descriptors were range-scaled because the absolute values of 
individual types could differ by orders of magnitude 16. Therefore, range scaling prevents 
undesirable overweighting of descriptors with high ranges of values in calculating compound 
similarities as part of QSAR modeling procedure. 
2.2.4. Generation of MOE Descriptors.  
The MOE2006.08 software 112 generates both 2D and 3D descriptors. 2D molecular 
descriptors include physical properties, subdivided surface areas, atom counts and bond 
counts, Kier and Hall connectivity and kappa shape indices, adjacency and distance matrix 
descriptors, pharmacophore feature descriptors, and partial charge descriptors 104,108,109,113-116. 
3D molecular descriptors include potential energy descriptors, surface area, volume and 
shape descriptors, and conformation-dependent charge descriptors 117. For model generation, 
we used 179 MOE descriptors with non-zero value and variance that were range-scaled. 
2.2.5. Selection of Training and Test Sets.  
The dataset was subdivided into multiple training/test set pairs using the Sphere 
Exclusion method developed in our laboratory 118,119. By default, fifty different training/test 
set splits were initially tried using probe sphere radii defined by the minimum and maximum 
elements, Dmin and Dmax, of the distance matrix D between compound-vectors in the 
descriptor space and forty-two splits were ultimately accepted. The number of compounds in 
the test set was varied to achieve the largest possible size of the test set, while ensuring that 
the training set models were still able to accurately predict the binding affinity of the test set 
compounds. 
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2.2.6. kNN Regression Method 
The k Nearest Neighbor (kNN) QSAR method used in this study employs the kNN 
pattern recognition principle 120 and variable selection method. In short, a subset of variables 
(descriptors) is selected randomly as a Hypothetical Descriptor Pharmacophore (HDP) 121. 
The HDP is validated by LOO-CV, where each compound is eliminated from the training set 
and its HDAC1 inhibition activity is predicted as the weighted average of the activity(ies) of 
the k most similar molecules (k varies from 1 to 5). The weighted molecular similarity is 
represented by the modified Euclidean distance between compounds in HDP 
multidimensional space as shown in Equations 1 and 2. Essentially, the neighbor with the 
smaller distance from a compound is given a higher weight in calculating the predicted 
activity. 
    ݓ௜ ൌ ௘
ష೏೔
∑ ௘ష೏೔೔                         (1) 
    ݕ෤ ൌ ∑ ݓ௜ݕ௜                       (2) 
where ݀௜  is the Euclidean distance between the compounds i and its kth nearest 
neighbors; wi is the weight for the kth nearest neighbor; ݕ௜ is the experimentally measured 
activity value for the kth nearest neighbor; and ݕ෤ is the predicted activity value. 
Simulated annealing and Metropolis-like acceptance criteria were used to optimize 
the variables. Details of the kNN method implementation, including the description of the 
simulated annealing procedure used for stochastic sampling of the descriptor space, are given 
elsewhere50. The statistical significance of the models were estimated by the LOO-CV q2 in 
the training set, a coefficient of determination R02 (Equation 3) and a linear fit predictive ܴଶ 
for both internal and external test sets. 
ݍଶሺܴ௢ଶሻ ൌ 1 െ ∑ሺ௬෤ೖି௬ೖሻ
మ
∑ሺ௬തି௬ೖሻమ  (3) 
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Here ݕ௞ and ݕ෤௞ are the observed and predicted activities of compound k, respectively, 
and ݕത is the average activity of all compounds. Model acceptability cutoffs were ݍଶ >0.60 for 
training set and correlation coefficient ܴଶ > 0.60 for the internal test set57. All models that 
satisfied both criteria were applied to external validation sets. 
2.2.7. SVM Regression Method 
Support Vector Machines (SVM) was originally developed by Vapnik 122 as a general 
data modeling methodology where the training set error and the model complexity are 
incorporated into a special loss function and simultaneously minimized during model 
development. The importance of the prediction error versus the model complexity can be 
tuned during the optimization process, in order to generate models with reasonable 
complexity and avoid overfitting. SVM was later extended to afford the development of 
SVM regression models for datasets with non-integer variables.  
We have implemented SVM for QSAR modeling as described earlier 123. In brief, 
given a training set of pairs (ݔ௜, ݕ௜ሻ, i ൌ 1…m, where x୧ is an array of descriptors of each 
compound andy୧  is its biological activity (e.g., IC50 value), the sought correlation between 
structure and activity can be represented as ݕ௜ ൌ ݂ሺݔ௜ሻ. For simplicity, we define ݂ሺݔ௜ሻ as a 
linear function: 
݂ሺݔ௜ሻ ൌ൏ ݓ௜, ݔ௜ ൐ ൅ܾ     (4) 
where ݓ௜ is the coefficient vector of the linear function and ܾ is the bias. A major 
goal of the SVM regression algorithm is to minimize the loss function, which are a 
combination of prediction error defined by ߦ௜ and the magnitude of the coefficient C in the 
following equation: 
݈݋ݏݏ௠௜௡ ൌ ԡ௪ԡଶ ൅ ܥ ∑ ߦ௜௠௜ୀଵ               (5) 
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with the constraint: 
|ݕ െ ሺݓ߶ሺݔ௜ሻ ൅ ܾሻ| ൌ ߦ௜   (6) 
Here the training vectors ݔ௜ are mappedointo a high dimensional space by a kernel 
function ߶. In the end, SVM regression is expected to find a linear correlation between the 
actual activity and this high dimensional space ߶ሺݔ௜ሻ. For this study, we have implemented a 
linear kernel. C is a penalty parameter of the error term that controls the weight between two 
terms in the SVM optimization process. 
In many cases, the biological activity may contain small errors or the kernel function 
may not be capable of perfectly representing the training compounds in a simplified manner. 
In order to penalize against complex models, we have added a slack variable   to the loss 
function 123 in addition to the penalty parameter C. It is a threshold of prediction error for any 
compound's activity before the algorithm is penalized for the poor prediction. Beyond this 
threshold the algorithm is penalized by the value of ߦ௜ െ ߝ . When combining the SVM 
optimization process defined in Equation 7 with this slack variable, the following loss 
function is obtained: 
݈݋ݏݏ௠௜௡ ൌ ԡ௪ԡଶ ൅ ܥ ∑ ൜
0 ݂݅ ߦ௜ ൑ ߝ 
ߦ௜ െ ߝ ݂݅ ߦ௜ ൐ ߝ
௠௜ୀଵ     (7) 
The nature of SVM regression requires one to specify the values of C and ߝ  a priori 
since it is not known beforehand which values may work the best for one particular dataset; 
thus, a parameter tuning must be performed. The goal is to identify optimal values of C and ߝ 
in that the model can give the best prediction for the test set. For this study we have chosen to 
use a "grid-search" scheme on C and ߝ. It starts with randomly choosing a training/test set 
split of the dataset, conducting a grid-search using those compounds, then fine-tuning the 
complete dataset over the parameter value ranges that exhibited the best results. Our coarse 
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grid-search of C varied from 50 to 1000 with an increment of 80, and ߝ varied from 0 to 1.5 
with an increment of 0.15. Once the best parameter ranges were found, a fine-tuned search 
was carried out to search values within 200 and 0.3 units for C and ߝ, with the steps of 5 and 
0.05 respectively. 
2.2.8. Applicability Domain 
Ideally, a QSAR model can predict the target property for any compound for which 
chemical descriptors can be calculated. However, since kNN QSAR modeling predicts test 
set compound activities by interpolating those of the nearest neighbor compounds in the 
training set, a special applicability domain, or similarity threshold, should be introduced to 
avoid extreme model extrapolation by making predictions for compounds that are 
significantly dissimilar to members of the training set 16. In order to measure similarity, each 
compound is represented by a point in the M-dimensional descriptor space (where M is the 
total number of descriptors selected in the descriptor pharmacophore) with the 
coordinates ሺ ௜ܺଵ, ௜ܺଶ,ڮ , ௜ܺெሻ , where ௜ܺௗ  are the values of individual descriptors for 
compound i. The similarity between any two molecules is characterized by the Euclidean 
distance between their representative points. The Euclidean distance between two points i 
and j in M-dimensional space can be calculated as follows: 
݀௜௝ ൌ ඥ∑ ሺ ௜ܺ௞ െ ௝ܺ௞ሻଶ௞   (8) 
Compounds with the smallest distance between them are considered to have the 
highest similarity. The distribution of pair wise compound similarity in the training set is 
analyzed to produce an applicability domain threshold, ܦ், as follows: 
ܦ் ൌ ݕത ൅ ܼߪ     (9) 
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Here, ݕത  is the average Euclidean distance ݀௜௝  of the k nearest neighbors of each 
compound within the training set, σ is the standard deviation of these Euclidean distances, 
and ܼ is an arbitrary parameter to control the significance level. Based on previous studies in 
our lab, we set the default value of ܼ as 0.5, which formally places the boundary for which 
compounds will be predicted at one-half of the standard deviation (assuming a Gaussian 
distribution between k nearest neighbor compounds in the training set). Thus, if the distance 
of an external compound from at least one of its nearest neighbors in the training set exceeds 
this threshold, the prediction is considered unreliable. 
2.2.9. External Validation and Y-Randomization Test  
It is critical to validate a QSAR model by assessing its prediction accuracy for an 
external set which was not used in model building. We have conducted extensive external 
validations on both kNN and SVM models using two external datasets as described above. In 
both cases, the prediction accuracy had to satisfy the following conditions: 
ܴଶ ൐ 0.60                  (10) 
ሺܴଶ െ ܴ଴ଶሻ/ܴଶ ൏ 0.10  and 0.85 < k < 1.15   (11) 
where ݇  is the slope of the regression lines (predicted versus observed activities) 
through the origin. The predictions were generated using consensus models and the model 
coverage for each external dataset was calculated as well (vide infra). 
Our previous experience suggests that more accurate results are obtained by 
consensus, i.e., by averaging predictions from multiple QSAR models 123,124 Thus, the 
consensus QSAR prediction scheme was applied to all validation set compounds found 
within individual applicability domains of models used in consensus prediction. The 
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averaged predicted activity, the fraction of models that predict the activity and the variance 
of the prediction values have been calculated for each compound. 
In addition to external validation, Y-randomization test was carried out to establish 
model robustness. The test consists of rebuilding models using shuffled activities of the 
training set and evaluation of such models’ predictive accuracy in comparison with the 
original model. It is expected that models obtained for the training set with randomized 
activities should have significantly lower values of statistical parameters such as ݍଶ, ܴଶ, ܴ଴ଶ, 
etc. for training and, especially, test sets. Therefore, if most QSAR models generated in the 
Y-randomization test exhibit relatively high values of the statistical parameters for both 
training and test sets, it implies that a reliable QSAR model cannot be obtained for the given 
dataset. This test was applied to all QSAR approaches in this study and was repeated twice 
for each division. 
2.2.10. QSAR-based Virtual Screening  
As illustrated in the workflow of Figure 2.1, the rigorously validated QSAR models 
were employed for virtual screening. A global applicability domain was applied first in the 
complete descriptor space in order to filter out compounds that differed in their structure 
from the modeling set compounds. All 59 known inhibitors were exploited as the probes 
during the calculation. During the consensus prediction, the results were accepted only when 
the compound was found within the applicability domains of more than 50% of all models 
used in consensus prediction and the standard deviation of estimated means across all models 
was small. Furthermore, we restricted ourselves to the most conservative applicability 
domain for each model using ܼ௖௨௧௢௙௙ ൌ 0.5. 
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2.2.11. Principle Component Analysis (PCA) 
The PCA calculations were carried out using the entire set of MolconnZ4.05 
descriptors calculated for all compounds in the modeling set, two external validation sets, 
and virtual screening hits. The purpose of these calculations was to provide a visual means to 
compare relative positioning of the three data sets plus hits in the chemistry (i.e., 
multidimensional descriptor) space. The programs in the kernlab package 125 of the latest 
version of R2.8.0 126 were employed. Using PCA, the distribution of compounds in the 
original descriptor space could be visualized in a lower dimensional space, normally in the 
3D space of the first three principal components. 
2.2.12. Experimental Validation of Screening Hits 
Recombinant HDACs were purchased from either BIOMOL International (Plymouth 
Meeting, PA) or PBS Bioscience (San Diego, CA). The inhibitor activity was determined 
using an HDAC Fluorimetric Assay/Drug Discovery Kit from BIOMOL International 
according to manufacturer’s protocols. Briefly, reactions were set up in 96-well plates in a 
total of 50 μL HDACs assay buffer (50 mM Tris-HCl of pH 8.0, 137 mM NaCl, 2.7 mM KCl, 
1 mM MgCl2) containing HDAC1 (or HDAC6), testing compounds, and HDACs substrate. 
Trichostatin A served as the positive control and the vehicle, 1% DMSO, was employed as 
the negative control. The reaction was initiated by the addition of HDACs substrate at room 
temperature and lasted for 30 minutes. The final concentration of HDACs substrate was 
around its apparent Km; For HDAC1, 50 μM of substrate was used and for HDAC6, 10 or 30 
μM was used. The reaction was then stopped by adding 50 μL of Fluor de Lys (TM) Assay 
Developer and the mixture had been incubated for another 15 minutes at room temperature. 
The Assay Developer was added to stop the deacetylation reaction and produce fluorophore 
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from the deacetylated substrate. The fluorophore can be excited at 360 nm and emits light at 
460 nm. The relative fluorescence is read by a FlexStation II plate reader (Molecular Devices, 
Sunnyvale, CA). Initial screening concentrations were 100 uM with samples with over 50% 
inhibition further tested in dose response assays. The raw data (relative fluorescence units) 
were plotted as a function of the molar concentration of test compounds (in logarithm) and 
fitted to the three-parameter logistic function to calculate pIC50 by Prism 5.0 (GraphPad 
Software, La Jolla, CA). Here the pIC50 is defined as the logarithm of molar concentration of 
test compound that inhibits the fluorescence production by 50%. 
2.3. Results and Discussion 
2.3.1. kNN QSAR Regression Modeling 
The statistical results for the 10 best kNN QSAR models using MZ4.05 descriptors 
are summarized in Table 2.2. 1385 models, that is, ~50% of the total number of models 
generated, were accepted for they had both the LOO-CV q2 values for the training set and 
linear fit predictive ܴଶ values for the test set greater than 0.60. Seventy models with ݍଶ/ܴଶ 
values exceeding 0.75/0.75 were retained for consensus prediction. As shown in Figure 2.2A, 
the most predictive model afforded ݍଶ value of 0.81 for 34 compounds and ܴଶ values of 0.80 
for 16 compounds (RMSE = 0.38). For models built with MOE descriptors, the best ݍଶ/ܴଶ 
values were as high as 0.70/0.76 (RMSE = 0.45, cf. Figure 2.2C). The statistics of the top 10 
kNN/MOE models are summarized in Table 2.3. Similarly, thirteen models with ݍଶ/ܴଶ 
values exceeding 0.70/0.70 were employed for consensus prediction. These results suggest 
that the intrinsic structure-binding affinity relationships exist for HDAC1 inhibitors that can 
be best described by kNN models using both independent descriptor sets. 
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To ensure that the models did not merely capture noise, Y-randomization test was 
carried out as described above. As expected, the best models using MZ4.05 descriptors and 
shuffled activities only produced training set models with q2 of less than 0.40 (data not 
shown). Also the best kNN/MOE models using randomized activity only yielded the ݍଶ/ܴଶ 
values less than 0.40/0.40. These results confirmed that kNN models uncovered non-spurious 
correlations between both MolConnZ and MOE descriptors and compound inhibition activity. 
2.3.2. SVM QSAR Regression Modeling 
The statistical results for top 10 SVM QSAR models using MZ4.05 descriptors are 
summarized in Table 2.4. The best ݍଶ, ܴଶ, ܴ଴ଶ, values are as high as 0.93, 0.87 and 0.62, 
respectively. Figure 2.2B shows the best predictive model with ݍଶ  value of 0.94 for 34 
compounds and ܴଶ values of 0.81 for 16 compounds (RMSE = 0.51). For this model, the 
optimum values of C and ε were found to be 200 and 0.30, respectively. The value of 0.30 is 
reasonable for ε, because it is common to observe a 0.30 log unit error in enzyme/inhibition 
assays. Seventeen models of SVM/MZ4.05 combination with ݍଶ/ܴଶ values exceeding 
0.70/0.70 were retained for consensus prediction. In comparison, the performance of 
SVM/MOE combination was much less satisfactory. The best ܴଶ and ܴ଴ଶ value were as low 
as 0.64 and 0.53, respectively. Meanwhile, the number of acceptable models was drastically 
small. Thus, we did not employ SVM/MOE models for consensus prediction because of their 
poor accuracy (ܴ௧௘௦௧ଶ ൏ 0.75). 
To ensure that our SVM QSAR modeling was based on non-spurious 
structure/activity relationship, the inhibition activities were randomly shuffled for the 
training set and all calculations were repeated following exactly same protocol. The best 
models using randomized data only produced a  ܴଶ of 0.20 for the test set (data not shown), 
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suggesting that the high ܴଶ is not due to a chance correlation and our accepted SVM models 
were robust. 
2.3.3. Model Validation using External Datasets 
Both kNN and SVM QSAR models validated by test sets were used to predict the 
inhibition activity of two external validation sets (Tables 2.5 and 2.6). For consensus 
prediction we have employed 70 best kNN/MolConnZ models and 17 best SVM/MolConnZ 
models. For the external validation set 1, the data reported in Table 2.7A-C suggests that both 
kNN/MolConnZ and SVM/MolConnZ consensus models afforded reasonable results. Figure 
2.3 shows the correlation between experimentally measured and calculated activities of the 
external validation set 1 using three types of consensus models. Among the three, 
kNN/MolConnZ consensus models showed the best performance, with the ܴଶ of 0.87, ܴ଴ଶ of 
0.78 and RMSE of 0.59 for 8 compounds (BC-2-83 was found to be out of applicability 
domain of most kNN/MolConnZ models, cf. Table 2.7A). For 7 out of these 8 compounds, 
the predicted activities were within a reasonable range of 0.5 log unit. However, one 
compound corresponding to the black circle in Figure 2.3A was predicted with a large error (> 
1.0 log unit). A possible explanation for this observation is that this compound is the only 
one that contains two metal binding groups but no aromatic group. The latter is known to be 
important for the inhibition activity as suggested by many SAR studies15. The 
SVM/MolConnZ models performed slightly worse than the kNN/MolConnZ models, despite 
the fact that the SVM/MolConnZ combination had better performance for both training and 
test sets. The ܴଶ and ܴ଴ଶ of consensus prediction by SVM/MolConnZ models was 0.71 and 
0.68, respectively, for all 9 compounds (Figure 2.3B). Interestingly, kNN/MOE models 
showed much worse statistics for the external set 1: The ܴଶ  was 0.60 but the ܴ଴ଶ was only 
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0.25, and the RMSE was as high as 0.84 for 9 compounds (Figure 2.3C). Though satisfying 
eq 10, the statistics is not acceptable for kNN/MOE combination because the value of 
ሺܴଶ െ ܴ଴ଶሻ/ܴଶ (cf. eq. 11) is too large. Thus, we did not apply this combination to external 
validation set 2 and the later virtual screening. These results demonstrate the critical need of 
external validation set for evaluating the model robustness as well as illustrate a known 
phenomenon that training set accuracy does not necessarily correlate with model 
performance for external data sets 127.  
We have used the statistical index ܴ଴ଶ ( eq 3) and RMSE to evaluate model robustness 
in addition to the correlation coefficient ܴଶ. Traditionally, the latter is considered as a good 
indicator of predictive power of models. In fact, this coefficient reflects the similarity in 
relative ranking of compounds based on actual vs. the calculated activities rather than the 
accuracy of the activity prediction. On the other hand, ܴ଴ଶ directly compares the actual vs. 
predicted activities because it estimates the fitness of the data to the line with the intercept of 
zero and the slope of one. It thus gives a better measurement of how well the model predicts 
compounds' activities, which is why we advocated its use as an important model accuracy 
metric in our previous studies 128,129. The above case of kNN/MOE consensus prediction 
illustrates the difference between ܴଶ  and ܴ଴ଶ, as underscored by eq 11. This suggests that ܴ଴ଶ 
and RMSE are also important indicators of model robustness especially when the size of the 
test set is small. 
External validation set 2 contains HDAC1 inhibitors of different chemical scaffolds, 
therefore it can be considered as a real test of the predictability of QSAR models. Besides, it 
is fully independent from the 59 compounds of modeling set. Among all 54 inhibitors, 41 
could be predicted by the majority of consensus models and the results are summarized in 
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Table 2.6. For both kNN/MolConnZ and SVM/MolConnZ models, 28 out of these 41 
compounds had the errors of their predicted activities of less than 1.0 log unit. The RMSE 
was 0.86 for kNN/MolConnZ models, 0.92 for SVM/MolConnZ models and 0.86 for the 
consensus averaged value of all models combined. It was shown in our recent study that 
consensus models afford higher prediction accuracy for the external validation data sets with 
the highest space coverage as compared to individual constituent models 130. The same 
pattern was observed in the present study as well. The RMSE of the consensus score is 
superior to constituent SVM/MolConnZ models and on par with constituent kNN/MolConnZ 
models. In addition, there is only one compound with a relatively large margin of error (> 1.5 
log unit) when the consensus prediction is used. For individual constituent models, however, 
there are three compounds with similarly large errors of prediction with kNN/MolConnZ 
models and five compounds with SVM/MolConnZ models. Compounds 6e_AE, 17j_AE and 
17d_AE are among those with a large margin of error (ca. 1.5 log unit). They could be 
analyzed to explore the reasons for QSAR prediction errors. It should be noted that both kNN 
and SVM methods converged on these three compounds and showed the similar trend of 
errors (cf. Table 2.6). It is feasible that these compounds could be the activity outliers 
because of experimental errors. 
2.3.4. QSAR-based Virtual Screening 
Based on the results of model validation in the previous section, only 
kNN/MolConnZ and SVM/MolConnZ approaches were used for virtual screening due to 
their good performances on both modeling set and two external validation sets. Therefore, 70 
kNN/MolConnZ models and 17 SVM/MolConnZ models with defined applicability domains 
were applied concurrently towards virtual screening of our chemical libraries. Prior to the 
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consensus predictions, our initial filtering using global applicability domain of modeling set 
reduced the total number of compounds from ca. 9.5×106 to 3.2 ×103. The predicted activities 
from individual models were averaged to yield a consensus pIC50 value. Finally, 45 hits 
were selected to be of high predicted activities (6.68-7.43 for kNN/MolConnZ and 5.94-7.77 
for SVM/MolConnZ) and structural uniqueness. 
As expected, the predicted activities of HDAC1 inhibitors by two different types of 
models were not identical but differed by less than 1.0 log unit in most cases. For each of the 
kNN/MolConnZ and SVM/MolConnZ consensus hit, we searched published literature to find 
out if any of these compounds was reported independently as HDAC1 inhibitors. We found 
that compounds #34 and #40 have been indeed cited as potential HDAC1 inhibitors (cf. 
Table 2.8) 131,132. Both compounds are structurally similar to SAHA which is a strong 
HDAC1 inhibitor included in the modeling dataset. Furthermore, compounds #2, #28 and 
#35 were reported to have anti-inflammatory activity that is commonly associated with 
HDAC1 inhibition, which may be viewed as indirect evidence in support of the prediction. 
In general, as shown in Appendix II, most hit compounds contain long aliphatic chain 
that permits the chelating group to reach the bottom of the binding pocket and coordinate 
with the zinc ion. An aromatic group at the opposite end of the chelating group is supposed to 
enhance inhibition through hydrophobic interaction with the capping region of the active site. 
These are actually the common structural features known for HDAC1 inhibitors. Furthermore, 
many additional features are also found in the hit compounds, such as triple bonds 
(compounds #2, #28) and 3-bromo-4-hydroxy-phenyl group (compounds #11, #14), which 
exist in HDAC1 inhibitors such as Oxamflatin and Psammaplin A 72,93. It should be pointed 
out that these functional groups were not present in the original modeling dataset, which 
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demonstrates the ability of QSAR-based virtual screening to uncover computational hits with 
novel chemical features. The existence of unsaturated bonds in the linker region between the 
chelating group and the cap region has been observed frequently among many screening hits. 
However, this feature is only found in TSA (that was included in the training set), which has 
the highest inhibitory activity (pIC50) of 8.46. Since this feature is not often seen in other 
known inhibitors, this observation should be additionally explored for lead optimization in 
future studies. The unsaturated bonds in the linker region likely restraint the conformational 
freedom of the long aliphatic chain, which could help decrease the unfavorable entropy 
change during the inhibitor binding. 
In recent years, our group has explored the hit identification strategy that combines 
rigorously validated QSAR models and virtual screening 123,133-137. It has been shown that our 
current workflow is capable of identifying potent compounds of novel chemical scaffolds as 
compared to modeling set compounds, especially in the cases of anticonvulsant agents 124 and 
D1 dopaminergic antagonists 123. There are several aspects of our current protocol for QSAR 
based virtual screening that need to be highlighted. First, models built using variable 
selection approaches only include a subset of all descriptors, i.e., those identified as 
significant in the process of model optimization. This feature of individual models coupled 
with the applicability domain threshold could result in mis-annotation of some structurally 
diverse molecules in the virtual screening databases as inactives. Consensus prediction 
scheme provides a viable solution to this problem because each model has its own limitations 
but the ensemble of models covers much greater chemical feature space and consequently, 
could identify putatively active compounds of greater chemical diversity. Second, the 
dependent variable in the current dataset is the continuous value of inhibition potency. 
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During model building, all descriptors with constant values have been eliminated and only 
the descriptor types that are used in predictive QSAR models were retained. Obviously, 
descriptors with the same values for all compounds in the training set could not contribute to 
the QSAR model that always correlates changes in chemical structure to changes in 
biological activity. However, there is a possibility that some of these eliminated descriptors 
(that apparently describe chemical features common to all inhibitors) are essential for 
discriminating inhibitors from non-binders. Thus, if these descriptors are not considered in 
virtual screening there is a probability of identifying false positives. To circumvent this 
problem, we have applied global applicability domain in the preliminary screening step to 
filter out compounds that are generally structurally dissimilar from the modeling set 
compounds. 
2.3.5. Experimental Validation 
Four structurally diverse hits with moderate to high predicted activity were selected 
from the 45 consensus virtual screening hits for experimental validation taking into account 
commercial availability. To our satisfaction, compounds #2, #28 and #35 were confirmed to 
be μM inhibitors against HDAC1 (Figure 2.4 and Table 2.8). Among them, compound #28 
showed the best inhibitory activity with pIC50 values of 6.00. The fourth compound, #47, did 
not inhibit HDAC1 at the concentration of 300 μM. However, interestingly enough this 
compound was later identified by us as a selective inhibitor for HDAC6, a class II HDACs 
enzyme. At the concentration of 30 μM, #47 inhibited about 42.6% of HDAC6 activity, 
while other three compounds (#2, #28 and #35) showed 105%, 101%, and 99% inhibition, 
respectively. Moreover, it is of notice that the chelating functional group in #47 is unique 
compared to other hits. This observation could be further explored for rational design of 
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class/subtype selective HDACI. Our current screening libraries include the WDI database, 
which contains approximately 59,000 approved or investigational drugs in the world. It has 
become a practical strategy to screen this database during the early phase of drug 
development. The hits identified in this library could be placed on the fast track and avoid the 
risk and length of preclinical/clinical studies. In our study, two hits that were submitted for 
experimental validation were actually identified from the WDI database. Compound #35 is 
Bufexamac, a marketed drug used for joint and muscular pain while the compound #47 is 
Roxatidine, a widely used competitive H2 receptor antagonist for the treatment of peptic 
ulcer. These two hits will enrich the candidates pool of HDACI and potentially facilitate the 
pipeline of drug development—a strategy known as repurposing 138. 
2.4. Conclusions 
We have employed a combinatorial QSAR approach to generate models for 59 
chemically diverse compounds tested for their inhibitory activity against HDAC1. The SVM 
and kNN QSAR methods were used in combination with MolConnZ and MOE descriptors 
independently to identify the best approach with the highest external predictive power. 
Highly predictive QSAR models were generated with kNN/MolconnZ and SVM/MolconnZ 
approaches. Rigorously validated QSAR models were then used to screen our in-house 
database collection of a total of over 9.5 million compounds. This study resulted in 45 
consensus hits that were predicted to be potent HDAC1 inhibitors. Two hit compounds that 
were not present in the original dataset were nevertheless reported recently as HDAC1 
inhibitors 131,132. Four hit compounds with interesting chemical features were purchased and 
experimentally validated. Three of them were confirmed to have inhibitory activities to 
HDAC1 (Class I HDACs) and the best activity obtained was IC50 of 1.00 μM. The fourth 
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compound was later identified to be a selective inhibitor to HDAC6, a Class II HDACs. 
Moreover, two of the confirmed hits are marketed drugs which could potentially expedite 
their development as anticancer drugs acting via HDAC1 inhibition. This study illustrates 
that validated QSAR models have the ability of identifying novel structurally diverse hits by 
the means of virtual screening. We believe that the technology described in this study could 
be used for data analysis and hypothesis generation in many computational drug discovery 
studies. 
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Tables and Figures 
 
 
Figure 2.1 The workflow of QSAR model building, validation and virtual screening as applied to 
HDAC1 inhibitors. The specific data for kNN/MolConnZ modeling are used for illustration purpose. 
59 HDAC1 
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Figure 2.2 Comparison of actual vs. predicted inhibition efficiency (pIC50) values for the best QSAR 
model for each combination of statistical modeling approach and descriptor type. A. For 
kNN/MolConnZ method (ݍଶ = 0.81, ܴଶ = 0.80). The training set contains 34 compounds (dark circles) 
and test set contains 16 compounds (empty circles). B. For SVM/MolConnZ method (ݍଶ = 0.94, ܴଶ = 
0.81). The training set contains 34 compounds (dark circles) and test set contains 16 compounds 
(empty circles). C. For kNN/MOE models (ݍଶ= 0.70, ܴଶ  = 0.76). The training set contains 35 
compounds (dark circles) and test set contains 15 compounds (empty circles). 
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Figure 2.3. Comparison of actual vs. predicted inhibition efficiency (pIC50) values for the best QSAR 
model as applied to the external validation set 1. A. For the kNN/MolConnZ method (ܴଶ= 0.87, 8 
compounds). The compound with the black circle is the possible structural outlier that has been 
discussed in the results. B. For the SVM/MolConnZ method (ܴଶ = 0.71, 9 compounds). C. For the 
kNN/MOE method (ܴଶ = 0.60, 9 compounds). 
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Figure 2.4. The full dose response curve for hit compounds #2 and #28 in human HDAC1 inhibition 
assay. 
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Table 2.2. The Statistics for Ten Best kNN Models for All Test Sets Using MolConnZ Descriptors. 
Model 
No. 
Training 
Set 
Size 
Test 
Set 
Size 
Descriptor
No. 
Nearest 
Neighbor No. 
ݍଶ 
(Training 
Set) 
ܴଶ 
 (Test 
Set) 
ܴ଴ଶ 
(Test 
Set) 
RMSE 
(Test 
Set) 
1 45 5 22 1 0.80 0.87 0.69 0.27 
2 41 9 20 2 0.80 0.81 0.77 0.49 
3 34 16 14 1 0.81 0.80 0.76 0.38 
4 35 15 12 2 0.82 0.79 0.70 0.48 
5 42 8 14 1 0.81 0.79 0.73 0.35 
6 34 16 26 1 0.80 0.79 0.78 0.37 
7 28 22 36 1 0.83 0.77 0.67 0.42 
8 40 10 12 2 0.81 0.77 0.77 0.43 
9 29 21 20 1 0.79 0.77 0.76 0.47 
10 34 16 16 1 0.79 0.76 0.74 0.40 
 
Table 2.3. The Statistics for Ten Best kNN Models for All Test Sets Using MOE Descriptors. 
Model 
No. 
Training 
Set 
Size 
Test Set 
Size 
Descriptor
No. 
Nearest 
Neighbor 
No. 
ݍଶ 
(Training 
Set) 
ܴଶ 
 (Test 
Set) 
ܴ଴ଶ 
(Test 
Set) 
RMSE 
(Test 
Set) 
1 35 15 14 1 0.70 0.76 0.76 0.45 
2 35 15 12 1 0.73 0.75 0.75 0.46 
3 35 15 30 1 0.73 0.75 0.75 0.47 
4 32 18 18 1 0.81 0.74 0.63 0.49 
5 35 15 16 1 0.72 0.74 0.74 0.48 
6 35 15 18 1 0.71 0.74 0.73 0.48 
7 35 15 24 1 0.72 0.73 0.73 0.48 
8 31 19 22 1 0.70 0.72 0.69 0.53 
9 35 15 14 1 0.77 0.71 0.70 0.51 
10 28 22 12 1 0.79 0.70 0.70 0.51 
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Table 2.4. The Statistics for Ten Best SVM Models for All Test Sets Using MolConnZ Descriptors. 
Model 
No. 
Training Set 
Size 
Test Set 
Size C Ε 
ݍଶ 
(Training 
Set) 
ܴଶ 
 (Test 
Set) 
ܴ଴ଶ 
(Test Set) 
RMSE 
(Test Set)
1 37 13 200 0.40 0.93 0.87 0.62 0.36 
2 37 13 200 0.50 0.91 0.86 0.66 0.34 
3 37 13 200 0.35 0.94 0.85 0.59 0.38 
4 37 13 200 0.55 0.90 0.85 0.67 0.34 
5 37 13 200 0.60 0.89 0.84 0.68 0.33 
6 34 16 200 0.30 0.94 0.81 0.76 0.51 
7 35 15 200 0.30 0.95 0.72 0.66 0.49 
8 39 11 200 0.30 0.94 0.72 0.71 0.51 
9 29 21 200 0.30 0.96 0.71 0.66 0.49 
10 35 15 200 0.35 0.94 0.71 0.66 0.49 
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Table 2.7Consensus Predictions for the External Validation Set 1 by A) kNN/MolConnZ B) 
SVM/MolConnZ, and C) kNN/MOE models 
A. Comp.ID Experimentally measured 
Total models 
used 
Consensus 
prediction 
std. of 
prediction 
BC-4-86 5.33  70/70 5.38  0.65  
BC-6-38 6.40  70/70 6.54  0.29  
BC-2-48 4.00  70/70 4.42  0.25  
YChdac0457.52  67/70 7.08  0.22  
Yc-II-88 8.10  70/70 7.64  0.35  
BC-4-56 5.96  70/70 6.44  0.27  
BC-4-4 5.30  69/70 6.14  0.30  
BC-4-2 5.00  50/70 6.13  0.12  
BC-2-83* 6.00  N/A N/A N/A  
RMSE 0.59        
ܴଶ 0.87    
ܴ଴ଶ 0.78       
*This compound was found to be out of applicability domain of kNN/MolConnZ models. 
B. Comp.ID Experimentally measured 
Total models
used 
Consensus 
prediction 
std. of 
prediction 
Ag-b-57 7.10  17/17 7.19  0.20  
AG-biph-
38 7.10  17/17 6.68  0.14  
AG-biph-
40 5.52  17/17 5.74  0.10  
BC-2-45 4.00  17/17 4.61  0.13  
BC-3-22 6.38  17/17 5.54  0.19  
BC-4-84 6.10  17/17 6.16  0.14  
BC-4-86 5.33  17/17 5.73  0.13  
BC-5-44 6.05  17/17 6.83  0.19  
YC-03065 6.52  17/17 7.09  0.15  
RMSE 0.52       
Rଶ 0.71   
R଴ଶ 0.68       
 
C. Comp.ID Experimentally measured 
Total models 
used 
Consensus 
prediction 
std. of 
prediction 
AG-biph-08 7.10 13/13 7.36 0.27 
Yc-II-84 7.26 13/13 7.10 0.00 
BC-1-30-2 4.00 13/13 4.15 0.38 
BC-4-54 6.26 13/13 5.00 0.41 
BC-4-55 6.70 13/13 5.45 0.42 
BC-4-93 5.77 13/13 5.96 0.45 
BC-6-26 7.30 13/13 5.93 0.67 
BC-6-38 6.40  12/13 5.76 0.57 
BC-6-40 6.60 13/13 5.77 0.54 
RMSE 0.84       
ܴଶ 0.60   
ܴ଴ଶ 0.25       
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Chapter 3. Comparative Studies of the Structural Models versus the X­
ray Crystal Structures of Human β2 Adrenergic GPCR in terms of 
applications to virtual screening 
(This chapter has been submitted to Proc Natl Acad Sci) 
3.1. Introduction  
Structure based drug discovery (SBDD) has become a major strategy in identifying 
novel leads for important biological targets. SBDD enabled well documented discovery of 
several approved drugs, e.g. dorzolamide and imatinib. Typically, the 3D structures of 
biomolecules obtained by the means of X-ray crystallography and NMR spectroscopy are 
needed for the purpose of virtual screening (VS), whose performance is strongly affected by 
the quality of biomolecular structure, especially with respect to binding site description. 
When no experimentally determined structures are available, theoretical models based on 
either homology or de novo modeling approaches are employed instead 35-38. However, there 
were some debates about the accuracy and applicability of theoretical models 38-44 in SBDD. 
In principle, the success of homology modeling is typically measured by how close the 
models could reproduce experimental structures, which implies that the latter are inherently 
more appropriate choice for SBDD applications. 
G-protein coupled receptors (GPCRs) is a protein family where theoretical models 
have been used widely because of GPCRs’ importance as targets for many drugs, on one 
hand, and the lack of experimental structures, until recently, on the other hand. The 
experimental effort to characterize the 3D structure of GPCRs were seriously hindered by 
membrane related issues 176. A large number of theoretical models have been employed in 
 47 
 
the past decades 177-180 for VS often yielding reasonable results 181-184. However, it was fully 
expected that the availability of the experimental structure of any GPCR would substantially 
enhance the efficacy of SBDD efforts. Thus, the recent publications of the crystal structure of 
human beta-2 adrenergic GPCR (β2AR)45-47 cleared the way for the validation of previous 
theoretical models, as well as provided critical data for building homology based models of 
other GPCRs as the most obvious structural template.  
It has been shown that human β2AR features a structurally conserved rhodopsin-like 
7TM core, but there exist novel structural features that had not been identified previously. It 
remained unclear as to whether these structural divergences would affect the outcome of VS 
studies. Dissimilarity of computational models relative to the crystal structure should lead to 
relatively poorer performance of the former in docking and scoring of known ligands; 
however, this general expectation should not necessarily be regarded as a law. One should 
take into account that some of the computational models are actually manually refined with 
known medicinal chemistry data and therefore, there is at least a possibility that theoretical 
models may be even more suitable for drug discovery by VS than the crystal structure. 
In this study, we have addressed this, both scientifically and pragmatically, important 
question directly. We have compared the x-ray structure of β2AR vs. several previously built 
theoretical models in terms of their respective ability to recover known β2AR ligands (both 
agonists and antagonists) from a large external compound library in VS experiments. None of 
these models were generated in our group to ensure objective and unbiased comparisons. 
Furthermore, although our group has developed both scoring functions 185 and virtual 
screening protocols 186, for the same reasons we restricted ourselves to using several popular 
commercial docking and scoring tools developed elsewhere. Thus, by design, this study 
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lacked any user biases concerning preferred homology models or most familiar 
computational tools to emulate the situation that is most commonly faced by the majority of 
molecular modeling practitioners both in academia and industry.  
There have been previous studies on comparing homology models among themselves 
or even with the crystal structure but to the best of our knowledge nobody asked the question 
poised herein as directly as we did.  For instance, Bissantz et al 40 employed three human 
GPCRs models derived from rhodopsin for virtual screening using multiple docking 
programs and scoring functions.  Their work proved that homology models are suitable for 
VS but there was no comparison to the crystal structure. After the crystal structure of human 
β2AR was published, Costanzi reported a pioneering study 187 where carazolol was docked 
both into two rhodopsin-based homology models of human β2AR as well as into the X-ray 
structure. The models afforded high accuracy of the docking poses, especially after 
incorporating the biochemical data to adjust the orientation of the binding pocket residues. 
However, this study was limited to the pose prediction only using in-house models. Most 
recently, Fan et al 39 reported that for 27 out of the 38 protein targets, the consensus 
enrichment for multiple homology models was better than or comparable to that of both the 
holo- and the apo- X-ray structures. However, that study was focused on soluble protein 
targets and used a single homology model building tool that employed x-ray characterized 
structural templates. In contrast, all models employed herein were built before the β2AR 
crystal structure became available as possible template. 
We have carried out a systematic study on a large collection of published human 
β2AR theoretical models and evaluated their structural accuracies and virtual screening 
performances in comparison with two crystal structures, i.e., 2RH1 (released by the RCSB 
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Protein Data Bank (PDB) on Oct. 30, 2007) and the latest, 3D4S (released by RCSB PDB on 
Jun. 17, 2008). Two other structures, 2R4R and 2R4S, were not employed because they came 
from the same source as 2RH1 but with lower resolutions. As shown in Table 3.1, we 
collected eight independently published theoretical models of human β2AR including both 
apo and holo structures. Both agonist and antagonist bound models were included to account 
for any structural features associated with functional activity. 
Surprisingly, we found that some of the theoretical models displayed better VS 
performances than the x-ray structure. This study by no means undermines the extreme 
significance of the x-ray structure of β2AR as well as other GPCRs 45,188-192 in understanding 
the intricate details of GPCR structure in relation to its function nor in the significance of x-
ray structures for SBDD. Nevertheless, it most certainly testifies to the importance of 
intelligent homology modeling approaches especially those incorporating comprehensive 
medicinal chemistry knowledge of receptor ligands for structure based virtual screening. 
3.2. Methods 
3.2.1. Structural Similarity Analysis. 
 In addition to 2RH1, the crystal structure of bovine rhodopsin (PDB ID: 1U19) chain 
B was also included in the analysis since it was used as major template for all β2AR 
homology models. The structural similarity was assessed in three aspects, i.e. the accuracy of 
the boundary definitions for each transmembrane (TM) helixes, the backbone root-mean-
square-deviation (RMSD) for TM regions, and the Cα RMSD of the binding pocket residues. 
The numbering of amino acids followed the conventions set by Weinstein et al 193. The 
highly conserved residues embedded in each TM region were used as anchors for the 
alignment. Each theoretical model was structurally aligned against 2RH1 or 1U19 by 
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individual TM helix as well as the whole TM bundle. The RMSDs were calculated using the 
entire lengths of the corresponding segments of 2RH1. 
3.2.2. Molecular Docking Calculation.  
To compile the screening database, we used 58 known antagonists of human β2AR 
reported in DrugBank 194 and GLIDA195 databases as seeds (cf. Table 3.3 of Supporting 
Information). All antagonists have sub-micromolar potency and can be found in additional 
external databases, such as PDSP Ki 196, PubChem (PubChem, 2007) and KEGG 197. A few 
of them are β2AR specific (e.g. butoxamine and aminoflisopolol) while others can act on 
both β1AR and β2AR. For comparison, thirteen agonists of human β2AR found in the 
DrugBank database were used in virtual screening experiments as well. In order to establish a 
reasonable decoy dataset for virtual screening, the World Drug Index (WDI) database 98 
(version 2004) was used since most its entries are drug-like compounds. The original 
collection  of 59,000 molecules was first cleaned by removing metals, salts and fragments, 
then filtered to eliminate unqualified compounds according to Lipinski's rule of five and later 
extensions of this rule 198. The remaining collection of ca. 38,000 compounds was further 
reduced to a diverse subset of 374 compounds using MOE2007.09. In addition, 12 binding 
decoys with similar chemical scaffolds but poor binding affinity (Ki > 10µM) were selected 
from the PDSP Ki database and merged into the WDI diverse subset. In the end, 58 human 
β2AR antagonists and 13 agonists were seeded amongst 386 decoys separately to constitute 
two different screening databases. 
We employed three popular docking programs, i.e. Glide4.01, AutoDock4.0 and 
eHiTS6.2, to evaluate the screening performance of structural models. The calculations by 
Glide version 4.01 199 was carried out using Schrodinger Suite 2007. The targeted protein and 
 51 
 
theoretical models were prepared through Protein Preparation module with the default setting 
and assigned with the OPLS 2001 force field atom types and partial charges. The screening 
databases were prepared within the LigPrep module and the ionization states of each 
molecule were calculated as to be compatible with the pH value of 7.0±2.0. All molecules 
were subjected to energy minimization with MMFFs force field before the docking 
computation. For x-ray structure and holo models, the center of the grid box was selected as 
the center of bound ligands. For apo models, their binding pockets were first aligned to that 
of 2RH1 and the center of co-crystallized carazolol was chosen. The proper size of the 
enclosing box was not set to be fixed but determined by the extent of the bound ligand. The 
Glide SP scoring function was used to rank the docking poses and the top-ranked poses for 
each database molecule were saved for post-docking analysis. 
We prepared the targeted protein and docking parameters for AutoDock version 4.0 
200,201 using the AutoDockTools graphic interface. Explicit hydrogen atoms were added to the 
receptor structures while atom types and partial charges were assigned to generate the pdbqt 
receptor files. The database molecules were prepared using the ‘prepare_ligand4.py’ script to 
merge non-polar hydrogen atoms and define flexible torsions. The center and dimension of 
the enclosing boxes were defined to include the whole binding pockets, similar to those in the 
Glide docking. The genetic algorithm were employed during the docking with a start 
population size of 150 individuals and 20 runs combined with a maximum number of 
12,500,000 energy evaluation for each molecule. Other parameters for genetic algorithm 
were kept by the default value. 
The eHiTS version 6.2 202 was used through the CheVi user interface. Protein 
preparations, such as protonation state determination for residues, hydrogen atoms addition 
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and partial charge assignment, were actually not needed since eHiTS’ docking and scoring 
are based on the prior training data of its knowledge base of 97 protein families. The grid box 
was assigned automatically using the bound ligand’s SDF file as the CLIP file. We employed 
the default settings for eHiTS docking and ranked the database molecule based on its lowest 
eHiTS score. 
In addition, we added eight more scoring functions of different types by rescoring the 
top-ranked poses generated by Glide4.01. The multiple scoring functions in Sybyl8.0 203 
CScore module and OpenEye 204  FRED 2.2.4 were applied, including Chemscore, D_score, 
Gold_score, PMF, Chemgauss3, PLP, Screenscore and Shapegauss. The consensus scores 
were also used for the above scoring functions through the rank by rank strategy. 
3.2.3. Assessment of Virtual Screening Performance 
To measure the efficiency of virtual screening we used the following conventional 
parameters: the enrichment factor and the receiver operating characteristic (ROC) curve that 
characterizes the ability if a method to recover known ligands among the top-scored 
screening molecules. The enrichment factor follows the most popular definition as to how 
many more seed compounds (i.e., known ligands) were found within a defined “early 
recognition” fraction of the ranked list relative to a random distribution: 
ࡱࡲ ൌ ࡴ࢙ࢉ࢘ ࡴ࢚࢕࢚⁄ ൈ ࡰ࢚࢕࢚ ࡰ࢙ࢉ࢘⁄    (1) 
where Hୱୡ୰ is the number of target-specific seeds recovered at a specific % level of 
the database; H୲୭୲  is the total number of seeds for the target; Dୱୡ୰   is the number of 
compounds screened at a specific % level of the database; D୲୭୲  is the total number of 
compounds of the database. The ROC curve is generated by plotting the sensitivity (Se) vs. 
(1 – specificity (Sp)) for a binary classifier system as its discrimination threshold is varied. In 
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the case of virtual screening for recovering the ith known active from the inactive decoys, the 
Se୧ and Sp୧ are defined as follows: 
ܵ݁ ൌ ܪ௦௖௥ ܪ௧௢௧⁄    (2)  
ܵ݌ ൌ ሺ஽೟೚೟ିு೟೚೟ሻିሺ஽ೞ೎ೝିுೞ೎ೝሻ஽೟೚೟ିு೟೚೟    (3)  
The area under the ROC curve (AUC) is the metric that is widely accepted for 
assessing the likelihood that a screening method assigns a higher rank to known actives than 
to inactive compounds. The AUC values at a specific percentage of the ranked database are 
calculated from the following equation: 
ܣܷܥ ൌ ∑ ሾܵ݁௜ሺܵ݌௜ାଵ െ ܵ݌௜ሻሿ௡௜ୀଵ     (4) 
Here n is the total number of known actives in the screening database. One additional 
parameter, the yield, is also employed as the percentage of true hits retrieved by the virtual 
screening method: 
ܻ݈݅݁݀ ൌ ܪ௦௖௥ ܪ௧௢௧⁄ ൈ 100     (5) 
Cluster Analysis of Binding Profiles.  
To closely evaluate the key receptor/ligand interaction patterns, we employed the 
LigX module 205 in MOE2007.09 to analyze the crystal structure of β2AR/carazolol complex 
and the docking poses generated by Glide4.01. For each antagonist, the top-ranked docking 
pose with the highest score was selected. Two major types of interactions that contribute to 
protein/ligand binding affinities were considered, i.e. hydrogen bonds (donor or acceptor) 
and non-bonded weak interactions. The score to assess the hydrogen bond is based on a scale 
of 0 to 100% that indicates the probability of being a geometrically perfect hydrogen bond 
while the score for non-bonded weak interaction is the pair wise distance between residue 
and ligand atoms. In our studies, we took the default parameters in which 4.5 angstrom is the 
 54 
 
cutoff for weak interactions and 2.5 angstrom is the closest distance between any 
residue/ligand atom pairs. The original score was normalized; thus, the values of the 
modified scores were between 0 and 1, which is proportional to the interaction intensities. To 
better visualize the binding patterns of docked poses for each theoretical models and crystal 
structures, the LigX scores were transformed into heat maps and clustered using the R 
statistical package 206. We applied the hierarchical clustering with the Ward linkage 
algorithm; thus, the patterns of interaction between 58 human β2AR antagonists and residues 
in the active sites of three different structural models would be expected to be similar if the 
respective clusters are similar (cf. Figure 3.3). 
In addition, we have exploited the Protein Ligand Interaction Fingerprints (PLIF, also 
available in MOE2007.09) for the same purpose (cf. Figure 3.6 of Supporting Information). 
PLIF can identify and score major protein/ligand interactions, including hydrogen acceptor 
from side chain, hydrogen donor to side chain, hydrogen acceptor from backbone, hydrogen 
donor to backbone, ionic attractions and surface contacts.  For each docking pose, the PLIF 
fingerprints ranging from 30 to 50 bits were generated. The relative frequencies of each 
identified fingerprint can be then used to produce fingerprint significance chart, which is 
based on the hypothesis that ‘if the bit is set, then the compound is active’. 
3.3. Results and discussion 
3.3.1. Comparison of Theoretical Models and the X-ray Structure of β2AR for 
Their Overall Structures and Protein Segments That are Critical for Ligand 
Binding 
 Prior to VS experiments, we analyzed the similarity between theoretical models and 
two x-ray structures, i.e. 2RH1 and 1U19 deposited to the Protein Data Bank 207. All 
theoretical models used in this study are listed in Table 3.1; each model was aligned against 
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the x-ray structures to evaluate relative definitions of transmembrane (TM) helices, their 
conformations, and relative orientation. The x-ray structure of bovine rhodopsin (1U19) was 
also included in addition to β2AR because the former had been used as a common template 
for GPCR homology modeling. In doing so, we were interested to explore if the failure to 
predict the structural conservation and/or divergence from the template structure may cause 
poor VS results for the theoretical models. 
Our initial efforts focused on evaluating the accuracy of TM helical boundaries as 
defined by models vs. x-ray structures. For this purpose we have employed MOE 2007.09 
software 208 to annotate the secondary structural elements in the 3D structures. We found (cf. 
Table 3.3 of Supporting Information) that the MOE module assigned boundaries either at 
exact positions or only one amino acid apart to over 90% of the TM segments of 2RH1 and 
1U19 in comparison to those in the PDB header. Thus, the MOE software was deemed 
reliable in identifying the helical boundaries; the results of applying MOE to the six 
theoretical models and two crystal structures (2RH1 and 1U19) are summarized in Figure 
3.1a. From the alignment of the eight structures, it can be seen that the apo models (AM1-
AM3) perform better than the holo models (CM1-CM3) in terms of accuracy of TM 
assignment. The location and length of the TM helixes for all three AM models are 
consistently close to those in the rhodopsin structure (1U19), with the only exception that 
TM6 and TM7 in the AM1 model are shorter than the corresponding helices in the crystal 
structures. This observation can be easily rationalized since AM1 and AM2 models are solely 
based on homology modeling whereas AM3 is a hybrid model developed with a  
combination of both threading and ab initio methods. In all cases, the crystal structures of 
bovine rhodopsin were used as a template for model building. Furthermore, we have 
 56 
 
concluded that individual TM helixes were very close in terms of helical length and relative 
orientation when compared to crystal structures of bovine rhodopsin and human β2AR 45. 
Thus, not surprisingly, given the methods used for model building, the secondary structural 
elements for all three AM models were found to be assigned very accurately as compared to 
their homologous experimental structures. 
The accuracies of TM helix boundaries assignments for CM models were less 
satisfactory. In general, seven TM helices in all three CM models were shorter than expected 
with the largest disagreements located at TM1, TM4 and TM5 (Figure 3.1a). The CM3 
model gave the largest deviation in terms of the percentage of correctly defined TM helical 
boundaries. Moreover, it had the shortest lengths for individual TM helices. For instance, it 
was eight residues shorter for TM1, fourteen for TM3 and eleven for both TM5 and TM6 in 
comparison to the β2AR crystal structure. One possible explanation is that all three CMs are 
de novo models, generated without any template structure. Both the Lybrand (CM1, 2) and 
the Goddard (CM3, 4) groups employed the standard alpha helix as a starting point and 
calculated the intrinsic tilt/kink and relative orientation of the TM helical bundle purely 
based on the physical considerations. If the rhodopsin structure is not employed as a 
reference, the secondary structure assignments could be affected by many factors, such as the 
type of phospholipids used in the MD simulations employed as part of model refinement in 
studies by the Goddard group 177,209. 
It should be noted that the engineered modification of the wild type protein using a 
segment of T4 lysozyme to replace most residues of IL3 introduced an artifact in the crystal 
structure (2RH1) of human β2AR. This modification led to altering the boundaries of IL3, 
thus affecting the correct locations of both the TM5 terminus and the start of the TM6. The 
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accurate definition of these two boundaries is less important in the comparison of structural 
similarities between theoretical models and the crystal structure. However, the accuracy of 
predicting the TM4 terminus and the beginning of TM5 is critical considering the functional 
roles of EL2 in both rhodopsin and human β2AR 210,211. As can be seen from Figure 3.1a and 
Table 3.4 of the Supporting Information among the three AM models, AM3 has the highest 
accuracy (1 residue error) for the segment between TM4 and TM5 (EL2) followed by AM2 
and AM1. CM3 model is comparable to AM2 while CM1 and CM2 had much larger errors 
with respect to TM helix assignments. 
The seven TM helices of each theoretical model were superimposed onto respective 
helices of β2AR as well as the rhodopsin structure, and the backbone pair wise RMSD of 
individual respective TM helices was calculated (Figures 3.1b, 3.1c and Table 3.4 of 
Supporting Information). As expected, the homology models (AMs) are generally more 
similar to the rhodopsin structure than to the β2AR structure. The RMSDs of most helices in 
AM1-3 range from 0.30 Ǻ to 1.00 Ǻ as compared to bovine rhodopsin where the RMSDs are 
as big as 1.60 Ǻ to 3.80 Ǻ when aligned against the human β2AR. For the whole TMs bundle, 
the RMSDs are 1.15 Ǻ to 1.88 Ǻ with respect to rhodopsin and 2.25 Ǻ to 3.19 Ǻ with respect 
to β2AR. In comparison, the de novo models (CMs) deviate more significantly from both 
crystal structures. The RMSDs of most helixes in CM1/CM2 are in the same range of 2.00 Ǻ 
- 5.50 Ǻ when aligned against both rhodopsin and β2AR. For CM3, the RMSD increases to 
2.60 Ǻ and 7.00 Ǻ, respectively. Similarly, the RMSDs of TMs bundle for CM1 are 3.20 Ǻ 
when aligned against the rhodopsin and 3.59 Ǻ for β2AR. For CM3, the corresponding 
RMSDs are 3.83 Ǻ and 4.41 Ǻ (cf. Table 3.4 of Supporting Information). 
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Consistently, the AMs models were observed to be aligned well to the rhodopsin 
structure (cf. AM2 in Figure 3.1b as an illustrative example). They deviated from the β2AR 
structure with the noticeable shifts for TM1, TM3 and TM5, although the secondary structure 
assignment for these regions was relatively accurate. The large RMSD differences for these 
three TMHs were obviously due to the differences between rhodopsin and β2AR crystal 
structures (7TMs backbone RMSD of 2RH1 vs. 1U19 is 1.85 Å). It was indeed reported in 
the original publication on β2AR crystal structure 45 that there is a noticeable shift in TM1 of 
β2AR relative to bovine rhodopsin, primarily at the extracellular portion which tilts away 
from the TM bundle compared to bovine rhodopsin 45,46. The long N-terminal fragment could 
not be observed in both crystal structures, but it could cause large flexibility/variation in the 
assignment of TM1 boundaries, especially in the upper helical region. TM5 has a proline-
induced kink at conserved positions along the transmembrane segments, which is believed to 
be responsible for the structural rearrangements required for the GPCR activation 193,212-215. 
The subtle difference in the activation status of the current β2AR structure (2RH1, bound to 
an inverse agonist carazolol) may lead to the structural diversification at the kink region, in 
terms of the amplitude of motion and rotation degree. Notably TM3 and TM5 form half of 
the binding pockets for the co-crystallized carazolol 45 (Figure 3.1b). 
Unlike AM models, three CMs deviate from both bovine rhodopsin and β2AR in a 
similar way (cf. CM1 in Figure 3.1c as the representative case). A large discrepancy can be 
found at TM1, 4, 6 and 7 for CM1/CM2 and TM1, 3, 5 and 6 for CM3. Here the similar 
reasoning used in the analysis of AMs can be applied to TM1 because the N-terminal 
fragment was not considered as part of model building and optimization. Interestingly, the 
RMSD of CM1’s TM4 is as large as 5.00 Ǻ with respect to rhodopsin and 5.21 Ǻ when 
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aligned against β2AR. It is surprising since TM4 seems the easiest one to model. Among all 
seven TMs, TM4 is the shortest and the most orthogonal to the plane of the phospholipid 
membrane. This observation indicates the limitation of computational protocols employed in 
developing the CM models in their ability to reproduce the conformation of this ‘anchor’ 
helix in the TM bundle. For TM5, 6 and 7, one of the common shared features is the proline-
induced kink. The comparison between β2AR models and the crystal structure highlights the 
difficulty associated with the accurate modeling of this unique structural feature of GPCRs. 
3.3.2. Comparison of VS Performance for Theoretical Models and X-ray Structure 
of β2AR.  
Figure 3.2 compares the virtual screening performances on discriminating 58 known 
β2AR antagonists against decoys by three docking methods. Both the enrichment factor plot 
(a,c,e) and ROC curves (b,d,f) were included for each method. The yield plot is shown in 
Figure 3.4 (a,c,e) of the Supporting Information since it essentially delivers the same 
information as the ROC curves. The detailed statistical parameters characterizing the VS 
performance, such as the maximum EF (EFmax), ROC AUC and the recently proposed 
Boltzmann-Enhanced Discrimination of ROC (BEDROC) 216,217, are summarized in Table 
3.2. All four holo models as well as the β2AR structure were used in the VS study. The data 
for only two apo models (AM1 and AM3) are included in the plots because of these models’ 
generally poor performance during virtual screening. In many cases, such as AM1 in Figures 
3.2d and 3.2f, the ROC curve is close to the random expectation (the diagonal line). It is 
understandable because the side chain rotamers of binding pocket residues in the AM models 
had not been optimized in the way it was done for holo models.  
Among all four CMs models, those from the Lybrand group (CM1, CM2) achieved 
better enrichment than the models from the Goddard group (CM3, CM4). In most cases, the 
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CM2 model yielded comparable results to the β2AR crystal structure. In the screening by 
Glide4.01, CM2 model gave higher EF at the very early phase (0% - 2% of ranked database, 
cf. Figure 3.2a and Table 3.2) After that, it remained up to one unit lower than the crystal 
structure until converging with the latter at the 22% of ranked database. In terms of ROC 
AUC, CM2 reached the value of 0.86, close to AUC of 0.88 for the crystal structure. Based 
on the BEDROC metric, CM2 was similar to 2RH1 when a weak emphasis or weight was put 
on early enrichment (tuning parameter α=20), while showing better performance when the 
emphasis increases (tuning parameter α=53.6 or 100).  
We note that Glide4.01 gave better VS results in this study compared to AutoDock4.0 
and eHiTS6.2. Thus, we placed more emphasis on the screening data/docking poses 
generated by Glide4.01. Nevertheless, the results obtained with both AutoDock4.0 and 
eHiTS6.2 highlighted the impressive performance of CM2. As demonstrated by both types of 
plots in Figures 3.2c-f and most criteria in Table 3.2, the CM2 afforded VS results superior to 
the crystal structure when using these two docking programs. Therefore, practically speaking, 
these results suggest that the use of crystal structure is not advantageous in terms of VS 
performance when the scoring function is not highly accurate. As mentioned above, CM3 
and CM4 had poorer performance than CM1 and CM2 but were comparable to AM1 and 
AM3 models in this case. 
The crystal structure of β2AR represents an inactive state of the receptor because it is 
bound to the inverse agonist, carazolol 45,218. Thus, it may be considered unfair to compare 
the crystal structure of β2AR with theoretical models as applied to agonist screening, 
especially when the models were created to capture known data on agonists. However, for 
comparison purposes, we did explore the possible utility of 2RH1 for screening for agonists. 
 61 
 
The screening results are summarized in Figures 3.5a,b and Table 3.5 of the Supporting 
Information. As expected, the CM2 model showed the best performance to enrich for thirteen 
β2AR agonists. With Glide4.01 method, the CM2 model could recover 100% of seed 
agonists at the 15% of ranked databases and its maximum EF could be as high as 36.09. Thus, 
it excelled over 2RH1 greatly in terms of these two parameters of VS performance. Taking 
into account the data for the antagonist virtual screening, we shall conclude that CM2 model 
demonstrated remarkable performance as a model of choice for virtual screening for both 
agonists and antagonists. 
The possible explanation for the better performance of CM1/CM2 models is that 
Lybrand et al 178,179 exploited many site-directed mutagenesis data during the model 
optimization. The important receptor/ligand interactions had been turned into the distance 
restraints that were applied explicitly to specific atoms of both the receptor and its ligands 
during molecular dynamics simulations 178. In comparison, CM3 and CM4 models from 
Goddard et al 177,209 did not employ such information; their models were built by optimizing 
the target/ligand interaction using physical force field. Obviously, the differences in the type 
of data utilized for theoretical model building and optimization can largely affect the 
accuracy of binding pocket modeling, and consequently, the model performance in virtual 
screening experiments. In order to evaluate the similarity between binding pockets of 
individual models, we superimposed Ca atoms of key residues inside the pocket with their 
counterparts in 2RH1. The binding pocket was defined by residues found within 4 Å of the 
co-crystallized carazolol. Carazolol was merged into the binding sites of all models as 
defined by the alignment. As shown in Figure 3.2a-g, the CM2 binding pocket (Figure 3.2b) 
is most similar to that of 2RH1 with respect to both the ligand pose and the position of 
 62 
 
residues interacting with the ligand. The RMSD for its Cα atoms was 2.40Ǻ while the one for 
CM1 was 2.33Ǻ (cf. Table 3.4 of Supporting Information). These two models also 
reproduced the contacts of carazolol with residues Ser203ହ.ସଶ  , Asn312଻.ଷଽ   and Phe193 . 
For three AMs models, the RMSDs ranged from 3.39Ǻ to 3.71Ǻ. CM3 and CM4 models had 
the largest deviation (RMSD = 5.64Ǻ), as can also be seen in Figures 3.2c and 3.2d. 
Furthermore, the close inspection of the top-ranked docking poses of all seed 
antagonists showed that the interactions between the antagonists and the binding site of the 
CM2 model were largely in agreement with the site-directed mutagenesis data. The 
protonated nitrogen in most β2AR antagonists formed salt bridges with Asp113ଷ.ଷଶ  and 
Asn312଻.ଷଽ  ; the amide hydroxyl group formed hydrogen bonds with Ser203ହ.ସଶ  , 
Ser204ହ.ସଷ or Ser207ହ.ସ଺  . Another important interaction was formed between antagonists 
and Phe193 of EL2, i.e., the residue that was also found to interact with carazolol within the 
crystallographic structure of β2AR 45,46,178 . It should be pointed out that CM2/CM1 models 
include both extracellular and intracellular loops, whereas CM3/CM4 and AM1 models did 
not incorporate these regions 46,177. 
To elucidate the molecular basis for dissimilar virtual screening performance of 
different CM2 and CM3 models in comparison with 2RH1 we have conducted the cluster 
analysis of the binding profiles of all 58 antagonists docked to the respective binding sites. 
Binding profiles reflected the strengths of interaction between antagonists and active site 
residues. Importantly, there were significant differences in the weak interaction patterns of 
CM2 (Figure 3.3b) and CM3 (Figure 3.3c) in comparison to 2RH1 (Figure 3.3a). The major 
clusters formed by CM2 in the region of conserved residues matched well to those found in 
2RH1, suggesting a critical role of weak interactions between binding site and antagonists. In 
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comparison, clusters formed by CM3 were scarce and many key interactions were missing, 
especially for residues Trp2866.48, Phe2896.51, Phe2906.52 and Asn2936.55 of the binding 
pocket. This analysis indicates that the binding pocket of CM2 was well-organized and 
similar to that of 2RH1 whereas the CM3 binding pocket was formed by somewhat different 
residues, with the key residues found in the binding site of the x-ray structure were 
inaccessible to the bound antagonists. The cluster profile of hydrogen bonding pattern was 
less informative as some prominent patterns at 2RH1 such as the ones with Asn312଻.ଷଽ  were 
absent at both CM2 and CM3. Notably, Ser204ହ.ସଷ  and Ser207ହ.ସ଺  of CM2 were found to 
be hydrogen bonded to ca. 15 antagonists, but the same pattern was not observed with either 
CM3 or 2RH1. 
During the course of our studies, the Kobilka et al. experimentally characterized two 
new structures of β2AR, one in a nanobody-stabilized active state and another in complex 
with an irreversible agonist. Compare with the inactive state β2AR structure, the agonist-
binding pockets have fairly subtle changes, with the major differences at the hydrogen 
bonding contacts with Ser203ହ.ସଶ  and Ser207ହ.ସ଺  . To determine whether these minor 
changes will increase receptor’s selectivity toward agonists, we carried out structure-based 
virtual screening studies using the nanobody-stabilized structure (PDB 3P0G), and compared 
its performances with the inactive state crystal structure as well as the collected theoretical 
structural models. As expected, the active state crystal structure showed better performances 
than the inactive state crystal structure in enriching the 13 agonists, and inferior 
performances in enriching the 58 antagonists (Figure 3.2 and supplementary Figure 3.5). 
With Glide4.01 method, the active state crystal structure could recover 100% of seed 
agonists at the 25% of ranked databases and its maximum EF could be as high as 30.69. On 
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the other hand, the performance of active state structure model CM2 showed relatively 
comparable performances to the active state crystal structure in terms of EF and AUC. (Table 
3.2, supplementary Table 3.5) As mentioned above, the theoretical model CM2 captured the 
critical agonist-protein interaction at Ser2075.46. This piece of evidence illustrated further that 
properly optimized theoretical models can provide a sensible picture for the active-state 
binding pocket, and can be employed for structure-based virtual screening of β2AR agonists.  
To summarize our observations, we have established that theoretical models of 
GPCRs generated with knowledge-based approaches can achieve similar if not better VS 
performance as structural models based on x-ray crystallographic studies. This somewhat 
surprising observation is reassuring with respect to using carefully developed theoretical 
models of protein structures for SBDD. 
3.4. Conclusions 
In this study we have addressed the long-standing debate about the structural 
accuracy and applicability of theoretical models vs. x-ray structures of proteins for SBDD. 
We have carried out a systematic study on a large collection of historical human β2AR 
theoretical models and evaluated their structural accuracies and screening performances in 
comparison with two recent crystal structures. We have shown that there exists a discrepancy 
between global structural accuracies of β2AR theoretical models and their screening 
performances. In general, β2AR theoretical models differ largely from the crystal structure in 
terms of TMHs definition and global packing while many can achieve the same performance 
in virtual screening and as demonstrated elsewhere 187, pose predictions. Our analysis 
indicates that the binding pockets of models showing the best performance are well-
organized and they also align well to active sites in the crystal structures. The key 
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interactions of residues in the active site with the bound antagonists were found to be 
preserved in models that were built and refined taking into account the site-directed 
mutagenesis and other experimental data. Our results emphasize that knowledge-based 
approaches result in structural models that can achieve the same or even better performance 
in virtual screening as those built with x-ray crystallographic data. At the same time, we must 
stress that our studies address very specific and pragmatic question concerning the use of 
protein models vs. experimental structures for virtual screening. They by no means 
undermine the critical importance of experimental structures for understanding protein 
structure-function relationships as well as the role that crystal structures serve as a critical 
reference for evaluating the accuracy of predicted protein/ligand interactions. 
 
 66 
 
Tables and Figures 
 
Figure 3.1. The structural similarity analysis of theoretical models in comparison with crystal structures. (a) The 
secondary structure assignment for TM segments of six theoretical models and two crystal structures (2RH1 and 
1U19). The numbers and their corresponding structures are coded by 1:2RH1, 2:AM1, 3:AM2, 4:AM3, 5:CM1, 
6:CM2, 7:CM3, 8:1U19. The remaining two models, i.e., AM4 and CM4, share similar backbone structures to 
CM3 with pair wise RMSD of TMs less than 0.4 Ǻ. Therefore only CM3 is included in the sequence alignment 
plot. The red bars indicate the helical structure elements identified by MOE. (b) The structural superposition of 
the theoretical models AM2 (rendered in pink) to 2RH1 (rendered in dark green) and 1U19 (rendered in blue). 
Note that the most structurally divergent TM regions are indicated. (c) The structural superposition of the 
theoretical models CM1 (rendered in pink) to 2RH1 (rendered in dark green) and 1U19 (rendered in blue). Note 
that the most structurally divergent TM regions are indicated. 
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Table 3.1. The synonym of eight human β2AR theoretical models employed in this study. 
Apo model Source Holo model Source 
AM1 
By G. Vriend, a homology 
model219 based on the 
crystal structure of bovine 
rhodopsin 
CM1 
By T. Lybrand, a de novo 
model178,179 bound by 
aminoflisopolol (β2AR 
antagonist) 
 
AM2 
By A. Sali, a homology 
model220 based on the 
crystal structure of bovine 
rhodopsin 
CM2 
By T. Lybrand, a de novo 
model178,179 bound by 
TA2005 (β2AR agonist) 
 
AM3 
By J. Skolnick, a hybrid 
model180 combined 
threading and ab initio 
methods 
CM3 
By W. Goddard, a de novo 
model177,209 bound by 
butoxamine (β2AR 
antagonist) 
AM4 
By W. Goddard, a de novo 
model177 based on first 
principles methods 
CM4 
By W. Goddard, a de novo 
model177,209 bound by 
salbutamol (β2AR agonist) 
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Supplementary Material 
 
a  
b 
c 
 
Figure 3.4. The yields of 58 known β2AR antagonists during the screening by three docking methods versus the 
crystal structure and six theoretical models. The annotations are (a) Glide4.01 (b) AutoDock4.0 and (c) 
eHiTS6.2. 
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a  b 
 
c d 
e f 
 
Figure 3.5.. The enrichments and ROC curves of 13 known β2AR agonists during the screening by 
three docking methods versus the crystal structure and six theoretical models. The annotations are (a) 
Glide4.01 (b) AutoDock4.0 and (c) eHiTS6.2. 
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Figure 3.6. The significance chart for PLIF fingerprints generated from docking poses against (a) 
β2AR crystal structure, (b) CM2 model and (c) CM3 model. The higher the bar (individual 
fingerprint bit) is, more frequently this type of interaction occurs in the dataset and of higher 
probability it contributes to the activities. The shade of the color indicates the significance of the 
particular bit to the actives, which is based on the hypothesis that ‘if the bit is set, then the compound 
is active’. The residues are randomly colored and several bars of the same residue indicate that they 
have different types of contacts. 
b 
a 
c 
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Table 3.8. The actual number of compounds used for calculating EF and AUC metrics. 
 
Structure/Model aAntagonists Num. bNonbinders Num. 
2RH1 29 272 
CM1 29 272 
CM2 30 245 
CM3 28 307 
CM4 30 307 
AM1 30 303 
AM3 30 205 
D-SS 30 374 
F-SS 30 374 
aThe bound ligand for 2RH1 and CM1~CM4  were excluded from the calculation. 
bA number of decoys were filtered by Glide before the refinement stage. They thus did not have a 
Glide score and were treated to be at the end of the ranked database. 
 
 
 
 
 
 
Chapter 4. Development, Validation and Application of Target­
specific Pose Filters in Structure­Based Virtual Screening of 
Subtype Selective Ligands  
4.1.  Introduction 
Traditional drug discovery and development approaches were generally applied for 
searching novel active compounds and optimizing compounds’ potency with a specific drug 
target in mind. Recent fast developments in proteomics and chemogenomics studies, 
however, have triggered a paradigm shift from this focus toward a more comprehensive 
analysis of the entire ligand space and target space and to explore all prospective drug-target 
interactions 3,8,221,222. The role of small molecules are no longer limited to a inhibitor or active 
compound that can be promoted to drug candidates, but more as a probe to understand 
biological functions through perturbing cellular circuits and pathways. Despite the increasing 
complexity and diversity of research evolved from this new field, the major questions could 
be generally categorized into two themes, for an interested organic compound with certain 
observed phenotype, how to identify the responsible biological target (target fishing); and 
what is the selectivity profiles of a known organic compound across all relevant targets 
(ligand profiling)4,5,33.  
The success of computational approaches, including structure-based drug design and 
Quantitative Structure-Activity Relationship (QSAR) analysis, has been well recognized in 
the field of rational drug design and discovery223. However, the rapid growing research in the 
area of chemogenomics and chemical biology propose new requests for the development of 
computational methods. There are already a number of reviews discussing possible 
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computational strategies that can be applied in this field 8,33,62. A main theme emerged from 
this area relates to prediction of small molecule’s selectivity profile at different levels, for 
instances, within a target family, or subfamily. Several previous studies have explored the 
effectiveness of using ligand-based approaches such as two-dimensional fingerprints and 
Quantitative Structure-Selectivity Relationship (QSSR) models in “selectivity searching”. It 
was shown that carefully designed fingerprints and QSSR models are capable of enriching 
subtype-selective ligands in small to medium size data sets 136,224,225. Several other groups 
aimed at structure-based approaches by incorporating information from predicted protein-
ligand contacts. Singh and colleagues 55,56 defined a series of protein-ligand interaction 
properties to generated Structural interaction fingerprint (SIFt) at protein-ligand’s binding 
site. Virtual screening studies using SIFt revealed superior performance as compared with 
traditional scoring functions.  Graaf and Rognan et al. showed that a topological scoring 
function based on their ligand protein interaction fingerprint (IFPs) was able to selectively 
identify agonists or antagonists of the beta2 adrenergic receptor 57-59. In addition, there is an 
increasing interest in the computational drug discovery community to build target-specific 
scoring functions, which have a straightforward application in exploring ligand’s binding 
profiles 60,61,226,227. 
Our lab has developed a novel type of four-body descriptor to effectively represent 
the protein-ligand interface: the PL/MCT-tess (Protein-Ligand atoms’ pair wise Maximal 
Charge Transfer potential based on Delaunay Tessellation) descriptor. Application of this 
descriptor to our routine QSAR modeling workflow resulted in predictive models for protein 
ligand binding affinity61. A recent study by Hsieh et al. in our group suggested that QSAR 
models developed based on multiple docking poses from a single cognate ligand can 
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effectively distinguish native-like docking poses from decoy poses, thus dramatically 
increased the virtual screening performance when combined with the traditional force-field 
based scoring functions60,61. Herein, we continue to use the PL/MCT-tess descriptors as an 
effective representation of the protein-ligand interface, and explored other pose-filters that 
explicitly account for small molecules’ subtype binding selectivity. In order to do this, a 
reference PL/MCT-tess profile (normally from the X-ray protein-ligand complex) was 
initially used to partition a training set of known actives’ docking poses into reference-
similar versus dissimilar class. Then a binary classifier was developed that can distinguish 
reference-similar poses from all available poses of known nonselective/inactive compounds. 
By changing the reference ligand type (non-selective or subtype selective ligand) and the 
calibration pool included in target-specific pose filter (treat inactive compounds only as 
decoys or include also non-selective compounds as decoys), we hope to direct the proposed 
pose-filters to selectively enriching subtype-biased ligands.  
As proof of concept, we first assessed the capabilities of the proposed pose filters to 
identify known active compounds using 13 subsets from the Directory of Useful Decoys 
(DUD). Compared with the traditional scoring function, namely Chemgauss3, from Fred, we 
found that our approach showed better performance for 10 out of 13 data sets, and similar 
performance for the remaining 3 receptor targets. The best data set provides an increase in 
the enrichment from 18- to 57-fold over random at a false positive rate of 1%. We further 
challenged our approaches on a data set of 189 compounds with known binding data of the 
beta adrenergic receptors (βAR) GPCR subfamily. The βARs belong to the extensively 
explored Class A Rhodopsin like GPCRs, and a plethora of experimental data is available for 
model evaluation and validation. The three most explored subtypes in the βAR family are 
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designated β1AR, β2AR, and β3AR. They are widely distributed and play critical biological 
functions on several tissues. The β1AR subtype is expressed predominantly in mammalian 
heart, while the β2AR is the major subtype in most vascular and bronchial smooth muscle 
cells, the β3AR is mostly located in adipose tissues 228,229. The βAR mediated signaling 
pathways play a critical role in regulating cardiac function, and βAR mediated relaxation of 
the smooth muscle also has essential therapeutic values in treating asthma 228-231. 
Identification of βAR ligands with the desired selectivity and activity patterns may lead to 
better drug candidates as the β1-stimmulating-effects of several β2-agonists determines their 
cardiac side effects in treating asthma. Similarly, the β2-activity of β1-antagonists may exert 
harmful effects when used in the treatment of heart diseases. With recent publication of the 
human β2AR and Turkey β1AR crystal structures 232-234, applying structure-based approach 
to explore ligand’s subtype selectivity has attracted further attention for the βAR sub-family. 
On the other hand, the sequence similarity among these three subtypes is quite high, 
especially near the ligand binding regions, making them challenging targets to elucidate 
ligand binding specificities. Herein, we reported the performance of a novel subtype biased 
scoring protocol in searching for selective ligands. Furthermore, by analyzing the derived 
computational tools for highly weighted PL/MCT-tess descriptors, we also proposed 
prospective protein-ligand contacts that may contribute to the ligands’ subtype specificity 
within the βAR family.  
4.2.  Pilot Study 
4.2.1.  Data Sets Selection ( the DUD Data Set) 
The structures were directly downloaded from the Directory of Useful Decoys (DUD) 
data sets: http://dud.docking.org 235. The DUD has been recently compiled by the Schoichet 
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group, specifically for benchmarking the performance of docking methods. The data sets 
contain a diverse set of 40 interesting protein targets, as well as a list of known ligands and 
decoys for each target. On average, 36 decoys were chosen for each active compound 
structure from the free ZINC database of commercially-available compounds. To minimize 
the physical bias in benchmarking docking methods, the decoys were chosen specifically to 
match the physical properties but topologically dissimilar to the known active structures. A 
number of criteria were explicitly considered such as molecular weight, cLogP, number of 
hydrogen bonding partners, and number of rotatable bonds. Recently, Good et al. carried out 
additional refinements of the DUD actives by applying a lead-likeness filter (AloP <4.5, MW 
<450) and clustering analysis. To be comparable with other virtual screening methods, we 
have also used the 13 data sets that contain at least 15 clusters. (see Table 4.1 for details) In 
total, there are six members of the kinase protein family (cdk, egfr, p38, pdgfrb, src, and 
vegfr2), two members of metalloenzymes (ace, pde5), one serine protease (fxa), and several 
other enzymes. To employ the proposed virtual screening methods, the original DUD 
protein-ligand crystal structures were used as the reference during pose filter training. For 
vegfr2 and pdgfrb where no co-crystallized ligand is provided, the top-scored pose from 
docking a known ligand to the apo protein structure was used. The data set was collected and 
cleaned by previous lab member, Dr. Jui-hua Hsieh.  
4.2.2.  Methods 
Docking Methods for Pose Generation 
Each protein target were prepared using the Molprobity server to add hydrogen atoms 
and assign partial charge, as well as correcting potential structure problems including missing 
atoms, potentially transposed heavy atoms in asparagine, glutamine, and histidine side chains. 
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The co-crystallized water molecules were removed in order to reduce bias during pose 
generation. On the other hand, the cofactors or metal atoms were preserved in cases where 
they are known to be critical for protein function or involved in ligand binding. The DUD 
actives and decoys were used directly from download, but ionized and converted to three-
dimensional conformers with Omega (version 2.2.1)236 using the default parameters. The 
Fred docking software (version 2.2.5)236 from OpenEye Scientific was then employed to 
generate docking poses for each conformer from the derived library. We employed the 
default settings for Fred docking except for changing to a larger number of preserved poses. 
For each molecule, the top 30 poses selected by the Fred’s default scoring function, 
Chemgauss3, were kept for post-docking analysis. For the 6 kinase protein targets, additional 
restraints were applied to preserve the canonical protein-ligand interactions at the hinge 
region 237. The final data of the docking poses and calculated Chemgauss3 scores were 
provided by previous lab member, Dr. Jui-hua, Hsieh. 
 Novel Descriptors of the Protein-Ligand Interface Based on Conceptual DFT 
Our group recently developed a set of simple yet effective geometrical descriptors, 
the ENTess descriptors, to describe the physicalchemical properties at the protein-ligand 
interface. It utilizes the Pauling electronegativity (EN) to annotate atom types and uses 
Delaunay Tesselation (Tess) to characterize the geometrical property at the interface. Briefly, 
for each protein-ligand complex, Delaunay Tessellation was first used to partition the space 
into an ensemble of tetrahedrons. Only interfacial tetrahedrons that are formed by both 
protein and ligand atoms were kept to define the protein ligand interface. Furthermore, a 
distance cutoff of 8A (distance for physically meaningful interactions) was used to exclude 
Delaunay quadruplets with long edges between atom vertices. Theoretically, a total of 554 
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types of Delaunay quadruplets were defined by their unique four-atom composition, 
including the atom types and the origins (receptor atom or ligand atom). The descriptor value 
was calculated by summing up the electronegativity values of the composing vertices/atoms. 
In our previous studies, we have successfully built quantitative structure-binding affinity 
relationship models for a data set of 264 x-ray crystallized protein-ligand complexes using 
the ENTess descriptors and a standard QSAR modeling workflow 238.  
More recently, our group improved the original ENTess descriptors by assigning a 
more physic-chemically rigorous property to be the descriptor values. Instead of using atom’s 
electronegativity values, pair wise atomic potentials for the protein-ligand complexes (PL) 
based on maximal charge transfer (MCT) were used to derive the novel PL/MCT-tess 
descriptors. The MCT is based upon the conceptual DFT 239 to determine the maximal 
electron flow between the donor and acceptor atoms. Assuming that the total energy of the 
system is perturbed by the charge transfer up to the second order: The MCT is calculated as 
follows, 
∆ܧ ൌ ߤ∆ܰ ൅ 1/2ߟΔܰଶ    (2) 
where ∆E and ∆N are energy change and charge transfer, respectively. When the total 
energy is minimized with respect to the charge transfer, i.e. ݀∆ܧ ݀∆ܰൗ ൌ 0, we have 
∆ܰ௠௔௫ ൌ െߤ/ߟ ؠ ܯܥܶ   (3) 
hereߤ ൌ ሺ߲ܧ/߲ܰሻఔ  ,   ߟ ൌ ሺ߲ଶܧ/߲ଶܰሻఔ   , are the chemical potential (negative of 
electronegativity) and the chemical hardness, respectively. ߥ represents the external potential 
formed by the framework of atomic nuclei. 
The values for a specific tetrahedron type ݉ can be calculated from the following 
equation:  
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PL MCT⁄ െ tess௠ ൌ ∑ ሺ∑ ∑ MCT௣ ൈ MCT௟/݀௣௟ሻ௞ଷ௟ୀଵଷ௣ୀଵ௡௞ୀଵ    (4) 
 where n is the number of occurrences of this tetrahedron type in a given protein-
ligand complex. For a specific tetrahedron k, p iterates through all vertices belong to the 
protein, while l iterates through all vertices belong to the ligand, and ݀௣௟  is the distance 
between the considered pair of protein and ligand atoms. It should be noted that we are only 
interested in the interfacial Delaunay tetrahedrons; therefore for each tetrahedron it contains 
at maximum of three protein atoms (p) or ligand atoms (l).  
The described descriptors were successfully employed in our previous studies to 
derive classification models that can differentiate native-like docking poses (showing low 
RMSD to the co-crystallized pose) versus non-native like decoy poses (showing high RMSD 
to the co-crystallized pose). After a rigorous validation using the 13 DUD datasets, it was 
shown to significantly improve the traditional physical force field-based hit scoring functions 
by combining the pose scoring from the classification models 60. These studies justified the 
application of PL/MCT-tess descriptors to explore the protein-ligand interface.  
Target Specific Classification Models for Discriminating Irrelevant Ligand 
Docking Pose  
 A number of recent studies showed that inaccuracy of the scoring functions have 
become one of the largest obstacles in applying molecular docking in structure-based virtual 
screening. It is not uncommon to find that the traditional scoring functions cannot identify 
the native-like ligand pose from the decoy poses, which have comparable binding energies 
but depicting irrelevant protein-ligand interactions. Figure 4.1A shows the RMSD to the co-
crystallized ligand pose versus the energy-based docking scores for 1000 poses of the 
cognate ligand generated by the Fred program. In Figure 4.1B, 4.1C, 4.1D, five different 
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beta2-adrenergic receptor inhibitors (including the cognate ligand, noted in red) were docked 
to a single protein structure (PDB: 2RH1) 233 using the Glide program 51. The RMSD were 
then calculated between the docked poses of each ligand with the corresponding co-
crystallized pose (PDB: 3D4S, 3NYA, 3NY8, 3NY9) 240,241. No relationships could be 
identified between the RMSD to the native-pose and the docking score. (Figure 4.1a, 4.1c) 
When evaluating the relationship between the RMSD to the x-ray pose and the similarities to 
the x-ray pose in terms of Euclidean distance in the PL/MCT-tess descriptor space, we 
observed stronger correlations (r=0.62 versus 0.38 for Glide scores, Figure 4.1d, 4.1c). By 
analyzing the average RMSD to X-ray poses against distances in the PL/MCT-tess descriptor 
space suggested that those docking poses with normalized PL/MCT-tess distance lower than 
-1 are highly likely to be within 4A RMSD to their corresponding x-ray pose. The 4A 
threshold is usually considered a reasonable indicator to quantify if a ligand pose is located 
inside its x-ray binding pocket with a roughly correct global orientation 242. Therefore, in this 
study, we define the native-like binding pose as those having similar binding mode to the 
target protein-ligand complex (i.e. with normalized distance to target ligand in PL/MCT-tess 
descriptor space lower than -1), and thus are potentially showing low RMSD to their own x-
ray binding pose. Furthermore, all the docking poses generated by known binding decoys, no 
matter how close they are to the co-crystallized ligand in the PL/MCT-tess descriptor space, 
are considered non-native like poses. By such definition, the problem of separating native-
like poses versus other decoy poses can be learned through training a standard classification 
model based on their PL/MCT-tess descriptors. The detailed workflow for selecting the 
native-like and decoy poses for model’s training set is described in Figure 4.2. Because there 
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is no cognate ligand with the vegfr2 and pdgfrb protein targets, the pose with the lowest 
MedusaScore was utilized as the native pose 243.  
To develop the classification model that can distinguish native-like poses from other 
irrelevant poses, we used the RandomForest correlation algorithm implemented in the freely-
available R package randomForest 17. RandomForest was known for its excellent prediction 
accuracy and efficiency at large data sets. It has an internal unbiased estimate of the 
generalization error during the growth of the forest, thus no additional model validation is 
necessary. In addition, it provides reasonable flexibility in dealing with imbalanced class 
ratio by imposing higher penalties on misclassification of the minority class. For details of 
the RandomForest algorithm, the parameters used, and the evaluating metrics see methods in 
Chapter 5.  
Virtual Screening Protocols Using Post-docking Pose Filters 
As described above, the 13 DUD data sets were docked to their corresponding protein 
target using the Fred docking program, and the default Chemgauss3 scoring function were 
used to select 30 poses per ligand for further analysis. We therefore calculated the PL/MCT-
tess descriptors for each preserved pose to describe its contacts with the protein residues. 
Three different approaches were used to assign the fitness score of each compound in the 
final ranking list: (Figure 4.3) 
i. (PL/MCT-dist) All the poses for the same compound were ranked by its similarity 
to the cognate ligand’s pose in terms of distance in the PL/MCT-tess descriptor 
space. The distance for the most similar pose was used as the final score of this 
compound in the ranking list. This approach purely uses the information from the 
PL/MCT-tess descriptors to select pose and rank the compound, thus providing a 
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direct evaluation on how this descriptors can distinguish ligands from decoys by 
its own. 
ii. (PL/MCT-similarityFilter) In this approach, a pose filter is first developed to 
exclude poses that are too dissimilar to the cognate ligand’s pose in terms of 
distance in the PL/MCT-tess descriptor space.  The cutoff for pose similarity is 
determined by using all the poses for the binding decoys that were in the 
randomly selected 10% hold-out data. Assuming the distance between the decoy 
pose to the native pose follows a normal distribution, we defined the distance 
cutoff as follows:  DT ൌ yത ൅ Zσ   where  ݕത  is the average Euclidean distance 
between each pose to the native pose, and Z is an arbitrary parameter to control 
the significance level. Here, we set the default value of Z  as -0.5 to obtain 
reasonable pose coverage. The final score of each compound is then determined 
by the best Chemgauss3 score for the remaining poses. 
iii. (PL/MCT-RFFilter) This approach is similar to PL/MCT-similarityFilter 
approach in that both approaches use a pose filter to exclude irrelevant poses of a 
compound and then rank compounds based on their best Chemgauss3 scored 
poses. The difference in PL/MCT-RFFilter is that it employs both the known 
active and decoys docking poses from the previously excluded 10% hold-out data 
to derive the pose filter, as described above. By using the machine learning 
algorithm random Forest, we are thus able to calibrate the contribution of each 
PL/MCT-tess descriptor type in the resulting pose filter.  
Assessment of Virtual Screening Performance 
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The conventional receiver operating characteristic (ROC) curve was used in this 
study to evaluate virtual screening protocol’s ability to recover known ligands from the top-
ranked screening library. In addition to report the area under the ROC curve (AUC) as an 
indicator for model performance across the entire screening library (see Chapter 3, methods), 
we used another metric, the ROC Enrichment (ROCE), to quantify model performance at the 
early stage. ROCE is defined as the ratio of true positive rate to the false positive rate, at a 
given percentage of recovered known decoys 244. This metric is similar to the conventional 
Enrichment Factor metric but is independent of the ratio of decoys to actives in evaluated 
screening library. We report ROCE values at 1%, 2%, and 5% as recommended in previous 
publications. To ensure fair comparison, any compound with missing scores, either from 
removal of all its poses by pose filter or by docking error, were placed at the bottom of the 
ranked list. To estimate errors, we did 100 independent runs, and then reported the average 
and standard deviations to approximate the errors. In each run, 10% of the data was randomly 
selected and used to train the filter, which will later be applied to rank the remaining 90% 
data. (Figure 4.3)  
Randomization Test 
To examine the robustness of the proposed pose filters, we generated two random 
pose filters and compared their performance with the corresponding real pose filters. The first 
test resembles the Y-randomization test, where we scrambled the activity labels before 
training the pose filters. While in the second test we keep the activity labels, but randomly 
shuffling the PL/MCT-tess descriptor profiles. The active to decoy ratio was preserved in 
both cases. In short, the PL/MCT-RFFilter calculations were repeated with the randomized 
activities or descriptor profiles of the training set.  The estimated prediction error from the 
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developed randomForest models and their virtual screening performance were compared with 
models generated from real data, and see if there are significant difference.  
4.2.3.  Results and Discussion 
Before applying the virtual screening protocol for any real analysis, I used the 
benchmarked DUD data sets to assess the performance of the proposed approach. Thirteen 
datasets with diverse chemical features were selected in this case. For each data set, 10% of 
decoys and known actives were excluded randomly at each calculation, and used as the 
calibration set to determine the pose filter as described (methods).   
The average number of poses used in the pose filter construction and the estimated 
prediction errors are shown in Table 4.2. The sensitivity, specificity and CCR were 
calculated based on the out of bag (OOB) estimates during model generation 17,163. The 
results show that the overall accuracy in terms of CCR exceeds 0.80 for all data sets except 
ace, ache and fxa data sets. The sensitivities are generally lower than specificities, most 
probably due to the extreme imbalance of the training set. It would be interesting as a future 
study to implement different sampling approaches to down-size the decoy set before training 
the randomForest classifier, and see if that improves models’ performance. The successful 
construction of randomForest classifiers for most data sets in part demonstrated that our 
definition of native-like poses is practically reasonable.  
The ROC curves of the individual 13 DUD datasets using Chemgauss3, PL/MCT-dist, 
PL/MCT-similarityFilter, and PL/MCT-RFFilter were compared in Figure 4.4. The data in 
Figure 4.4 took the results from one of the 100 repeated studies as an example. Figure 4.5 
and 4.6 illustrates model performances in terms of overall ROC-AUC, ROCE at 1%, 2% and 
5%. It is obvious from the plots that the PL/MCT-RFFilter performs best compared to other 
 93 
 
approaches, showing good performance in both overall ranking and early enrichments. For 
all data set except cdk2 and hivrt, the PL/MCT-RFFilter approach gives AUC higher than 
ranking by the empirical scoring function Chemgauss3 score. On the contrary, we did not 
observe consistent improvements in terms of ROC-AUC after applying the PL/MCT-dist and 
PL/MCT-similarityFilter approach. It is in fact within our expectation that the PL/MCT-dist 
should show inconsistent performance across different data sets. The assumption behind the 
PL/MCT-dist protocol is simple and most often too optimistic: it uses the similarity of a 
ligand’s docking pose to the x-ray crystallized conformation as the only indicator of this 
pose’s fitness in the protein binding pocket. Any other favorable contacts that could lead to 
gain of energy are underestimated in this case. In compare with the PL/MCT-RFFilter, the 
PL/MCT-similarityFilter ignores the set of pre-excluded known actives when generating pose 
filter and does not acknowledge the distinct importance of each interaction descriptor type 
for classifying irrelevant versus native-like poses. Therefore, the PL/MCT-similarityFilter 
achieved better performance than using the Chemgauss3 scoring functions for a number of 
data sets, such as the ache, cox2, and pde5, with the best case of 32.3 fold enrichment at 1% 
of FPR. But in other cases, PL/MCT-similarityFilter has similar or even worse performance. 
Therefore, we could conclude that the relative better performance of PL/MCT-RFFilter can 
be attributed to its inclusion of more information during pose filter generation stage, which 
has been extensively discussed in a number of previous publications 60,226,227.  
In virtual screening, early recognition is a very critical criterion for evaluating model 
performances, because only the top fraction of ranked list will be subjected to further 
experimental validation in practice. The PL/MCT-RFFilter approach also showed clear better 
performance when early enrichment is considered, with the best example (cox2) giving an 
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enrichment of 56.9 fold at the false positive rate of 1%. Across all the evaluated data sets, the 
PL/MCT-RFFilter approach gives a substantially higher number of data sets with ROCE 
higher than 15 (10 out of 13 data sets) compared to using docking scores alone (6 out of 13 
data sets, Table 4.3 ). This further demonstrates the advantages of using PL/MCT-RFFilter 
approach, and the implementation of this interaction will be useful. Furthermore, the 
PL/MCT-dist method performs better than using Chemgauss3 scores in five data sets in terms 
of ROCE at 1% of false positive rate, especially for difficult cases like ache, pde5, and 
pdgfrb. This demonstrates that the statistical information contained in the protein ligand 
interaction descriptors alone can be informative in certain cases. It needs to be noted that the 
native-pose for pdgfrb and vegfr2 were not from experimentally solved x-ray complex 
structure, and that the receptor structure for pdgfrb is a homology model. So it is not 
surprising that the Chemgauss3 scoring function did not give good results for these two 
targets. The PL/MCT-RFFilter approach, however, gives good enrichment of 24.9 and 32.3 
fold, respectively, at the false positive rate of 1%. This result suggests that a reasonable 
prediction of the native-like ligand pose and including the knowledge of the critical protein-
ligand contacts can rescue virtual screening performance for likely inaccurate receptor 
structural models.  
To demonstrate the virtual screening results from PL/MCT-RFFilter approach is not 
by chance, we applied two types of fake pose filters during virtual screening and compared 
their performances with the pose filters constructed from the real data. These two artificial 
sets differ in whether the descriptor profiles are randomly shuffled or the activity labels are 
randomly shuffled. The pose filter trained from randomized descriptor or activity profile 
showed close to random classification accuracy, practically put every instance to the 
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dominant class, the decoy class. As shown in Figure 4.7, the virtual screening performance 
derived from scrambling the activity files will result in inseparable class distributions, 
leading to a pose filter that will classify any pose as decoys and eliminate them from further 
evaluation. On the other hand, the pose filter generated from randomly shuffled the 
descriptor files is able to derive a tentative pose filter, but this information is not relevant to 
the selection of native-like poses. As illustrated in Figure 4.7, this filter excluded 
indiscriminately of a fraction of the entire collection of poses, resulting in a similar or worse 
virtual screening performance as using the docking scores alone. In summary, this 
randomization test showed that the information extracted by the filter is not spurious, and 
could effectively guide the selection of native-like pose during virtual screening.  
4.3. Virtual Screening of Subtype Selective Ligands for the Beta Adrenoceptor Protein 
Family 
The major focus for this study is to evaluate whether the information from PL/MCT 
descriptors are capable of improving virtual screening of subtypes selective ligands. For the 
βAR protein family, there have been extensive studies on putative recognition sites in the 
binding pocket that can differentiate the binding propensities of a small molecule 245-247. 
General docking programs that evaluate ligands fitness solely based on energy considerations 
thus have difficult to discriminate these types of interactions. Imposing a number of 
intermolecular or pharmacophoric constraints can partially solve the problem, but is often too 
restrictive and yield few interesting hits. The PL/MCT-tess descriptors provide an option to 
include ligand information automatically during training the pose filter, for example, by 
including interfacial descriptors for non-selective ligands in the calibration set. However, it 
should be employed with great cautious, since it represents a much challenging task than 
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differentiate binding decoys or geometrical decoys from the active compounds, and requires 
discerning more delicate preferences of the different protein-ligand contacts. We have carried 
out a systematic study on a large collection of published human β1AR, β2AR, and β3AR 
structural models as well as two β2AR crystal structures, i.e., 2RH1 (released by the RCSB 
Protein Data Bank (PDB) on Oct. 30, 2007) and the latest, 3P0G (released by RCSB PDB on 
Jan. 19, 2011) (Table 4.4). The de novo designed structural models were collected from the 
same group whose β2AR model has shown a comparable or better virtual screening 
performance to the X-ray structures (Chapter 3). The five homology models were retrieved 
from the well-recognized modeling server ModWeb 248 and GPCRDB 249.  Both agonist and 
antagonist bound models were included when possible to account for any structural features 
associated with functional activity. 
4.3.1.  Small Molecule Data Set 
To perform any meaningful evaluations of the virtual screening performance for 
subtype selective binders within the beta adrenergic receptors family, we will need a 
reasonably large and accurate dataset representing different types of compounds targeting the 
beta-adrenergic receptor family. A dataset of 207 compounds were collected from the 
ChEMBL database, incorporating the data published from 1996 through 2009. Although the 
binding data were extracted from multiple sources, the protocols for binding assay were kept 
similar. Among all the binding data, only measurements using I-CYP as the radio-labeled 
ligand were considered. For purpose of identify subtype selective ligands, the compounds 
included in the final data set are mostly tested against two of three or all three subtypes of 
adrenergic receptors. (Exceptions were made for 11 compounds that are β2AR non-binders. 
They were included later during the QSAR modeling process to improve models’ 
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classification accuracy). In summary (Figure 4.8), for each subtype of βAR, there are 196 
compounds in β1AR data set (Ki from 0.017nM to 1mM) ; 207 compounds in β2AR data set 
( Ki from 0.14nM to 0.1mM ) ; and 166 compounds in β3AR data set (Ki from 1.1 nM to 
0.15mM). To simplify the situation, we did not distinguish between agonist, inverse agonist, 
and neutral antagonist within binders. This is also a legitimate approximation, because as 
shown in our previous studies, as well as in others’ work, the crystal structures represent a 
putative early activation stage, and is capable of retrieving both agonists and antagonists 
58,250-252. In addition, data for function assays often varies in experimental settings, making it 
difficult for a direct comparison. However, it would be definitely interesting in the future to 
explore the applicability of the described approach in predicting the overall complex 
pharmacological profiles of β adrenoceptor ligands.  
To date, NC-IUPHAR (International Union of Basic and Clinical Pharmacology 
Committee on Receptor Nomenclature and Drug Classification) has not published any 
recommendations to define a compound as selective ligand for a given receptor subtype 
within the protein family. However, although the selectivity varies based on the receptor 
types in consideration, a compound can be considered selective if its ratio of binding affinity 
is higher than 100 times 253. Here, due to the limited data sources for highly selective βAR 
ligands, we define a compound as selective if it has a modest selectivity and binding affinity:  
difference in pKi ≥1.5, and pKi >=6 for the desired subtype. By this definition, there are 20 
β1AR selective ligands, 8 β2AR selective ligands, and 12 β3AR selective ligands. We should 
note that the available β2 selective ligands are generally in a lower activity range, it 
represents a difficult case in this task.  
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4.3.2. Methods 
Drug-like Decoys Set:  
A standard decoy set was downloaded from Schrodinger’s website. It contains 1000 
decoys with drug-like properties. Unlike the DUD data sets where the decoys were specially 
designed to challenge the docking algorithms, the compounds from this decoy set resemble 
more of a real virtual screening campaign, where non target-specific, drug-like compounds 
were used. 
Protein Set Up and Docking Programs 
The protein structures were prepared with Glide protein preparation wizard to add 
missing hydrogen and assign partial charges (see Chapter 3). We used two different popular 
docking programs, the Glide (methods in Chapter 3) and Fred (see above in Pilot study). 
Both of the implemented scoring functions (Chemgauss3 and GlideScore) belong to the class 
of empirical scoring functions. Because Glide docking pose with GlideScore showed 
consistent better performance (0~5 fold better in ROCE at 1% of specificity) than 
Chemgauss3, I only report here the results from Glide docking.  
Assessment of Virtual Screening Performance 
Same performance evaluation metrics were used as in the pilot study.   
4.3.3. Results and Discussion 
Virtual Screening Using Pose Filters Generated from Known Inactives 
Initially, we tested whether the proposed approaches are able to identify active 
ligands from known inactives as well as drug-like decoys.  To generate the pose filters, the 
binding pose of a co-crystallized ligands (for β2Xtal୧, β2Xtalୟ), the binding pose derived 
from a simulation study (for β1EPIୟ, β2TAୟ,β3AJୟ), or the top Glide-score pose of a selected 
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potent ligand (for β1GPCRDB୧,  β1ModWeb୧, β1ModWebୟ, β3GPCRDB୧, β3ModWeb୧)  was 
employed as the reference pose, while the known inactives for each receptor type were 
utilized as the calibration set to derive the pose filters. Because the Glide docking was 
observed with good fidelity in pose predictions with our previous studies as well as other’s 
published work, it is reasonably safe to use the top-scored binding pose of the reference 
ligand from Glide docking to set the reference descriptors. Table 4.5 listed the information of 
the number of seeds and decoys used for each receptor model. Figure 4.9 shows the model 
performance using the default empirical scoring function GlideScore, versus the PL/MCT-
dist approach, PL/MCT-similarityFilter approach, and the PL/MCT-RFFilter approach as 
defined in the pilot study. The improvements from applying PL/MCT-similarityFilter or 
PL/MCT-RFFilter, however, were only marginal for most receptors, with the best case of 
β1ModWebୟ where the PL/MCT-RFFilter increases the ROCE at 1% from 4-fold to 8-fold 
compared with the Glide scores. There are several possible reasons for this marginal 
improvement in compare with those observed in the pilot study. First the poses selected via 
Glide score could be generally more native-like than the poses selected via Chemgauss3 
score 242,254, thus the improvements from applying a native-like pose classifier (pose filter) 
would be less prominent. This is highly likely the major cause, because we observed 
consistently better virtual screening performance of Glide score versus Chemgauss3 (up to 
200% increase in ROCE at 1%, data not shown). This is consistent to our previous 
observations 60, suggesting that the outcomes of applying the target-specific pose filter is 
dependent on the parent scoring function used. Second, we used a set of known inactives to 
generate the pose filter, instead of using the “putative inactive” decoys as in the pilot study. 
This is good in a sense that those compounds are true inactives, so all the docking poses 
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generated from this set can be safely put into the class of irrelevant binding poses. However, 
this set consists of relatively small number of chemical scaffolds, leading to a more biased 
calibration set and pose filters with less general applicability domain.   
Besides evaluating proposed approaches’ ability at identifying active compounds, we 
also evaluated how good they can enrich selective ligands at early stage. As we expected, all 
structural models except for β2Xtalୟ showed no preference for subtype selective ligands. The 
virtual screening results showed a much lower enrichment factor on selective ligands versus 
all known actives. Similarly, because the pose filters were not designed to differentiate 
subtype selective ligands, neither of the PL/MCT-similarityFilter and PL/MCT-RFFilter help 
to enrich subtype selective ligands. On the other hand, the PL/MCT-dist approach showed 
surprisingly good virtual screening performance on enriching selective ligands when using 
β1GPCRDB୧, β1ModWeb୧, and β2Xtal୧ models. This suggests that for certain receptor model 
and reference ligand combinations, the simple distance calculation between a docking pose 
and the reference pose could provide reasonable judgment as how likely the pose represents a 
selective ligand. More detailed discussions on how the selection of reference ligand could 
influence the virtual screening performance are provided in the next section.   
Virtual Screening of Selective Ligands using Subtype-biased Pose Filters 
In this study, we evaluated the possibility of selectivity biased pose filter by using the 
subtype selective ligand as reference and including the non-selective ligands into the 
calibration set when deduce the pose filters (Figure 4.2). Similar to what have been described 
in the previous section, the PL/MCT-tess descriptors derived from the top GlideScore pose of 
the reference ligand was used to define the native-like pose during the pose-filter training 
stage. Here, the two classes employed to derive randomForest models become putative 
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native-like poses of known selective ligand versus all poses of known non-selective and 
inactives. It should be emphasized again that all the pose information used during model 
training come from the hold-out set, which has been excluded from later model evaluation. 
As an example, Figure 4.10 showed the virtual screening performance using 
 β1ModWeb୧,  β2Xtalୟ, and β2TAୟ  receptor models. Comparing Figure 4.10F with Figure 
4.9B on the performance using β2TAୟmodel, it is clear that the virtual screening protocol of 
PL/MCT-similarityFilter and PL/MCT-RFFilter in combination with the subtype-biased 
setting (Figure 4.9 B) has the best ability to enrich β2 selective ligands. The two approach 
enabled a favorable ROCE reaching approximately 16-fold and 8-fold, respectively, over 
random at a false positive rate of 1%. Considering the fact that the reference ligand (β2 
selective agonist TA2005) used are same between these two tests, the different results 
suggest that using the subtype biased pose-filters are indeed helpful in discriminating non-
selective ligands from selective ones. The performance on enriching overall β2 active ligands 
did not change very much between these two experiments, showing that the employed pose-
filters only focus on the desired subset of ligand types. In addition to the implementation of a 
subtype biased pose-filter, the choice of reference ligand is also essential on the virtual 
screening results. When β1ModWeb୧ receptor structure model was used for docking and the 
non-selective β1 active compound Cyanopindolol was used as the reference, there is 
negligible difference between using the non-biased and subtype-biased pose filter (Figure 
4.10A versus Figure 4.9A). To further explore the influence of the choice of reference 
ligands, we used a β2 selective binder TA-2005 in combination with β2Xtalୟ, and repeated 
the pose filtering and scoring protocol (Figure 4.10D versus 4.10E). Both PL/MCT-
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similarityFilter and PL/MCT-RFFilter showed over 50% increase in early enrichment of β2 
selective ligands.  
As observed in Chapter 3, the structure models derived directly from homology 
modeling are usually having a suboptimal set of conformation of its binding pocket residues, 
making it difficult to establish favorable contact between receptor and known ligands. 
Although for each homology model (β1GPCRDB୧,  β1ModWeb୧, β1ModWebୟ, β3GPCRDB୧, 
β3ModWeb୧) we already adapted the receptor side chain conformations to a known potent 
ligand through the protein preparation wizard in Glide, their virtual screening outcomes are 
still unsatisfactory. There have been plenty studies trying to optimize structure models after 
homology modeling in order to promote ligand binding 58,251,252,255-257. In this study, we did 
not change the global packing of the trans-membrane regions or their relative orientations, 
but performed induced fit docking with selected ligands in hope of deriving receptor binding 
pocket models that are more appropriate for ligand binding. Briefly, the homology models 
and ligands tested were β1ModWeb୧ (with β1 selective ligand ICI89406), β1ModWebୟ (with 
β1 selective ligand Dobutamine) and β3ModWebୟ (with β3 selective ligand AJ-9677). The 
derived top-scored 10 receptor-ligand complexes were manually inspected and one protein-
ligand complex was selected for further virtual screening analysis. Structure conservation on 
those experimentally confirmed receptor-ligand interactions such as the Asp1133.32 and 
Asn3127.39 were closely examined. As a result, the shape of the selected binding pocket and 
the orientation of key residues are adapted to a known potent and subtype selective ligand. It 
should be noted that we only use induced fit docking in preparing the receptors and that the 
receptor side chains were kept rigid during the process of virtual screening. Take the 
β1ModWeb୧_refined model for example (Figure 4.10C GlideScore versus Figure 4.10B, 
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GlideScore), the customized binding pocket showed better recognition for β1 active as well 
as selective ligands, with an increased enrichment (ROCE at 1%) from 1.5 to 12.5 for actives 
and 0 to 15.1 for selective ligands. Applying the PL/MCT-dist, PL/MCT-similarityFilter and 
PL/MCT-RFFilter protocols on the docking poses further augmented the enrichment of 
selective ligands to 25.0-fold , 25.1-fold and 20.7-fold over random, respectively. 
The Molecular Basis of Subtype Selectivity from Identified Important PL/MCT-
tess Descriptors  
Using the RandomForest pose filter allows a systematic analysis of the importance of 
each protein-ligand interaction descriptors. We then counted the frequency of descriptors out 
of the 100 runs for their occurrence at the top 20 important descriptors. As an example we 
showed in Figure 4.11 for three most frequently observed descriptor types when using the 
combination of β2Xtalୟreceptor models with the β2-selective ligand TA2005. The ligand 
TA-2005 has a selectivity ratio of ~50 and ~150 for β2- versus β1 and β3 receptors, 
respectively 245,258. Three of the frequent observed PL/MCT-tess descriptors observed for 
TA-2005 are ClNlOlOr, ClOlNrOr, and ClClOlNr (Figure 4.11).  The ClNlOlOr descriptor 
depicted the salt bridge between TA-2005 with Asn3127.39, and the hydrogen bonds formed 
with Ser203ହ.ସଶ  and Ser204ହ.ସଷ . These residues have been shown to be important in binding 
b2AR agonists. The ClOlNrOr descriptor highlighted two other critical protein ligand 
interactions with Tyr3087.35 and Asn2936.55, both of which are believed to be involved in 
determining ligand selectivity 246. The ClClOlNr descriptor mapped an interesting contact 
between the N-substituent of the ligand with Lys305. This residue is an aspartic acid 
(Asp356) in β1, and a glycine (Gly325) in β3. These three residues are significantly different 
in size, and charge state, thus could have potential impact on subtype selectivity.   
 104 
 
4.3.4.  Conclusions 
In summary, we have proposed a general pose filter using the DFT derived protein-
ligand interaction descriptors (PL/MCT-tess) in structure-based virtual screening. The pose 
filter was validated with the 13 benchmarked DUD datasets with Fred docking program. The 
pose filter enables consistent improvement over using the default scoring functions by Fred 
for up to 6 fold in terms of ROCE at 1% of false positive rate. We further challenged the pose 
filter to identify subtype selective beta-adrenergic ligands. The results showed that it is 
possible to achieve reasonable results with carefully designed subtype biased pose filters, 
preferably using a selective ligand as the reference and a calibration set including both 
known nonselective and inactive molecules. In addition, we found that the homology models 
showed poor virtual screening performance in general, but can be further improved with an 
optimized conformation of the binding site residues. For instance, after optimize the binding 
pocket of the homology model β1ModWeb୧  with a selective β1AR ligand ICI89406, we 
observed an increase of ROCE from 0 to 15 fold over random at a false positive rate of 1%. It 
should be noted that the success of the proposed approach is heavily dependent on the 
previous knowledge, especially the selection of proper reference ligands to guide the 
structure modeling as well as docking pose selection. In future studies, it would be interesting 
to see how additional knowledge about the receptors, such as the conformational flexibility 
of the binding pockets can be employed into structure-based docking, and affect the virtual 
screening performance.  
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Tables and Figures 
 
A.  B.   
 
C.  D.  
 
Figure 4.1. The distribution of docking poses’ RMS deviation from the X-ray pose versus similarity 
of PL/MCT-tess descriptors calculated by Euclidean distances. A) for pdgfrb homology model and B-
D) for PDB 2RH1. A) The pose with the best MedusaScore is served as the reference to calculate the 
RMSD value of poses. The plot shows the pose distribution based on RMSD values (y-axis) versus Z-
score values of MedusaScore (x-axis, Z-score is calculated based on MedusaScore distribution of the 
decoy sets).  B) Average RMSD and standard deviation values for increasing distance to the reference 
pose in PL/MCT-descriptor space. A total of 1000 poses from 5 X-ray co-crystallized ligands were 
used. The distances are converted to Z-scores based on distribution of distances calculated by a drug-
like decoy set to the X-ray pose of PDB 2RH1. (see Table 4.5 for detail information of the decoy set). 
C) The pose distribution based on Z-score values of GlideScore (x-axis) vs. RMSD values (y-axis). D) 
The pose distribution based on Z-score values of distance to the native pose in PL/MCT-tess 
descriptor space (x-axis) vs. RMSD values (y-axis). The data points for the cognate ligand in PDB 
2RH1 is indicated with red circles.  Plot A. adapted from Hsieh et al.61. 
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Figure 4.2.  Flowchart of pose selection in training the proposed target-specific pose filter, PL/MCT-
RFFilter. 
  
 
 
 
Figure 4.3.  Flowchart of using the three described PL/MCT-dist, PL/MCT-similarityFilter, and 
PL/MCT-RFFilter approaches in structure-based virtual screening.  
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model of protein-ligand complex
DUD decoys (calibration set)
Known actives
Calculate PL/MCT-tess descriptors
30 docking poses per compound
Native pose
All docking poses for known actives
Determine the mean and standard deviation 
from the calibration set (μ,σ) 
Native-like poses with PL/MCT-tess
distance Z-score less than -1
Build randomForest binary 
classification model
Distribution of distances to the native pose in 
PL/MCT-tess descriptor space for decoys’ 
docking poses
All docking poses for DUD decoys
Virtual screening library
Test set
Training set
Known actives
+ DUD decoys
10%
90%
Calculate PL/MCT-tess descriptors
1.Rank by conventional scoring function
2.Rank by distance to cognate ligand
pose in PL/MCT-tess descriptors
(PL/MCT-dist)
Determine the distance cutoff in 
PL/MCT-tess descriptor space to filter 
irrelevant poses
(PL/MCT-similarityFilter)
Cleaned set A of docking poses
Cleaned set B of docking poses
Construct the randomForest
classifier to filter irrelevant poses
(PL/MCT-RFFilter)
3.Rank by conventional scoring function
4. Rank by conventional scoring function
 107 
 
 
 
 
 
 
Figure 4.4.  ROC enrichment plots for each of the 13 DUD data set. Dark red lines are based on 
Chemgauss3 scores, orange lines are based on PL/MCT-dist score, yellow lines are based on 
PL/MCT-similarityFilter approach, and green lines are based on PL/MCT-RFFilter approach.  
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Figure 4.5. ROC-AUC for each of the 13 DUD data set using Chemgauss3 scores (dark red), 
PL/MCT-dist (orange), PL/MCT-similarityFilter approach (yellow), and PL/MCT-RFFilter approach 
(green).   
 
 
 
 
Figure 4.6.  ROC enrichment for each of the 13 DUD data set using Chemgauss3 scores (dark red), 
PL/MCT-dist (orange), PL/MCT-similarityFilter approach (yellow), and PL/MCT-RFFilter approach 
(green).   
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E. ROC-AUC 
F. ROCE at 1% 
  
 
 Figure 4.7.  The ROC-AUC metric and ROC enrichment (ROCE) for each of the DUD data set with 
randomized activity/descriptor profiles. The results using Chemgauss3 scores (dark red) and 
PL/MCT-dist (orange) based on non-randomized profiles were regenerated from Figure 4.5, Figure 
4.6 for comparison. Yellow bars represent PL/MCT-RFFilter approach with scrambled activities. 
Green bars represent PL/MCT-RFFilter approach with scramble descriptor profiles. 
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Figure 4.8.  Activity distributions of the βAR data set. 
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Figure 4.9. The ROC-AUC metric and ROC enrichment (ROCE) for each of the βAR receptor type 
and structure model. 
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Figure 4.10. The ROC-AUC metric and ROC enrichment (ROCE) for each of the βAR receptor type 
and structure model with subtype biased pose filters.  
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A. ClNlOlOr B. ClOlNrOr 
C. ClClOlNr 
 
 
Figure 4.11. Important PL/MCT-tess descriptors summarized from subtype biased PL/MCT-RFFilter using 
β2Xtalୟ structure model and TA-2005 as the reference ligand. The  β2Xtalୟ receptor structure is colored in blue, 
while the β2 selective ligand is colored in orange. The tetrahedrons corresponding to the specified PL/MCT-tess 
descriptor are shown in stick. 
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Table 4.1. Summary of benchmark data sets used for pilot studies. Table adapted from 60  
Target Function PDB # of ligands # of decoys # of clusters
ace metallopeptidase 1o86 46 1726 19 
ache acetylcholine esterase 1eve 99 3631 19 
cdk2 serine/threonine kinase 1ckp 47 1776 32 
cox2 cyclooxygenase 1cx2 212 11841 44 
egfr tyrosine kinase 1m17 365 14516 40 
fxa serine protease 1f0r 64 1888 19 
hivrt HIV reverse transcriptase 1rti 34 1415 17 
inha enoyl ACP reductase 1p44 57 2501 23 
p38 serine/threonine kinase 1kv2 137 6230 20 
pde5 phosphodiesterase 1xp0 26 1562 22 
pdgfrb tyrosine kinase modela 124 5265 22 
src tyrosine kinase 2src 98 5216 21 
vegfr2 tyrosine kinase 1vr2b 48 2479 31 
a: protein structure is homology model, the ligand structure is taken from the DUD website 
b: apo structure, the ligand structure is taken from DUD website 
HIV: Human Immunodeficiency Virus; ACP: Acyl Carrier Protein  
 
 
 
Table 4.2. Statistics of target-specific pose filter PL/MCT-RFFilter calculated based on out of bag 
(OOB) estimates. Data is based on the average statistics derived from 100 runs of 10% randomly 
selected hold-out set.  
 TP FP TN FN SE SP CCR 
ace 71.71 1.76 5389.24 76.29 0.48 1.00 0.74 
ache 77.04 1.38 7782.62 137.96 0.36 1.00 0.68 
cdk2 151.74 1.50 6180.30 54.16 0.73 1.00 0.86 
cox2 1070.98 7.72 39844.28 208.02 0.84 1.00 0.92 
egfr 191.24 1.20 47972.20 79.11 0.70 1.00 0.85 
fxa 209.17 7.01 17150.79 229.83 0.48 1.00 0.74 
hivrt 95.93 0.55 4556.45 34.07 0.74 1.00 0.87 
inha 147.89 1.72 9796.28 90.11 0.62 1.00 0.81 
p38 226.89 3.26 7787.14 41.01 0.83 1.00 0.91 
pde5 214.79 1.62 5926.38 50.21 0.79 1.00 0.90 
pdgfrb 274.52 0.54 13159.06 80.38 0.77 1.00 0.88 
src 355.54 1.04 18944.26 95.36 0.79 1.00 0.89 
Vegfr2 198.57 1.69 8699.01 57.43 0.77 1.00 0.88 
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Table 4.4. The synonym of ten human βAR structural models employed in this study. 
Receptor 
subtype 
Models 
name 
Model type Details 
β1AR β1EPIa de novo 
model 
In complex with endogenous βAR agonist epinephrine 
(T. Lybrand group ) 
 
 β1GPCRDBi Homology 
model 
Based on the crystal structure of inactive state turkey  
β1AR (PDB 2VT4) (retrieved from GPCRDB website, 
constructed in G. Vriend group ) 
 
 β1ModWebi Homology 
model 
Based on the crystal structure of inactive state turkey  
β1AR (PDB 2VT4) (retrieved from ModWeb server, 
provided by A. Sali group ) 
 β1ModWeba Homology 
model 
Based on the crystal structure of active state turkey  
β1AR (PDB 2Y00) (retrieved from ModWeb server, 
provided by A. Sali group ) 
β2AR β2TAa de novo 
model 
In complex with selective β2AR agonist TA2005 (T. 
Lybrand group ) 
 
 β2Xtali X-ray crystal 
structure 
Crystal structure of human β2AR (PDB 2RH1) in 
complex with non-selective antagonist carazolol. 
 
 β2Xtala X-ray crystal 
structure 
Crystal structure of human β2AR (PDB 3P0G) in 
complex with non-selective agonist BI-167107. 
β3AR β3AJa de novo 
model 
In complex with selective β2AR agonist AJ-9677 (T. 
Lybrand group ) 
 
 β3GPCRDBi Homology 
model 
Based on the crystal structure of inactive state turkey  
β1AR (PDB 2VT4) (retrieved from GPCRDB website, 
constructed in G. Vriend group ) 
 β3ModWebi Homology 
model 
Based on the crystal structure of inactive state β2AR 
(PDB 3kj6) (retrieved from ModWeb server, provided by 
A. Sali group ) 
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Table 4.5. The actual number of compounds used for deriving pose filters and calculating ROCE and 
AUC metrics. 
 
 
 
 
 
 
 
aThe bound ligand for each structure model  were excluded from the calculation. 
bA number of decoys were filtered by Glide before the refinement stage. They thus did not have a 
Glide score and were treated to be at the end of the ranked database.
Structure/Model Reference 
ligand 
aBinders 
Num. 
aSelective 
binders Num. 
bNonbinders 
Num. 
β1EPIa Epinephrine 42 20 32 
β1GPCRDBi Cyanopindolol 42 20 32 
β1ModWebi Cyanopindolol 42 20 32 
β1ModWeba Dobutamine 42 20 32 
β2TAa TA-2005 45 8 43 
β2Xtali Carazolol 45 8 43 
β2Xtala BI-167107 45 8 43 
β3AJa AJ-9677 58 12 21 
β3GPCRDBi Cyanopindolol 58 12 21 
β3ModWebi Cyanopindolol 58 12 21 
 
 
Chapter 5. Development of Predictive in vivo toxicity Models from 
Combined Knowledge of Chemical Structure Information and the 
ToxCastTM in vitro Data  
5.1.  Introduction 
Chemical toxicity is associated with many hazardous biological effects in rodents and 
humans, such as gene damage, carcinogenicity, or induction of lethal diseases. It is essential 
to evaluate potential toxicities of all commercial chemicals before releasing them into the 
market, among which High Production Volume (HPV) compounds and drugs are of highest 
priority. However, traditional research in toxicology mostly relies on animal toxicity tests 
which are both labor and resource intensive, so only a very limited number of the chemicals 
in commerce have been evaluated 145-148. With the recent ban on using animal for toxicity 
testing of cosmetics in the European Union, it becomes more urgent for industry to develop 
novel solutions for toxicity assessment 23,149. In this context, the use of fast computational 
toxicology and high-throughput in vitro toxicity assays is gaining widespread interest 
because of their promise for supporting reduction, refinement, and/or replacement (the 3Rs) 
of the reliance on animal toxicity experiments147,150.  
However, accurate prediction of in vivo toxicity using computational tools is always 
challenging. Although cheminformatics approaches such as Quantitative Structure-Activity 
Relationship (QSAR) modeling have been widely used in computational toxicology 151,152, 
most existing tools can not generate models that afford reasonable prediction accuracy when 
applied to external compounds, resulting in inadequate model applicability for regulatory 
purposes 153,154. Possible causes for such unsatisfactory performance are first, small 
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molecules and their metabolites can act through multiple mechanisms and hit various 
physiologically important targets to cause distinct adverse effects 20,21, herein, little variance 
in molecular structure could lead to distinct biological outcomes, making it hard to generalize 
rational rules from QSAR modeling. Also, the small molecules in the screening database 
were designed for different reasons with various scaffolds (e.g. pesticides, food additives, 
cosmetic ingredients). Most previous QSAR models were constructed from cogeneric 
compounds and had limited extrapolation power to deal with these structurally diverse 
compounds. On the other hand, the development of various in vitro toxicity testing methods, 
such as cell-based and cell-free HTS techniques, as well as toxicogenomic technologies, 
offered potential biological basis for estimating the adverse effects of chemicals22-24,147,155. It 
is intriguing to incorporate the knowledge from in vitro testing data to improve traditional 
QSAR modeling.  
In 2007, the U.S. Environmental Protection Agency (U.S. EPA) initiated a chemical 
prioritization research program, the ToxCastTM project, to outline future toxicity evaluation in 
vivo 22. The overall goal of this program is to explore a diverse array of in vitro toxicity 
assays, such as cell-based and cell-free HTS techniques, as well as toxicogenomic 
technologies, to estimate the adverse effects of environmental chemicals and prioritize 
candidates for animal testing in the future. To support ToxCastTM’s endeavor of predictive 
toxicology, U.S. EPA compiled and curated an array of high-quality historical animal 
toxicity data on several hundred chemicals in the Toxicity Reference Database (ToxRefDB) 
156. Phase I of ToxCastTM is primarily consisted of chemicals from these available animal 
toxicity data, and produced data from ~600 high-throughput and high content in vitro toxicity 
assays. Hence, the ToxCastTM program provides a valuable data set that could be used to 
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study the relationships between chemical structures, short term in vitro data and long term in 
vivo toxicity experiments.  
In this study, we endeavored to improve the risk estimates for chemical toxicity 
through a series of novel computational approaches. To have an unbiased assessment of the 
derived models, these models were all developed and validated with the extensive collection 
of data enabled by the ToxCastTM project. The QSAR modeling workflow developed in-
house for many years has been successfully applied to develop computational models for 
mutagenicity 157, carcinogenicity 25, aquatic toxicity 130 and acute toxicity158,159. In the first 
part, we employed a similar workflow to evaluate the possibility to build statistically robust, 
validated, and externally predictive QSAR models based on chemical descriptors alone. We 
employed multiple machine-learning algorithms, namely Random Forrest (RF), Support 
Vector Machines with linear kernel (SVM-linear), and Support Vector Machine with RBF 
kernel (SVM-RBF). The modeling results showed that four (two chronic and two 
reproductive rat toxicity endpoints) out of the eighteen evaluated in vivo toxicity endpoints 
yielded reasonable Correct Classification Rate (CCR) for external sets: consistently above 60% 
using all three types of modeling algorithms. In addition, another group member in our lab 
demonstrated that by using specific chemical scaffolds to pre-cluster the original data set, we 
could further improve the external predictivity of the resulting model. Thus, the results 
indicate that the development of externally validated toxicity predictors, while through 
careful study design, is feasible for at least some of the ToxRefDB endpoints.  
              In addition to advancing the traditional QSAR modeling approaches that 
depend on the explicit information about chemical structure alone, we have continued to 
develop novel Quantitative Structure in vitro-in vivo Relationship (QSIIR) approaches to 
 122 
 
enable robust and predictive cheminformatic predictors of animal toxicity. Our recent studies 
have shown that it is possible to utilize the correlation between rodent acute toxicity data (in 
vivo data) and cytotoxicity data (in vitro data) to enhance the performance of traditional 
chemical-descriptors-based QSAR models 27,28. In this project, we further explored our 
methodologies by applying a similar modeling workflow to three rat reproductive toxicity 
endpoints for the ToxCastTM Phase I compounds. The prediction accuracy for the best models 
was in the range of (70-71%) for all three in vivo endpoints, while that achieved by 
conventional QSAR models was only (57-64%) for the same external set. Furthermore, the 
external predictivity of individual models was employed to infer important ToxCastTM in 
vitro assays. The validated hierarchical models could be helpful for future toxicity testing by 
prioritizing high-risk compounds for animal tests, identifying informative in vitro assays, as 
well as providing hypothesis for specific signaling or biochemical pathways that are relevant 
to potential disease development and thus have the possibility of going beyond hazard 
identification. 160 
5.2.  Data Set Overview 
The ToxCastTM phase I study consisted of 320 molecules with diverse chemical 
scaffolds. Five duplicates and three triplicates of eight randomly selected compounds were 
deliberately included to quantify the reproducibility of the bioassay protocols.161 In this study, 
the eleven replicated compounds were excluded. Furthermore, we excluded all molecules 
that cannot be appropriately handled by conventional cheminformatics techniques, e.g. 
inorganic and organometallic compounds or mixtures. The final ToxCastTM data set used in 
this study contained 291 unique organic compounds.  
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The relevant animal toxicity data were obtained from ToxRefDB, developed by the 
National Center for Computational Toxicology (NCCT) in partnership with U.S. EPA’s 
Office of Pesticide Programs (OPP). The in vivo toxicity endpoints included in ToxRefDB 
were based on rat, mouse and rabbit 2-year chronic/cancer, 2-generation reproductive, and 
developmental toxicity study. Each of the 291 ToxCastTM compounds has experimental 
results for up to 78 different in vivo toxicity endpoints in ToxRefDB. Most of the in vivo 
endpoints had few numbers of active responses among all ToxCastTM compounds and were 
not suitable for QSAR modeling. For this reason, we selected 18 (Table 5.1) out of the 78 
published in vivo endpoints that had the most experimentally active results. In addition, in the 
original ToxRefDB record, toxic compounds were stored with their associated Lowest Effect 
Level (LEL) values with units of mg/kg/day. We converted it to binary form, where 
compounds’ activities are defined according to NCCT as either active (toxic) or inactive 
(non-toxic)148. The numbers of ToxCastTM phase I compounds in each toxicity endpoint 
subset range from 224 to 235, and the active compound ratio ranges from 17.4% to 44.6% 
(Table 5.1). 
The ToxCastTM Phase I compounds have been tested against 615 various bioassays as 
listed in Table 5.2. These in vitro assays aimed to characterize a wide range of chemical 
biology interactions through a number of protein function assays, transcriptional reporter 
assays, multi-cell analysis, and developmental studies using zebra fish embryos 162. These 
assays were developed by different biological companies and have been used for toxicity 
screening tests over years. All endpoints were presented as Inhibition Concentration by 50% 
(IC50), Lowest Effect Level (LEL) or Lethal Dose Concentration by 50% (LD50). Similar to 
how we handled the in vivo data above, we converted the experimental values into binary 
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form for active/inactive responses. It is noticeable that some bioassays are not informative 
due to the low ratio of signals on the 291 compounds. (Table 5.2) To avoid possible 
complications introduced by these assays during QSAR modeling process, they were 
excluded from the scope of work. Finally, 284 out of 615 assays were selected for which 
there are at least 10 active responses for the curated chemical data set. 
5.3. Methods:  
5.3.1. Generation of Chemical Descriptors 
A set of 2,489 theoretical molecular descriptors was initially generated from the 
canonical SMILES notation using the software Dragon v.5.5 (version 5.5; Talete SRL, 
Milano, Italy). Only 0D, 1D and 2D descriptors were considered in this study. We then 
removed descriptors that are constant or near constant (all, or all but one value is constant). If 
two descriptors are highly correlated (pair wise correlation over 95%), one of them, chosen 
randomly, was also deleted. The final set include 1,128 descriptors, and were range scaled to 
0~1. A detailed description for descriptor generation and preparation can be found in 10. 
5.3.2.  In vitro – In vivo Correlation for Data Classification 
The relationship between the results obtained from an in vitro test and a specific in 
vivo toxicity endpoint could be summarized as 4 categories. (Figure 5.1) The Class B and C 
compounds have consistent results in vivo and in vitro. In this study, we merge them together 
into a new class, which is called Group 1; and Class A and D compounds, which have 
conflicting results in vivo and in vitro, were combined to be Group 2.  Through this way, we 
could generate new compound classes based on the in vitro – in vivo correlation between 
each in vivo endpoint results in ToxRefDB and every individual ToxCastTM bioassay testing 
result.  
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5.3.3.  QSAR Modeling Workflow and Model Validations 
A rigorous modeling workflow was carried out in order to ensure the selected models 
are statistically significant and externally predictive. (Figure 5.2) Key steps of the workflow 
are described below. Binary classification QSAR models were generated based on the 
chemical information only (traditional QSAR workflow) 10, or employing the chemical 
information and in vitro vs. in vivo correlation data (novel hierarchical workflow).  
Balancing the Dataset 
For each toxicity endpoint in this study, there were many more inactives than actives. 
This imbalanced class ratio is notorious in skewing the modeling procedure and result in 
biased statistics, e.g., much lower sensitivity than specificity of predictions. To address this 
bias, the following methodology excluded a considerable fraction of inactive compounds 
from the dataset to balance the active/inactive ratio. We used the active compounds from 
each endpoint results to create a probe subset and calculated the similarity between each 
inactive compound and the probe subset based on the Euclidean distance of all chemical 
descriptors between this inactive compound and the most similar active compound. We 
selected the inactive compound most similar to the active compounds into the modeling set 
and repeated this procedure for each active compound until the ratio of inactives in each 
modeling set was between 50% and 55%. This effort resulted in final datasets for all 18 
toxicity endpoints for the classification QSAR modeling consisting of 45-50% actives and 
50-55% inactive compounds. (Table 5.4) 
Modeling Algorithms 
Random forest and Support Vector Machines (SVM) algorithms were used in this 
study. In machine learning, a Random Forest (RF) predictor 163,164 consists of many decision 
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trees and calculates a prediction based upon the combined output from individual trees. For 
the RF modeling procedure, n samples are randomly drawn from the original data. These 
samples are then used to construct n training sets and to build n trees. For each node of the 
tree, m variables are randomly chosen from the descriptor set. The best data split for each 
training set was calculated using these m variables. In this study, only the defined parameters 
(n = 500 and m = 13) were used for the model development 17. 
The Support vector machine (SVM), developed by Vapnik 165, serves as a general 
data modeling methodology where both the training set error and the model complexity are 
incorporated into a special loss function that is minimized during model development. SVM 
has since become a popular method in statistical learning because of its consistently 
outstanding performance in many studies and lower risk of over fitting 166,167 . In brief, an 
SVM model finds a separating hyperplane with a maximal margin in the feature space by 
minimizing a special-loss function that incorporates both the training set error and the model 
complexity. To cope better with different classification tasks, e.g. linear vs. nonlinear 
correlations, a handful of kernel functions were developed to map the original descriptor 
space to a higher dimensional feature space for modeling purpose.   
In this study, we used the SVM implementation in the R package kernlab to build 
models with both linear kernels and Radial Basis Function (RBF) kernels. The RBF kernel 
was chosen due to its superior performance in a previous research 18. In developing our 
models, a hard margin of cost=10 was used, and the RBF kernel parameter γ  was 
automatically estimated with the sigest function in the kernlab package 125. 
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Model Applicability Domain 
 A properly defined applicability domain (AD) of a model was considered critical to 
determine if a given query compound can be predicted by this model within a reasonable 
error. For each model used in this study, an AD was determined by a threshold distance DT 
between a query compound and its nearest neighbors in the training set, calculated as follows:  
DT ൌ yത ൅ Zσ  Where ݕത  is the average Euclidean distance between each compound in the 
training set and its k nearest neighbors (here, k=1), σ is the standard deviation of these 
Euclidean distances, and Z is an arbitrary parameter to control the significance level. Here, 
we set the default value of  Z as 0.5 to obtain reasonable prediction coverage. Thus, if the 
distance of a query compound from any of its k nearest neighbors in the training set exceeds 
this threshold, the prediction is considered unreliable and will not be included.  
Model Validation 
As emphasized in our earlier reports14, modeling of only training sets is insufficient to 
achieve predictive power. For this reason, model validation in this study was carried out in 
three levels: 1. 5-fold internal cross validation prediction accuracy for the test set CCRtest; 2. 
5-fold external cross validation prediction accuracy for the external validation set CCRext; 3. 
Y-randomization test that consists of rebuilding models using randomly shuffled activity 
labels, and subsequent evaluation of their predictive power on the external validation set. 
Finally, in the novel hierarchical modeling workflow (Figure 5.2), individual models each 
associated with a specific in vitro vs. in vivo correlation will be employed for consensus 
prediction of the external set. The new compounds will first be predicted as Group 1 or 2 for 
their in vitro – in vivo correlations. The in vitro testing results for the same compounds will 
then be used to convert the predicted correlation groups to the predicted in vivo toxicity. 
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Finally, the consensus prediction value of any compound from the external set was calculated 
as follows: y୮୰ୣୢ ൌ ሺ∑ y୮୰ୣୢ୨ୱ୨ୀଵ IAD୨ ሻ/ሺ∑ IAD୨ୱ୨ୀଵ ሻ  ;  IAD୨ ൌ ቄ1 in AD0 out ofAD    For a query 
compound, we calculated the mean of the prediction values (y୮୰ୣୢ୨ ሻfor this compound from 
all of the selected models (j=1~s). Each model has a model specific applicability domain (IAD୨ ) 
as defined above. The compound will be labeled active or inactive based on the average 
prediction value.  
To develop models from imbalanced data, the overall classification accuracy is less 
objective to evaluate the performance of models. To obtain an unbiased metric for 
classification ability, sensitivity and specificity are used to separately monitor the 
classification accuracy on two classes, and the CCR is calculated by averaging the prediction 
accuracies.  
ܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕ ൌ ܶܲܶܲ ൅ ܨܰ ;  ܵ݌݂݁ܿ݅݅ܿ݅ݐݕ ൌ
ܶܰ
ܶܰ ൅ ܨܲ ;   ܥܥܴ ൌ
ሺܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕ ൅ ܵ݌݂݁ܿ݅݅ܿ݅ݐݕሻ
2  
where TP and FP represent the numbers of predicted true and false positive 
compounds, and TN and FN represent the number of predicted true and false negative 
compounds, respectively. A permutation test (10,000 permutations) was developed to 
identify hierarchical models with significant better CCRext in comparison with the 
corresponding traditional QSAR models utilizing chemical descriptors only.  If the 
differences between the real pair of CCRext fell within the upper 95th percentile (p < 0.05) of 
the permuted data, then the corresponding hierarchical model was considered statistically 
superior than traditional QSAR models. The permuted CCRext percentile values for all 
hierarchical models were then employed to rank the importance of the corresponding in vitro 
assays for a specific in vivo toxicity effect.  
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5.4.  Results 
5.4.1. Traditional QSAR Modeling with chemical descritors only 
For each individual in vivo endpoint, we first evaluated the performance of predictors 
developed by conventional QSAR modeling approaches. All 18 in vivo toxicity subsets were 
compiled based on the 291 ToxCastTM compounds and their toxicity data in ToxRefDB. The 
QSAR toxicity models were developed for each in vivo endpoint subset using the Dragon 
descriptors of the relevant compounds.  We employed RF, SVM-linear, and SVM-RBF 
algorithms with default parameters and five-fold internal/external cross validation for model 
training and testing. Therefore, we developed fifteen individual models for each toxicity 
endpoint, five models for each modeling algorithms. External cross-validation predictions 
were characterized by Correct Classification Rate (CCRext), sensitivity, and specificity, and 
are summarized in Figure 5.3A, 5.3B and 5.3C, respectively. The bean plots in Figure 5.3 
simultaneously show the distribution of the 15 cross-validation predictions, and the mean of 
the performance evaluation metrics for each in vivo endpoint, grouped by the choice of 
applicability domain. Models for two (ChrRatCholinesteraseInhib and MgrRatLiver) of these 
eighteen toxicity endpoints demonstrated CCR above 60% for all three types of QSAR 
models. After implementing the applicability domain for each individual model, four toxicity 
endpoints, including two chronic (ChrRatCholinesteraseInhib and ChrMouseTumorigen) and 
two reproductive rat toxicity endpoints (MgrRatLiver and MgrRatKidney), were shown to 
have CCR over 0.60 (Figure 5.3, Table 5.3). However, in general, there is no consistent 
enhancement in models’ external predictivity after the application of model AD. In fact, the 
CCRs of four toxicity endpoints, namely ChrRatLiverhypertrophy, 
DevRabbitPregEmbryoFetalLoss, DevRabbitPregMaternalPregLoss, and MgrRatLiver were 
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reduced after AD application. Therefore, we showed that we can achieve moderate 
improvement for some but not all toxicity models by using AD.  
In addition, the models typically had poor prediction performance on the minority 
class (less than 0.4 in sensitivity for 14 toxicity endpoints), which is common when dealing 
with imbalanced data sets. Although we only selected the endpoints which were relatively 
rich in toxic signal, the curated data still had considerably more non-toxic than toxic 
chemicals for each toxicity endpoint subset. To address this bias, we balanced each modeling 
set by excluding non-toxic chemicals that are dissimilar to the toxic set. In summary, up to 
70 % of non-toxic compounds were excluded to achieve a relatively balanced data sets (with 
class ratio in the range of 1~1.2).  Classification QSAR models were then re-trained only on 
compounds remaining in the balanced modeling set, and their predictive power was 
estimated using the unmodified external sets.  With this procedure, we made it more 
challenging to attain predictive QSAR model as it has to discriminate toxic chemicals from 
most chemically similar non-toxic chemicals.  
As expected, balanced datasets afforded improved prediction accuracy for the toxic 
class (Figure 5.4, Table 5.4). The sensitivity increased by 0.15 in most cases. Models for six 
out of eighteen endpoints showed reasonable accuracy for the toxic class with sensitivities 
higher than 0.6.  However, the overall external prediction accuracy in CCR showed only 
moderate improvements due to a decrease in specificity after such data modification. The 
best external predictivity was achieved for ChrRatCholinesteraseInhib endpoint using 
SVM_Rbf and SVM_Linear models with CCR 0.88; ChrRatLiverhypertrophy endpoints 
using all three models with CCR 0.61; MgrRatKidney endpoint using RF models with CCR 
0.67; and MgrRatLiver endpoint using RF and SVM_rbf models with CCR 0.62. It should be 
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noted that differ from the rest endpoints, the ChrRatCholinesteraseInhib endpoint was 
derived from single-target focused assays, which measure compounds’ inhibition rates on 
Cholinesterase. So it represents an “easy” case for QSAR modeling, and was used as a 
positive control in this study. These results suggest that employing traditional QSAR 
modeling with chemical descriptors alone; it is possible to develop externally validated 
toxicity predictors for several of the ToxRefDB toxicity endpoints.  
5.4.2.  Evaluation of the Activity Landscapes of Toxicity Data Sets  
The failure of conventional QSAR models to achieve statistically significant models 
for most in vivo toxicity endpoints may be due to lack of sufficient chemical space coverage 
and inability of chemical descriptors to account for the toxicity mechanisms involved with 
the relevant endpoints. To visualize the level of activity landscape discontinuity in the dataset, 
we plotted pair wise similarities between compounds of the same (i.e. both toxic, or both 
non-toxic) and different (i.e. one toxic and another non-toxic) in vivo toxicity labels. Figure 
5.5 illustrated such visualization for the rat toxicity endpoint measured on kidney 
microscopic and gross pathologies (MgrRatKidney). We found a large proportion of pairs 
with divergent toxicity effects which are chemically and/or biologically similar when 
measured with Dragon chemical descriptors, and ToxCastTM assays, respectively. The 
comparison of Metolachlor and its nearest neighbor in chemical space, Acetochlor, may 
serve as a good example for such discontinuity (so called “activity cliff”168). Since 
Acetochlor and Metolachlor are chemically similar (with the Tanimoto similarity coefficient 
of 0.82 calculated using MACCS keys), they are expected to have similar biological 
activities. However, their toxicity profiles in three rodent reproductive toxicity endpoints are 
remarkably different; they only have similar effects for MGR_Rar_Viability endpoint (Figure 
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5.5B). Although there are examples where small changes to key molecular features give rise 
to significant changes in activity, existence of a large number of such conflicting pairs in the 
database lowers its generalization power during modeling and, as a result, make it difficult to 
achieve externally predictive models. On the other hand, Acetochlor and Metolachlor can be 
viewed as quite dissimilar when, instead of structural features, they are compared by their 
results in in vitro assays (Figure 5.5B).  Therefore, we tried to rebuild QSAR modeling using 
the in vitro assay results as the biological descriptors or using the hybrid descriptors by 
combining chemical descriptors and biological descriptors. Depite previous successful 
application of these protocols26,159, we could not achieve significant improvents using either 
one for the ToxCast data. Possible causes could be that the available in vitro assays have low 
informative signals for the concerned in vivo endpoints, especially when compared with the 
influence from the chemical descriptors. These observations suggest that it is, indeed, 
challenging to develop robust QSAR models with either chemical descriptors or biological 
descriptors alone. However, as shown in the Figure 5.5A, most chemical-similar pairs of 
compounds with conflicting toxicity lables can be differentiated in the biological space, and 
vice versa. It is reasonable to expect that the additional knowledge embedded in the in vitro 
biological profiles could be useful to differentiate pairs of chemically similar compounds that 
have different toxicity profiles.  
5.4.3.  Hierarchical QSAR Modeling Using in vivo versus in vitro Correlations  
It is well known that in vitro testing results, especially those obtained from HTS 
bioassays, have unsatisfactory correlations with systemic toxicity endpoints when any 
relatively large set of compounds is considered. The ToxCastTM bioassay data is no exception. 
There is no direct correlation between most ToxCastTM bioassay and any ToxRefDB in vivo 
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endpoint results (e.g.  1.5% of assay-in vivo toxicity endpoints pairs showed p-value of less 
than 0.01, calculated with fisher’s exact test). As expected, no significant improvements in 
the model accuracies were observed whether using the in vitro assay alone as descriptors, or 
using the hybrid descriptors that directly combine the chemical and in vitro biological 
descriptors. How to extract relevant information from the ToxCastTM bioassay data and to 
apply it for QSAR modeling became a critical question. In this study, we extended the 
concept of “in vitro vs. in vivo correlation” that has been successfully employed to utilize 
information from cytotoxicity bioassays to predict rodent acute toxicity 158. Similar 
approaches were reviewed elsewhere 169. Using this criterion, for each of the reproductive 
toxicity data set, we can first select one in vitro assay as the basis and then partition the 
ToxCastTM compounds into two groups: Group 1, in which compound’s in vivo toxicity 
agrees with the in vitro results of the ToxCastTM bioassay; and Group 2, if otherwise (Figure 
5.2). Picking a different ToxCast assay as a basis, partitioning can be redefined. As a result, 
multiple assay-specific QSAR models were developed to classify compounds into assay-
specific partitions, instead of directly predicting compounds’ in vivo toxicities. The derived 
QSAR models were then used to assign compounds in an external dataset to one of the in 
vitro vs. in vivo correlation groups (i.e. group 1 or group 2). The group membership was 
converted into the associated in vivo toxicity based on the known in vitro response of the 
assay used as a basis. 
To demonstrate the effectiveness of this hierarchical workflow, we applied it to three 
rodent reproductive endpoints: 1) Multigeneration Reproductive Rat Kidney toxicity 
(MgrRatKidney); 2) Multigeneration Reproductive Rat Liver toxicity (MgrRatLiver); and 3) 
Multigeneration Reproductive Rat Endpoint for Viability Index (MgrRatViabilityPND4). 
 134 
 
After processed the original data with the above described procedure, the size ratio of the 
created partitions was again balanced with the same down-sampling approach, until it 
reached a balanced ratio in the range of 1~1.2. We applied the hierarchical modeling 
workflow for each of the 284 ToxCastTM in vitro assays and, therefore, 284 individual QSAR 
models of one type (RF, SVM_linear or SVM_rbf) were generated for each reproductive 
toxicity endpoint. Next, the consensus prediction results were derived by averaging all 
predictions from the 284 models.  
Compared to their conventional QSAR model counterparts, only marginal 
improvement seems to have been achieved by using the consensus hierarchical models. 
Considering the fact that there are many irrelevant bioassays included for consensus 
prediction, it is possible that the models based on such bioassays would only contribute noise 
and thus lower the accuracy of the final consensus estimation. Indeed, we observed similar 
prediction accuracies by using hierarchical models only from a subset of the bioassays (Table 
5.5). The subset of assays was selected based on their active ratio for the compounds in the 
modeling set. For each modeling set, a different list of assays with the highest active ratio 
was collected, and the predictions from their associated hierarchical models were employed 
for consensus prediction of the independent external set. While using a very small number of 
assays was shown to weaken the predictive power by consensus prediction (data not shown), 
we observed comparable model performance by including a number of 80 top-ranked 
bioassays. This result suggests that current consensus hierarchical models could be improved 
with a rational selection of the relevant bioassays, such as by incorporating the knowledge of 
the toxicity pathways to identify essential ToxCastTM assays.  On the other hand, considering 
the fact that the bioassays are not entirely independent, generally, with multiple assays 
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targeting the same signaling pathways, or even the same macromolecular targets, consensus 
predictions can be biased towards pathways that have been tested more often than the others.  
To reduce such artificial noise, instead of using individual assays, it might be helpful to 
employ “composite” assays, for instance, merge all signals from nuclear receptor assays to 
one. Then build hierarchical QSAR models and calculate consens predictions based on those 
composite assays.  
Here, we employed another solution to reduce the influence of irrelevant bioassays is 
to exclude a fraction of compounds whose consensus scores did not reach certain level. 
Ideally, the distribution of predicted values for the toxic and non-toxic compounds should 
yield clear separation (Figure 5.6B). Irrelevent predictions tend to blur the boundaries of the 
consensus values, but the prediction confidence increases as the consensus score reaches a 
higher level.  For instance, we can arbitrarily defined a compound as “toxic” if more than 70% 
of individual models predicted it to be toxic and as “non-toxic” if more than 90% of 
individual models predicted it as non-toxic. Predictions for compounds that did not satisfy 
these two confidence levels were excluded as “inconclusive”. Using this definition, the 
external predictivity of all the models for the three rodent endpoints was improved (up to 
0.08 increase in average CCRext) at the cost of reduced prediction coverage (27% to 45% 
decrease; Table 5.5).  Figures 5.7A, 5.7C and 5.7E show the relationship between external 
CCR and different toxic/non-toxic confidence breakpoints for MGR_Rat_Liver models. It 
should be noted that all three types of models for this specific endpoint have the highest 
external predictivity when the confidence breakpoints for toxic compounds are between 60-
90% and the confidence breakpoints for non-toxic compounds are between 80-95%. The 
performance of RF and SVM-RBF models were relatively insensitive to different breakpoint 
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values, whereas the external accuracy of the SVM-linear model strongly depended on the 
breakpoint values being used. In addition to external cross-validation, we also tried to assess 
model robustness by Y randomization test, where QSAR models were rebuilt using modeling 
sets with shuffled toxicity data. The prediction accuracy of shuffled models was close to 
random (Figures 5.7B, 5.7D and 5.7F). 
5.4.4. The Relationship between Individual ToxCastTM Bioassays and the 
Reproductive Toxicity Endpoints 
We observed significant variation in prediction performance of hierarchical models 
based various bioassays. By analyzing hierarchical models with high external predictivity 
(CCRext) values, we expected to identify critical bioassays that are informative of in vivo 
toxicity effects. Therefore, we performed a permutation test (10,000 times) to evaluate each 
model’s performance in compariaon to the conventional chemical-descriptors-only QSAR 
model. Table 5.6 lists the top 20 best-performing ToxCastTM bioassays for each multi-
generation reproductive toxicity endpoint. Many of these assays were targeting genes in the 
family of cytochrome P450 enzymes, which are involved with the xenobiotic metabolism 
pathways. Several conjugating–enzymes that are active in placental xenobiotic metabolism 
are also identified: glutathione S-transferase (GSTA2), uridine 5’-diphosphate-
glucuronosyltransferase (UGT1A), and sulfotransferase (SULT2A1). During pregnancy, the 
mothers are exposed to a wide variety of environmental chemicals. Placental xenobiotic-
metabolizing enzymes will respond to those foreign chemicals, and can either reactivate or 
detoxify those compounds 170,171. Those metabolites were observed, at least partially, to cross 
the placenta into the fetal circulation172. Therefore, understanding how placenta xenobiotic 
metabolizing enzymes react to the environmental hazards could provide the basis for 
predicting and analyzing reproductive and developmental toxicity. Estrogen receptor alpha 
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(ATG_ERa_TRANS) and estrogen-related receptor gamma (ATG_ERRg_TRANS) were 
also shown to be informative for estimating reproductive toxicity, especially on early 
offspring survival. Environmental chemicals are believed to interfere with the endocrine 
system by acting through estrogen receptors, thus generating adverse reproductive effects, 
including decreased fertility and implantation loss 173. In addition, our results also showed 
high relevance of multigenerational reproductive toxicity to assays targeting serotonin 
receptors (HTR4, HTR6, and HTR7) and nuclear receptors (human pregnane X receptor 
(NR112), NR113). Thus, based on current understanding of mechanisms of toxicity, these 
data suggest that our methods are capable of selecting physiologically relevant assays, and 
thus can also be applied to guide potential mode-of-action analysis for future toxicity testing. 
5.5.  Discussion 
A great number of computational technologies such as QSAR are increasingly 
involved in all aspects of risk assessment of environmental chemicals. Many of such 
approaches, however, were initially developed for use in drug discovery, which differs from 
toxicity evaluation in a number of important ways 174. For example, chemical diversity of 
environmental toxicants is usually higher than in case of drug candidates, making it a 
challenging task to derive statistically robust models. In addition, unlike drug candidates that 
are developed with specific targets in mind, and have optimized physicochemical properties 
for proper absorption, distribution, metabolism, and excretion, environmental chemicals do 
not have uniform and well understood mechanisms behind their toxicity effects. The 
requirements to the QSAR models for regulatory purpose are also different from that for drug 
design. Accurately predicting “toxic” class (i.e. high recovery rate) and not so accurate 
prediction of “non-toxic” class is preferred for regulatory purpose, because predicted as non-
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toxic would label compounds for low-priority in experimental tests, so toxic compounds 
predicted as “non-toxic” falsely would not be tested. The opposite may be desired in drug 
design, where the emphasis is to identify drug candidates with minimus experimental effort 
(high hit rate). Large number of false positives, inactive compounds predicted as active, will 
thus not favored. In sum, it is crucial to take into account of these differences during model 
development.  
The compounds included in Phase I data of ToxCastTM project are also quite 
structurally diverse, as indicated by the distribution of Tanimoto coefficient (MACCS key) 
calculated for each compound to its most chemical similar counterpart. Around 30% of the 
ToxCastTM compound pairs have Tanimoto coefficients lower than 0.7, the cutoff 
commonly used to define structurally similar compounds. In comparison, the 644 compounds 
in the aquatic toxicity dataset130 are much more structurally similar. Only 10% of compound 
pairs in the aquatic toxicity data set have Tanimoto less than 0.7, and over 44% of compound 
pairs have Tanimoto over 0.9. To evaluate the correlation of structural similarity/diversity 
with the performance of our models, we calculated the average Euclidean distances between 
each toxic compound and its most similar toxic compound for the 18 data sets. The dragon 
descriptors were used here for distance calculation because they were employed during 
model development. Our results showed that the toxic compounds are most similar to each 
other in the best chemical-descriptors-based QSAR model, the 
ChrRatCholinesteraseinhibition model. Thus, it indicates that the structural elements 
responsible for in vivo toxicity may not be sufficiently present in the ToxCastTM compounds 
to afford their statistical identification/generalization. Additional experiments for a diverse 
set of chemicals should be beneficial for the development of robust predictors.  
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It is understandably challenging to establish, for large and diverse data sets, direct 
correlation between chemical structures and their observed effects in biological systems. 
Chemical compounds and their metabolites can elicit similar toxicity effect through different 
mode-of-actions and perturbing different biological pathways. Indeed, we could only derive 
reasonably predictive QSAR models for four out of the eighteen in vivo toxicity endpoints. 
One of the endpoints ChrRatCholineInhibitor showed exceptionally high accuracy at CCR 
over 0.80, primarily because this toxicity response was measured on the interaction with a 
specific target, unlike the rest toxicity endpoints. As described above, a marginal structural 
variation from Metolachlor to Acetochlor leads to very different in vivo toxicity profiles for 
these two compounds. On the other hand, test results from a wide series of in vitro assays in 
ToxCastTM could provide preliminary information on how chemicals interact with various 
toxicity pathways, and thus are expected to be useful for predictive models. To unite these 
two sources of information most effectively, we propose a novel hierarchical workflow to 
incorporate data from in vitro assays and chemical structure information into the prediction 
of systemic toxicity effects observed in animal tests. The rationale of the hierarchical 
modeling described in this chapter is that by grouping compounds exhibiting the same 
agreement between selected in vitro and in vivo responses, we are in a better position to 
identify and generalize those factors affecting in vitro to in vivo extrapolation (i.e. similar 
patterns of metabolism or modes of action). In our studies, the models derived from 
hierarchical modeling workflow has best prediction accuracy in the range of (0.70~0.71) in 
comparison to traditional QSAR models (0.57~0.64). However, predictions from general 
consensus of the hierarchical models are not always optimal; we can achieve comparable 
modeling performance with 80 in vitro assays with the highest signal contesnts. Due to the 
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fact that many irrelevant in vitro assays may contribute noise to the consensus predictions, 
we expect to see an increase in model performance if those assays could be identified and 
removed from consideration. Indeed, another group member, Liying Zhang, showed that by 
pre-clustering the in vitro assays according to known biological pathways, and using only the 
assays that fall into several biologically relevant pathways could enhance the model 
performance in certain cases. To better test capability of this modeling workflow, it would be 
interesting to apply it to other ToxCastTM data sets.    
5.6. Conclusions 
In conclusion, we have examined the utility of the chemical structure descriptors and 
the ToxCastTM bioassay data for predicting in vivo toxicity of environmental chemicals using 
QSAR modeling approaches. Our results indicate that the conventional QSAR models using 
chemical descriptors alone and the ToxCastTM bioassay results individually have limited 
predictive power. For some endpoints, e.g. MGRRatLiver, it is possible to use conventional 
QSAR models to achieve good predictivity for a subset of compounds with restricted 
scaffolds. Furthermore, although the ToxCastTM bioassay data have low correlations with in 
vivo toxicity data, they can still be useful for improving the predictive power of QSAR 
models when implemented within the novel two step hierarchical QSAR modeling workflow. 
This hierarchical QSAR modeling workflow, although dependent on availability of in vitro 
data, can help to identify relevant in vitro toxicity assays for particular in vivo endpoints and 
thus could be a helpful tool for elucidating mechanisms of toxicity. Overall, the derived 
models could be used to guide future toxicity studies by choosing in vitro assays and by 
prioritizing compounds for in vivo toxicity evaluation.  
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Tables and Figures 
 
Figure 5.1. Data set partitioning based on the in vivo and in vitro toxicity responses. Class 1 consists 
of compounds whose in vitro and in vivo responses agree:  toxic in vivo and in vitro, or non-toxic in 
vivo and in vitro; Class 2 consists of compounds whose in vitro and in vivo responses disagree: toxic 
in vivo but non-toxic in vitro, or non-toxic in vivo but toxic in vitro. 
 
Group1: in vivo/ in vitro agree
Group2: in vivo/ in vitro disagree
 142 
 
A. 
B. 
C. 
* In the later section, we compared the results for after applying or not the strategies to re-balance 
class ratio of the modeling set 
Figure 5.2. Modeling workflow. (A)  Preparation of the target data set. (B) Modeling procedure for 
the data set.(C) external prediction procedure 
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ATG_AHR_CIS 0 0 
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SOLIDUS_P450 0 1 
*1: toxic or active; 0: non-toxic or inactive. 
 
Figure 5.5. Illustration of activity discontinuities in the chemical and biological space. A. Pair wise 
distance map with data pairs color-coded by in vivo toxicity class measured for MGR_Rat_Kidney 
(black, pairs of nontoxic compounds; green, pairs of toxic compound; red, pairs of toxic and nontoxic 
compound.) The arrow indicates the pair of compounds: Metolachlor and Acetochlor. B. In vivo and 
in vitro toxicity profiles of Metolachlor, and its nearest neighbor in chemical descriptor space, NN1-
Acetochlor.  
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A. 
 
B. 
Figure 5.6. Distribution of predictions of the ideal case (A) and the hierarchical QSAR models 
(RandomForest approach) for MgrRatLiver endpoint (B). As can be seen better separation of two 
experimental categories is achieved by using two breakpoints at 0.10 and 0.70 (such classification 
would correspond to CCR=0.70 and Coverage~37%). 
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A. RF B. RF with randomized toxicity data 
C. SVM-linear D. SVM-linear with randomized toxicity data 
E. SVM-RBF F. SVM-RBF with randomized toxicity data 
Figure 5.7. Heatmap illustration of CCRext for MGR_Rat_Liver endpoint when different breakpoints 
values are used to define toxic or non-toxic compounds. 
  
 
150
Ta
bl
e 
5.
1.
 O
ve
rv
ie
w
 o
f 
re
sp
ec
tiv
e 
ch
em
ic
al
 s
ub
se
ts
 f
or
 t
he
 1
8 
in
 v
iv
o 
to
xi
ci
ty
 e
nd
po
in
ts
 u
se
d 
in
 t
hi
s 
st
ud
y 
(s
ee
 U
.S
. 
EP
A
 1
61
 f
or
 f
ur
th
er
 
in
fo
rm
at
io
n 
of
 th
es
e 
as
sa
ys
) 
En
dp
oi
nt
s 
Sy
no
ny
m
 
C
at
eg
or
y 
Te
st
 
sp
ec
ie
s 
N
um
be
r o
f 
C
om
po
un
ds
 
A
ct
iv
e 
R
at
io
 
(%
) 
C
H
R
_M
ou
se
_L
iv
er
P
ro
lif
er
at
iv
eL
es
io
ns
 
C
hr
M
ou
se
Li
ve
rP
ro
lif
Le
si
on
s 
C
hr
on
ic
 to
xi
ci
ty
 
M
ou
se
 
22
8 
38
.2
 
C
H
R
_M
ou
se
_L
iv
er
Tu
m
or
s 
C
hr
M
ou
se
Li
ve
rT
um
or
s 
C
hr
on
ic
 to
xi
ci
ty
 
M
ou
se
 
22
8 
29
.8
 
C
H
R
_M
ou
se
_T
um
or
ig
en
 
C
hr
M
ou
se
Tu
m
or
ig
en
 
C
hr
on
ic
 to
xi
ci
ty
 
M
ou
se
 
22
8 
38
.6
 
C
H
R
_R
at
_C
ho
lin
es
te
ra
se
in
hi
bi
tio
n 
C
hr
R
at
C
ho
lin
es
te
ra
se
In
hi
b 
C
hr
on
ic
 to
xi
ci
ty
 
R
at
 
23
5 
17
.4
 
C
H
R
_R
at
_L
iv
er
H
yp
er
tro
ph
y 
C
hr
R
at
Li
ve
rh
yp
er
tro
ph
y 
C
hr
on
ic
 to
xi
ci
ty
 
R
at
 
23
5 
26
.0
 
C
H
R
_R
at
_L
iv
er
P
ro
lif
er
at
iv
eL
es
io
ns
 
C
hr
R
at
Li
ve
rP
ro
lif
Le
si
on
s 
C
hr
on
ic
 to
xi
ci
ty
 
R
at
 
23
5 
25
.5
 
C
H
R
_R
at
_T
um
or
ig
en
 
C
hr
R
at
Tu
m
or
ig
en
 
C
hr
on
ic
 to
xi
ci
ty
 
R
at
 
23
5 
39
.1
 
D
E
V
_R
ab
bi
t_
G
en
er
al
_F
et
al
W
ei
gh
tR
ed
uc
tio
n 
D
ev
R
ab
bi
tG
en
er
al
Fe
ta
lW
gt
Lo
ss
 
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
ab
bi
t 
22
4 
20
.0
 
D
E
V
_R
ab
bi
t_
P
re
gn
cy
R
el
at
ed
_E
m
br
yo
Fe
ta
lL
os
s 
D
ev
R
ab
bi
tP
re
gE
m
br
yo
Fe
ta
lL
os
s 
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
ab
bi
t 
22
4 
29
.5
 
D
E
V
_R
ab
bi
t_
P
re
gn
cy
R
el
at
ed
_M
at
er
na
lP
re
gL
os
s
D
ev
R
ab
bi
tP
re
gM
at
er
na
lP
re
gL
os
s
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
ab
bi
t 
22
4 
44
.6
 
D
E
V
_R
ab
bi
t_
S
ke
le
ta
l_
A
xi
al
 
D
ev
R
ab
bi
tS
ke
le
ta
lA
xi
al
 
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
ab
bi
t 
22
4 
22
.8
 
D
E
V
_R
at
_G
en
er
al
_F
et
al
W
ei
gh
tR
ed
uc
tio
n 
D
ev
R
at
G
en
er
al
Fe
ta
lW
gt
Lo
ss
 
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
at
 
23
5 
33
.2
 
D
E
V
_R
at
_P
re
gn
cy
R
el
at
ed
_E
m
br
yo
Fe
ta
lL
os
s 
D
ev
R
at
P
re
gE
m
br
yo
Fe
ta
lL
os
s 
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
at
 
23
5 
21
.7
 
D
E
V
_R
at
_P
re
gn
cy
R
el
at
ed
_M
at
er
na
lP
re
gL
os
s 
D
ev
R
at
P
re
gM
at
er
na
lP
re
gL
os
s 
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
at
 
23
5 
19
.1
 
D
E
V
_R
at
_S
ke
le
ta
l_
A
xi
al
 
D
ev
R
at
S
ke
le
ta
lA
xi
al
 
D
ev
el
op
m
en
ta
l 
to
xi
ci
ty
 
R
at
 
23
5 
43
.0
 
M
G
R
_R
at
_K
id
ne
y 
M
gr
R
at
K
id
ne
y 
R
ep
ro
du
ct
iv
e 
to
xi
ci
ty
 
R
at
 
23
2 
29
.3
 
M
G
R
_R
at
_L
iv
er
 
M
gr
R
at
Li
ve
r 
R
ep
ro
du
ct
iv
e 
to
xi
ci
ty
 
R
at
 
23
2 
43
.1
 
M
G
R
_R
at
_V
ia
bi
lit
yP
N
D
4 
M
gr
R
at
V
ia
bi
lit
yP
N
D
4 
R
ep
ro
du
ct
iv
e 
to
xi
ci
ty
 
R
at
 
23
2 
28
.0
 
  
 
151
Ta
bl
e 
5.
2.
 O
ve
rv
ie
w
 o
f t
he
 se
le
ct
ed
 2
84
 T
ox
C
as
t b
io
as
sa
ys
.  
(s
ee
 U
.S
. E
PA
 16
1,
17
5  f
or
 fu
rth
er
 in
fo
rm
at
io
n 
of
 th
es
e 
as
sa
ys
) 
  
C
om
pa
ny
 
So
ur
ce
 
D
es
cr
ip
tio
n 
N
um
be
r o
f a
ss
ay
s 
se
le
ct
ed
 (p
ro
vi
de
d 
as
sa
ys
) 
Sp
ec
ie
s 
En
dp
oi
nt
M
ax
im
um
 te
st
ed
 
co
nc
en
tr
at
io
n 
(μ
M
) 
A
ct
iv
e 
da
ta
 ra
tio
 
(%
 ) 
A
C
E
A
 
R
ea
l-t
im
e 
C
el
l 
El
ec
tro
ni
c 
Se
ns
in
g 
6 
(7
) 
H
um
an
 
IC
50
 
10
0 
17
.4
 
A
tta
ge
ne
 
Tr
an
sc
rip
tio
n 
fa
ct
or
 
as
sa
ys
 
31
 (7
3)
 
H
um
an
 
LE
L 
10
0 
22
.0
 
B
io
S
ee
k 
C
el
l-b
as
ed
 p
ro
te
in
 le
ve
l 
as
sa
ys
 
10
1 
(1
74
) 
H
um
an
 
LE
L 
40
 
22
.7
 
C
el
lu
m
en
 
C
el
l i
m
ag
in
g 
as
sa
ys
 
46
 (5
7)
 
H
um
an
 
IC
50
 
20
0 
12
.7
 
C
el
lz
D
ire
ct
 
Tr
an
sc
rip
tio
n 
as
sa
ys
 
31
 (4
2)
 
H
um
an
 
LE
L 
40
 
11
.6
 
G
en
tro
ni
x 
H
TS
 g
en
ot
ox
ic
ity
 
1 
(1
) 
H
um
an
 
LE
L 
20
0 
10
.3
 
N
C
G
C
 
N
uc
le
ar
 re
ce
pt
or
 a
ss
ay
s
7 
(1
8)
 
H
um
an
; R
at
; 
IC
50
 
20
0 
2.
0 
N
ov
aS
cr
ee
n 
R
ec
ep
to
r b
in
di
ng
 a
nd
 
en
zy
m
e 
in
hi
bi
tio
n 
as
sa
ys
 
57
 (2
39
) 
H
um
an
; R
at
; M
ou
se
; 
R
ab
bi
t; 
P
ig
; G
ui
ne
a 
P
ig
; 
S
he
ep
; C
ow
 
IC
50
 
20
 a
nd
 5
0 
2.
8 
S
ol
id
us
 
P
45
0 
vs
. c
yt
ot
ox
ic
ity
 
as
sa
ys
 
4 
(4
) 
H
um
an
 
LC
50
 
96
0 
22
.1
 
  
 
152
Ta
bl
e 
5.
3.
 P
re
di
ct
io
n 
ac
cu
ra
cy
 o
f 5
-f
ol
d 
ex
te
rn
al
 v
al
id
at
io
n 
fo
r R
an
do
m
Fo
re
st
 (R
F)
 a
nd
 tw
o 
ty
pe
s o
f S
V
M
 (S
V
M
_l
in
ea
r, 
SV
M
_r
bf
) m
od
el
s. 
H
er
e,
 
on
ly
 sh
ow
s t
ox
ic
ity
 m
od
el
in
g 
re
su
lts
 fo
r e
nd
po
in
ts
 th
at
 h
av
e 
m
od
el
s w
ith
 re
as
on
ab
le
 p
re
di
ct
io
n 
ac
cu
ra
cy
 (C
C
R
 >
=0
.6
). 
En
dp
oi
nt
 
M
od
el
_t
yp
e
A
ct
iv
e 
ra
tio
 
M
od
el
in
g 
se
t
Ex
te
rn
al
 s
et
 
A
D
-a  
A
D
+b
 
%
 a
cc
ur
ac
y 
 
C
C
R
 
SE
 
SP
 
C
C
R
 
SE
 
SP
 
C
ov
er
ag
e 
C
hr
M
ou
se
Li
ve
rP
ro
lif
Le
si
on
s 
R
F 
38
.2
 
0.
52
~0
.5
7 
0.
56
 
0.
22
 
0.
90
 
0.
57
 
0.
21
 
0.
93
 
0.
69
 
S
V
M
_l
in
ea
r 
0.
50
~0
.5
9 
0.
57
 
0.
47
 
0.
67
 
0.
55
 
0.
43
 
0.
67
 
0.
69
 
  
S
V
M
_r
bf
 
  
0.
53
~0
.5
8 
0.
60
 
0.
41
 
0.
79
 
0.
61
 
0.
45
 
0.
77
 
0.
69
 
C
hr
M
ou
se
Tu
m
or
ig
en
 
R
F 
38
.6
 
0.
57
~0
.6
4 
0.
58
 
0.
28
 
0.
89
 
0.
61
 
0.
35
 
0.
87
 
0.
68
 
S
V
M
_l
in
ea
r 
0.
47
~0
.5
8 
0.
55
 
0.
43
 
0.
67
 
0.
55
 
0.
42
 
0.
68
 
0.
68
 
  
S
V
M
_r
bf
 
0.
49
~0
.6
4 
0.
57
 
0.
38
 
0.
77
 
0.
59
 
0.
43
 
0.
76
 
0.
68
 
C
hr
R
at
C
ho
lin
es
te
ra
se
In
hi
b 
R
F 
17
.4
 
0.
73
~0
.8
0 
0.
75
 
0.
51
 
0.
98
 
0.
76
 
0.
54
 
0.
98
 
0.
69
 
S
V
M
_l
in
ea
r 
0.
80
~0
.8
6 
0.
83
 
0.
71
 
0.
95
 
0.
85
 
0.
75
 
0.
96
 
0.
69
 
S
V
M
_r
bf
 
  
0.
79
~0
.8
2 
0.
81
 
0.
66
 
0.
97
 
0.
84
 
0.
71
 
0.
97
 
0.
69
 
M
gr
R
at
K
id
ne
y 
R
F 
29
.3
 
0.
58
~0
.6
1 
0.
59
 
0.
25
 
0.
93
 
0.
62
 
0.
32
 
0.
91
 
0.
72
 
S
V
M
_l
in
ea
r 
0.
52
~0
.6
2 
0.
51
 
0.
37
 
0.
66
 
0.
54
 
0.
43
 
0.
65
 
0.
72
 
S
V
M
_r
bf
 
  
0.
60
~0
.6
4 
0.
59
 
0.
37
 
0.
82
 
0.
62
 
0.
45
 
0.
78
 
0.
72
 
M
gr
R
at
Li
ve
r 
R
F 
43
.1
 
0.
59
~0
.6
8 
0.
68
 
0.
53
 
0.
83
 
0.
63
 
0.
46
 
0.
79
 
0.
64
 
S
V
M
_l
in
ea
r 
0.
48
~0
.6
0 
0.
60
 
0.
55
 
0.
66
 
0.
57
 
0.
52
 
0.
62
 
0.
64
 
  
S
V
M
_r
bf
 
0.
54
~0
.6
1 
0.
63
 
0.
58
 
0.
68
 
0.
61
 
0.
58
 
0.
64
 
0.
64
 
S
ta
tis
tic
s 
ra
ng
e 
fo
r 1
8 
en
dp
oi
nt
s:
  
0.
44
~0
.8
5
0.
00
~0
.7
5
0.
53
~0
.9
8
0.
64
~0
.7
2 
a.
 M
od
el
 p
er
fo
rm
an
ce
 w
ith
ou
t u
si
ng
 a
pp
lic
ab
ilit
y 
do
m
ai
n.
 M
od
el
 c
ov
er
ag
e 
is
 1
00
%
 
b.
 M
od
el
 p
er
fo
rm
an
ce
 a
fte
r u
si
ng
 a
pp
lic
ab
ili
ty
 d
om
ai
n 
 
  
 
153
Ta
bl
e 
5.
4.
 P
re
di
ct
io
n 
ac
cu
ra
cy
 o
f 
5-
fo
ld
 e
xt
er
na
l 
va
lid
at
io
n 
on
 b
al
an
ce
d 
m
od
el
in
g 
se
ts
 u
si
ng
 R
an
do
m
Fo
re
st
 (
R
F)
 a
nd
 t
w
o 
ty
pe
s 
of
 S
V
M
 
(S
V
M
_l
in
ea
r, 
SV
M
_r
bf
) m
od
el
s. 
H
er
e,
 o
nl
y 
sh
ow
s 
to
xi
ci
ty
 m
od
el
in
g 
re
su
lts
 fo
r e
nd
po
in
ts
 th
at
 h
av
e 
m
od
el
s 
w
ith
 re
as
on
ab
le
 p
re
di
ct
io
n 
ac
cu
ra
cy
 
(C
C
R
 >
=0
.6
). 
 En
dp
oi
nt
 
M
od
el
_t
yp
e
A
ct
iv
e 
ra
tio
M
od
el
in
g 
se
t
Ex
te
rn
al
 s
et
 
A
D
- 
A
D
+ 
C
C
R
_C
V*
  
C
C
R
  
SE
  
SP
  
C
C
R
 S
E 
SP
 C
ov
er
ag
e 
C
hr
M
ou
se
Li
ve
rP
ro
lif
Le
si
on
s 
R
F 
49
.1
 
0.
53
~0
.6
4 
0.
61
 0
.6
4 
0.
58
0.
62
 
0.
66
 
0.
58
 
0.
69
 
S
V
M
_l
in
ea
r 
0.
49
~0
.6
7 
0.
55
 0
.5
9 
0.
52
0.
52
 
0.
55
 
0.
48
 
0.
69
 
  
S
V
M
_r
bf
 
  
0.
50
~0
.6
7 
0.
57
 0
.6
2 
0.
51
0.
57
 
0.
61
 
0.
53
 
0.
69
 
C
hr
R
at
C
ho
lin
es
te
ra
se
In
hi
b 
R
F 
45
.5
 
0.
75
~0
.8
8 
0.
82
 0
.7
8 
0.
85
0.
79
 
0.
65
 
0.
94
 
0.
36
 
S
V
M
_l
in
ea
r 
0.
71
~0
.8
6 
0.
80
 0
.8
3 
0.
77
0.
88
 
0.
85
 
0.
91
 
0.
36
 
S
V
M
_r
bf
 
  
0.
72
~0
.8
6 
0.
82
 0
.8
8 
0.
76
0.
88
 
0.
85
 
0.
91
 
0.
36
 
C
hr
R
at
Li
ve
rh
yp
er
tro
ph
y 
R
F 
47
.3
 
0.
54
~0
.6
2 
0.
59
 0
.6
6 
0.
53
0.
61
 
0.
52
 
0.
70
 
0.
43
 
S
V
M
_l
in
ea
r 
0.
45
~0
.6
0 
0.
54
 0
.5
9 
0.
49
0.
61
 
0.
55
 
0.
67
 
0.
43
 
  
S
V
M
_r
bf
 
  
0.
47
~0
.6
6 
0.
53
 0
.6
6 
0.
41
0.
61
 
0.
55
 
0.
67
 
0.
43
 
D
ev
R
at
G
en
er
al
Fe
ta
lW
gt
Lo
ss
 
R
F 
47
.3
 
0.
45
~0
.5
9 
0.
52
 0
.4
9 
0.
55
0.
59
 
0.
60
 
0.
58
 
0.
63
 
S
V
M
_l
in
ea
r 
0.
40
~0
.5
1 
0.
46
 0
.4
1 
0.
52
0.
49
 
0.
46
 
0.
52
 
0.
63
 
S
V
M
_r
bf
 
  
0.
42
~0
.5
6 
0.
47
 0
.4
4 
0.
50
0.
49
 
0.
50
 
0.
49
 
0.
63
 
M
gr
R
at
K
id
ne
y 
R
F 
47
.7
 
0.
55
~0
.7
0 
0.
60
 0
.5
6 
0.
64
0.
64
 
0.
67
 
0.
60
 
0.
63
 
S
V
M
_l
in
ea
r 
0.
47
~0
.5
8 
0.
50
 0
.4
9 
0.
52
0.
53
 
0.
51
 
0.
55
 
0.
63
 
S
V
M
_r
bf
 
  
0.
48
~0
.5
8 
0.
55
 0
.5
0 
0.
59
0.
59
 
0.
59
 
0.
60
 
0.
63
 
M
gr
R
at
Li
ve
r 
R
F 
48
.8
 
0.
58
~0
.6
3 
0.
69
 0
.6
7 
0.
70
0.
63
 
0.
59
 
0.
67
 
0.
62
 
S
V
M
_l
in
ea
r 
0.
51
~0
.5
4 
0.
58
 0
.6
0 
0.
56
0.
56
 
0.
59
 
0.
53
 
0.
62
 
  
S
V
M
_r
bf
 
0.
53
~0
.5
7 
0.
64
 0
.6
3 
0.
65
0.
59
 
0.
59
 
0.
59
 
0.
62
 
S
ta
tis
tic
s 
ra
ng
e 
fo
r 1
8 
en
dp
oi
nt
s:
 
0.
35
~0
.8
8
0.
26
~0
.8
5
0.
33
~0
.9
4
0.
36
~0
.7
2
 
  
 
154
Ta
bl
e 
5.
5.
 P
re
di
ct
io
n 
ac
cu
ra
cy
 o
f e
xt
er
na
l v
al
id
at
io
n 
se
ts
 fo
r t
hr
ee
 ra
t i
n 
vi
vo
 re
pr
od
uc
tiv
e 
to
xi
ci
ty
 e
nd
po
in
ts
 u
si
ng
 c
on
ve
nt
io
na
l Q
SA
R
 m
od
el
in
g 
w
or
kf
lo
w
 u
til
iz
in
g 
ch
em
ic
al
 d
es
cr
ip
to
rs
 o
nl
y 
ve
rs
us
 h
ie
ra
rc
hi
ca
l Q
SA
R
 m
od
el
in
g 
w
or
kf
lo
w
. B
ol
d 
fo
nt
 s
ho
w
s 
pr
ed
ic
tio
n 
ac
cu
ra
cy
 a
fte
r u
si
ng
 th
e 
co
nf
id
en
ce
 th
re
sh
ol
d 
(>
0.
7 
fo
r t
ox
ic
 a
nd
 <
=0
.1
 fo
r n
on
-to
xi
c)
. A
bb
re
vi
at
io
ns
: C
on
v.
 Q
SA
R
, C
on
ve
nt
io
na
l Q
SA
R
; H
ie
r. 
Q
SA
R
-2
84
, H
ie
ra
rc
hi
ca
l 
Q
SA
R
 u
si
ng
 th
e 
en
tir
e 
bi
ol
og
ic
al
 p
ro
fil
e 
fr
om
 th
e 
28
4 
in
 v
itr
o 
as
sa
ys
 f
or
 c
on
se
ns
us
 p
re
di
ct
io
n;
 H
ie
r. 
Q
SA
R
-8
0,
 H
ie
ra
rc
hi
ca
l Q
SA
R
 u
si
ng
 8
0 
as
sa
ys
 w
ith
 th
e 
hi
gh
es
t a
ct
iv
e 
ra
tio
 fo
r c
on
se
ns
us
 p
re
di
ct
io
n 
(s
ee
 te
xt
 fo
r d
et
ai
ls
). 
M
od
el
 ty
pe
 
R
F 
 
SV
M
-L
in
ea
r 
 
SV
M
-R
B
F 
En
dp
oi
nt
s 
C
C
R
SE
SP
C
ov
er
ag
e
R
O
C
-
A
U
C
 
C
C
R
SE
SP
 C
ov
er
ag
e
R
O
C
-
A
U
C
 
C
C
R
SE
SP
C
ov
er
ag
e
R
O
C
-
A
U
C
M
gr
R
at
K
id
ne
y 
C
on
v.
 
Q
SA
R
 
0.
64
0.
67
0.
60
0.
63
 
 
0.
53
0.
51
0.
55
 
0.
63
 
 
0.
59
0.
59
0.
60
0.
63
 
H
ie
r. 
Q
SA
R
-2
84
 0
.6
5
0.
51
0.
79
0.
72
 
0.
70
 
0.
56
0.
51
0.
61
 
0.
72
 
0.
62
 
0.
61
0.
55
0.
68
0.
72
 
0.
67
0.
71
0.
75
0.
67
0.
35
 
 
0.
62
0.
83
0.
41
 
0.
30
 
 
0.
69
0.
85
0.
52
0.
33
 
H
ie
r. 
Q
SA
R
 -8
0 
0.
63
0.
45
0.
81
0.
72
 
0.
70
 
0.
58
0.
53
0.
63
 
0.
72
 
0.
63
 
0.
58
0.
51
0.
65
0.
72
 
0.
66
0.
75
0.
84
0.
67
0.
17
 
 
0.
56
0.
82
0.
31
 
0.
10
 
 
0.
62
0.
81
0.
42
0.
15
 
M
gr
R
at
Li
ve
r 
C
on
v.
 
Q
SA
R
 
0.
63
0.
59
0.
67
0.
62
 
 
0.
56
0.
59
0.
53
 
0.
62
 
0.
56
 
0.
59
0.
59
0.
59
0.
62
 
0.
59
H
ie
r. 
Q
SA
R
-2
84
 0
.6
4
0.
52
0.
75
0.
64
 
0.
69
**
 
0.
58
0.
58
0.
58
 
0.
64
 
0.
60
 
0.
63
0.
60
0.
67
0.
64
 
0.
67
*
0.
70
0.
73
0.
66
0.
37
 
 
0.
59
0.
82
0.
36
 
0.
31
 
 
0.
68
0.
82
0.
55
0.
36
 
H
ie
r. 
Q
SA
R
 -8
0 
0.
61
0.
51
0.
72
0.
64
 
0.
68
*
 
0.
61
0.
60
0.
62
 
0.
64
 
0.
60
 
0.
64
0.
60
0.
69
0.
64
 
0.
65
0.
65
0.
68
0.
63
0.
20
 
 
0.
40
0.
70
0.
10
 
0.
09
 
 
0.
67
0.
86
0.
48
0.
15
 
M
gr
R
at
Vi
ab
ili
ty
PN
D
4 
C
on
v.
 
Q
SA
R
 
0.
57
0.
55
0.
58
0.
56
 
 
0.
47
0.
40
0.
55
 
0.
56
 
 
0.
49
0.
43
0.
56
0.
56
 
H
ie
r. 
Q
SA
R
-2
84
 0
.6
2
0.
45
0.
79
0.
71
 
0.
69
**
 
0.
54
0.
52
0.
57
 
0.
71
 
0.
55
 
0.
54
0.
48
0.
60
0.
71
 
0.
56
**
0.
70
0.
73
0.
67
0.
35
 
 
0.
56
0.
84
0.
29
 
0.
26
 
 
0.
53
0.
70
0.
37
0.
34
 
H
ie
r. 
Q
SA
R
 -8
0 
0.
61
0.
48
0.
75
0.
71
 
0.
66
*
 
0.
55
0.
50
0.
61
 
0.
71
 
0.
58
*
 
0.
53
0.
40
0.
66
0.
71
 
0.
43
0.
68
0.
71
0.
64
0.
16
 
 
0.
55
0.
80
0.
31
 
0.
10
 
 
0.
62
0.
80
0.
44
0.
12
 
* 
p 
<0
.0
5,
 *
*p
<0
.0
1,
 b
y 
tw
o-
ta
ile
d 
St
ud
en
t’s
 t 
te
st
 o
n 
R
O
C
-A
U
C
 b
et
w
ee
n 
m
od
el
s d
er
iv
ed
 fr
om
 C
on
v.
Q
SA
R
 a
nd
 th
os
e 
fr
om
 H
ie
r.Q
SA
R
. 
 155 
 
Table 5.6. The top 20 ToxCastTM bioassays for each reproductive toxicity endpoint based on the 
prediction accuracy of their associated hierarchical models.    
A. MGR_Rat_Kidney   
Assay Gene Gene name/ Description 
ATG_VDRE_CISa CYP27B1 cytochrome P450, family 27, subfamily B, polypeptide 1 
BSK_3C_Vis_downa  HUVEC (IL-1b+TNFa+IFN-g): Visual 
BSK_4H_Eotaxin3_downa CCL26 chemokine (C-C motif) ligand 26 
BSK_4H_Pselectin_downa SELP selectin P (granule membrane protein 140kDa, antigen CD62) 
BSK_BE3C_hLADR_upa HLA-DRA major histocompatibility complex, class II, DR alpha 
BSK_hDFCGF_EGFR_upa EGFR epidermal growth factor receptor 
BSK_KF3CT_IL1a_downa IL1A interleukin 1, alpha 
BSK_KF3CT_IP10_downb CXCL10 chemokine (C-X-C motif) ligand 10 
BSK_LPS_VCAM1_downa VCAM1 vascular cell adhesion molecule 1 
BSK_SAg_CD40_upa CD40 CD40 molecule, TNF receptor superfamily member 5 
BSK_SAg_PBMCCytotoxicity_downa  HUVEC/PBMC (TCR): Cytotoxicity 
CLM_MicrotubuleCSK_Destabilizer_24hra  HCS Microtubule Destabilization 
CLM_p53Act_1hra TP53 tumor protein p53 
CLM_p53Act_72hra TP53 tumor protein p53 
CLZD_ABCB11_48a ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 
CLZD_GSTA2_24a GSTA2 glutathione S-transferase alpha 2 
CLZD_SULT2A1_24a SULT2A1 
sulfotransferase family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA)-preferring, 
member 1 
NCGC_PXR_Agonist_humana NR1I2 nuclear receptor subfamily 1, group I, member 2 
NVS_GPCR_g5HT4a HTR4 5 hydroxytryptamine (serotonin) receptor 4 
NVS_GPCR_h5HT6a HTR6 5-hydroxytryptamine (serotonin) receptor 6 
 
B. MGR_Rat_Liver 
Assay Gene Gene name/ Description 
ATG_ERRg_TRANSb ESRRG estrogen-related receptor gamma 
ATG_HIF1a_CIS HIF1A hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 
ATG_Pax6_CIS PAX6 paired box 6 
BSK_4H_VCAM1_down VCAM1 vascular cell adhesion molecule 1 
BSK_hDFCGF_CollagenIII_upa COL3A1 collagen, type III, alpha 1 
BSK_KF3CT_IL1a_downa IL1A interleukin 1, alpha 
BSK_LPS_MPC1_down CCL2 chemokine (C-C motif) ligand 2 
CLM_Hepat_CellLoss_1hra  Cellumen_Hepat_CellLoss 
CLM_Hepat_NuclearSize_48hra Ratus Norvegicus Cellumen_Hepat_NuclearSize 
CLM_MicrotubuleCSK_Destabilizer_24hra  HCS Microtubule Destabilization 
NCGC_ERalpha_Agonista ESR1 estrogen receptor 1 
NVS_ADME_hCYP1A2 CYP1A2 cytochrome P450, family 1, subfamily A, 
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polypeptide 2 
NVS_ADME_hCYP2C8a CYP2C8 cytochrome P450, family 2, subfamily C, polypeptide 8 
NVS_ADME_rCYP2A2 CYP2A2 cytochrome P450, subfamily 2A, polypeptide 1 
NVS_ADME_rCYP2C6a CYP2C6 cytochrome P450, subfamily IIC6 
NVS_GPCR_g5HT4a HTR4 5 hydroxytryptamine (serotonin) receptor 4 
NVS_GPCR_hOpiate_mua OPRM1 opioid receptor, mu 1 
NVS_NR_bPRa PGR  
NVS_NR_hCAR173 NR1I3 nuclear receptor subfamily 1, group I, member 3 
NVS_NR_hPPARg PPARG peroxisome proliferator-activated receptor gamma 
 
C. MGR_Rat_Viability   
Assay Gene Gene name/ Description 
ATG_ERa_TRANSa ESR1 estrogen receptor 1 
ATG_ERRg_TRANSa ESRRG estrogen-related receptor gamma 
ATG_THRa1_TRANSa 
THRA thyroid hormone receptor, alpha (erythroblastic 
leukemia viral (v-erb-a) oncogene homolog, avian) 
BSK_3C_uPAR_downb PLAUR  
BSK_3C_Vis_downa  HUVEC (IL-1b+TNFa+IFN-g): Visual 
BSK_BE3C_hLADR_upb 
HLA-
DRA 
major histocompatibility complex, class II, DR alpha 
BSK_hDFCGF_MIG_downa CXCL9 chemokine (C-X-C motif) ligand 9 
BSK_KF3CT_ICAM1_down ICAM1 intercellular adhesion molecule 1 
BSK_KF3CT_MMP9_downb MMP9  
BSK_LPS_PGE2_downa PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa 
BSK_LPS_PGE2_upb PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa 
BSK_SM3C_Proliferation_downa 
 HUVEC/Primary Human Vascular Smooth Muscle 
Cells (IL-1b+TNF-a+IFN-g): Proliferation 
CLZD_GSTA2_48 GSTA2 glutathione S-transferase alpha 2 
CLZD_UGT1A1_6a UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1 
NVS_ADME_hCYP2C9b CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9 
NVS_ADME_hCYP3A5b CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5 
NVS_ADME_rCYP2C6b Cyp2c6 cytochrome P450, subfamily IIC6 
NVS_ENZ_rAChEb Ache acetylcholinesterase 
NVS_GPCR_h5HT7a 
HTR7 5-hydroxytryptamine (serotonin) receptor 7 (adenylate 
cyclase-coupled) 
NVS_GPCR_hDRD1 DRD1 dopamine receptor D1 
a. Assays considered to be related with in vivo test results, based on permutation test (p<0.05, 
10,000 times) to show statistically better external predictivity CCRext than conventional QSAR model.  
b. Assays that showed high correlation with in vivo test results based on association analysis 
using Fisher’s exact test (p<0.05) , in addition to better external predictivity than  conventional QSAR 
model in permutation test. 
 
 
 
 
 
Chapter 6. Conclusions and Future Studies 
6.1. Combi-QSAR Modeling Approach and Virtual Screening for Novel Inhibitors of 
Human Histone Deacetylase (HDAC)  
Histone deacetylases inhibitors (HDACIs) have emerged as a new class of drugs for 
the treatment of human cancers and other diseases due to their effects on cell growth, 
differentiation, and apoptosis. In chapter 2, we have employed a combinatorial QSAR 
approach to generate models for 59 chemically diverse compounds tested for their inhibitory 
activity against HDAC1. The SVM and kNN QSAR methods were used in combination with 
MolConnZ and MOE descriptors independently to identify the best approach with the highest 
external predictive power. Rigously validated QSAR models were used to screen our in-
house database collection of a total of over 9.5 million compounds. This study resulted in 45 
consensus hits that were predicted to be potent HDAC1 inhibitors. Two hit compounds that 
were not present in the original dataset were nevertheless reported recently as HDAC1 
inhibitors 131,132. Four hit compounds with interesting chemical features were purchased and 
experimentally validated. Three of them were confirmed to have inhibitory activities to 
HDAC1 (Class I HDACs) and the best activity obtained was IC50 of 1.00 μM. The fourth 
compound was later identified to be a selective inhibitor to HDAC6, a Class II HDACs. 
Moreover, two of the confirmed hits are marketed drugs which could potentially expedite 
their development as anticancer drugs acting via HDAC1 inhibition. We believe that the 
technologies described in this study could be used for data analysis and hit identification for 
other drug discovery studies. 
 158 
 
6.2. Development, Validation and Application of Target-specific Pose Filters in 
Structure-based Virtual Screening of Subtype Selective Ligands 
In Chapter 3and 4, we have proposed a general pose filter using the DFT derived 
protein-ligand interaction descriptors (PL/MCT-tess) in structure-based virtual screening. 
The pose filter was validated with the 13 benchmarked DUD datasets and FRED2.2.5 
docking program. The pose filter enables a constant improvement over using the default Fred 
scoring functions for active compounds. We further challenged the pose filter to identify 
subtype selective beta-adrenergic ligands. The results showed that it is possible to achieve 
reasonable early enrichment with carefully designed subtype biased pose filters, preferably 
using a selective ligand as the reference and a calibration set including both known 
nonselective and inactive molecules. It should be noted that the success of the proposed 
approach is heavily dependent on the previous knowledge, especially the selection of proper 
reference ligands to guide the structure modeling as well as docking pose selection. 
 For future studies, it would be interesting to see how additional knowledge about the 
receptors, such as the conformational flexibility of the binding pockets can be employed into 
structure-based docking, and affect the virtual screening performance. It is believed that the 
binding sites of GPCRs are very flexible in the absence of a bound ligand. Therefore, virtual 
screening with one static binding pocket from individual structure models or X-ray crystal 
structure may not be able to capture the real binding mode of some ligands. One possible 
solution is to include a set of experimentally solved structures, or in case of βAR, a set of 
representative structures extracted from molecular dynamic simulation study, to perform 
virtual screening in parallel, and combine the derived ranking lists for a consensus rank. In 
addition, the current pose filter does not explicitly apply any kind of model applicability 
domain.  It is expected that small molecules with larger molecular volume could form more 
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non-specific contacts with receptor side-chains, and contribute to the false positive class. It 
should be beneficial to filter out or penalize those molecules from the ranking list. However, 
preliminary studies on applying a QSAR-like applicability domain for the pose filter did not 
show significant benefits for virtual screening performance. Further studies are needed to 
explore this issue. 
6.3. Development of Predictive in vivo Toxicity Models from Combined Knowledge of 
Chemical Structure Information and the ToxCastTM in vitro Data 
In Chapter 5, we have examined the utility of the chemical structure descriptors and 
the ToxCastTM bioassay data for predicting in vivo toxicity of environmental chemicals. Our 
results indicate that the conventional QSAR models using chemical descriptors alone and the 
ToxCastTM bioassay results individually have limited predictive power. For some endpoints, 
e.g. MGRRatLiver, it is possible to use conventional QSAR models to achieve good 
predictivity for a subset of compounds with restricted scaffolds. On the other hand, although 
the ToxCastTM bioassay data have low correlations with in vivo toxicity data, they can still be 
useful for improving the predictive power of QSAR models when implemented within the 
novel two step hierarchical QSAR modeling workflow. This novel hierarchical QSAR 
modeling workflow can also help to estimate possible mechanisms of the toxicity pathways 
by evaluating the in vitro toxicity assays associated with top-ranked models. The derived 
models thus could be used to guide the future toxicity studies by choosing in vitro assays, 
prioritizing compounds for in vivo toxicity evaluation, as well as directing potential mode-of-
action analysis by evaluation of the molecular targets and pathways of the most predictive in 
vitro assays.  
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As shown from our studies, the proposed QSAR modeling workflow can improve 
toxicity predictions with a reduced applicability domain. The coming phase II ToxCastTM 
data that was tested against an additional 1000 compounds would provide an objective test 
set to evaluate models’ applicability as well as prediction accuracy. In addition, it is well 
known that the toxicity effects are dose-dependent. For current studies, the toxicity 
observations as well as the bioassay responses have been simplified into active (toxic) or 
inactive (non-toxic) classes. It would be interesting if we can include the dose-response data 
in the QSAR modeling, and test whether we can achieve better performance. Indeed, a recent 
publication by Sedykh et al.26 showed that it is possible to use the concentration-response 
data in the prediction of rodent acute toxicity. Furthermore, it would be beneficial to combine 
the prediction results with the results from bioinformatics analysis of the inherent 
connections between protein targets and bioassays.   
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APPENDICES 
Appendix I: Structure and pIC50 of fifty-nine HDAC1inhibitors used for model building and 
validation.  
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